SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules — TEI-tagged view

Antoine Daina, Olivier Michielin, Vincent Zoete · 2017 · computational chemistry · doi:10.1038/srep42717 · TEI xml · tagged edition · index · concepts · authors
Where this record's text came from. 2026-08-30 schema-0.3 pass: every quote verified as an exact substring of the staged text and anchored at merge time; concept terms verified present; every edge endpoint an existing node.
16 quotations on this page contain a reference number where the paper printed a superscript. This journal style prints citations as raised numerals — parameters12,13 — and the extraction flattened them into the line, so the sentence reads parameters 12 , 13 . The digits are citation markers and not part of what the author wrote. The quotes keep them for the same reason they keep every other extraction fault: a quote is reproduced exactly or it proves nothing.
Other fields define these differently the same word, defined another way in another discipline
interoperability 6 fields · saturation 4 fields · SVM 3 fields · SMILES 2 fields · feature selection 2 fields · central nervous system 2 fields · and 2 more →
Tags on this paper every tag the record carries, whether or not the words occur in the text below — a number is how many papers in the corpus carry that tag; a tag with no number is unique to this paper
SwissADME web tool SwissADME absorption, distribution, metabolism and excretion ADME computer models experiments3 predictive models physicochemical properties2 physicochemical parameters pharmacokinetics drug-likeness medicinal chemistry friendliness BOILED-Egg iLOGP Bioavailability Radar substructure searches Structural Alert PAINS molecular descriptors4 physicochemical descriptors molecular fingerprint FP FP2 method sequence of bits virtual screening3 support vector machine7 SVM6 computer-aided drug design CADD freely available in silico ADME tools generalist ADME packages consensus view multiple predictions molecular sketcher SMILES6 one-panel-per-molecule molecular weight molecular refractivity polar surface area PSA2 topological polar surface area TPSA partition coefficient between n -octanol and water log P o/w consensus log P o/w Water Solubility log S skin permeability coefficient log K p human gastrointestinal absorption HIA blood-brain barrier BBB permeability glycoprotein P-gp central nervous system2 cytochromes P450 CYP Inhibition of these isoenzymes pharmacokinetics-related drug-drug interactions toxic or other unwanted adverse effects training and test sets cross-validation accuracy external area under ROC curve overfitting biases applicability domains rule-based filters rule-of-five2 Bioavailability Score leadlikeness leads drug-like molecules synthetic accessibility SA Score molecular fragments OpenBabel ESOL model QSPR model in-house physics-based methods RBF Gaussian kernel function SwissDrugDesign program SwissDrugDesign web tools interoperability9 system-or-tool-building173
Method, as described: web-software implementation plus published and in-house QSPR, rule-based, graphical, and support-vector models validated by cross-validation and external test sets

Colour legend

Scientific Reports<title level="j">A work — the journal / venue title.
2017<date>A year or date.

Antoine DainapersName, Olivier MichielinpersName, Vincent ZoetepersName (2017date). “SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules.” Scientific Reportstitle·j.

Object of study — SwissADMEterm's property models, molecule interface, classifier validation, drug-likenessterm filters, and interoperable outputs

Research question — how to provide fast, robust, interpretable, and freely accessible multi-property prediction for small-molecule drug discovery

Contribution — a login-free web tool pooling predictive modelsterm for physicochemical propertiesterm, pharmacokineticsterm, drug-likenessterm, and medicinal-chemistry friendliness

Cross-disciplinary analysis
content-tags & facets: phenomenon · claim-type · cross-domain-transfer · mechanism · claim-relation · replication-status · limitation — grounded in the full text
phenomenoncomputational appraisal of ADME, oral bioavailability, structural liabilities, and synthetic accessibility from molecular structure — “To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur. Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. In that context, computer models constitute valid alternatives to experiments. Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar. Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch . Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours”
claim-typemethod — “To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur. Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. In that context, computer models constitute valid alternatives to experiments. Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar. Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch . Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours”
method — evidence — “SwissADME’s backend calculations were ran to generate 50 molecular and physicochemical descriptors per molecule (described in the Supplementary Table S1 ). For a given model, a descriptor was rejected if non-zero values for all molecules in the training set are less than 20% or if the coefficient of variation is less than 3%. In case of correlation higher than 0.9 between remaining descriptors, a selection is made based on F-score. The selected descriptors for each model are shown in Supplementary Tables S2–S7 . These tables also include the minimum and maximum values for each descriptor among all molecules used in the training. This enables beholding the broadness of physicochemical space involved and the applicability domain of the SVM models. The predictive capability of each model can be further appraised on Supplementary Table S8 , where external accuracy was split in sensitivity and specificity to ensure that positive and negative molecules are predicted with the same level of robustness. The final training and test sets with selected descriptors were normalized and the respective model ready to be built. First, the libSVM support vector machine python library (version 3.20, 2015, https://www.csie.ntu.edu.tw/~cjlin/libsvm/ ) 74 was used for multi-step grid-based optimization of the best coefficients for the above-selected descriptors as well as for the soft-margin permissivity (C) and the hyper-parameter (ϒ) of the RBF Gaussian kernel function. The 10-fold crossvalidated accuracy (ACC CV ) for each model was so maximized and AUC CV was calculated. In a second step, the so-built models were used on the external test sets (normalized according to the training set) in order to evaluate predictive power in terms of external accuracy (ACC ext ) and AUC ext . All final SVM models were stored in separate files, which are read through the libSVM API upon SwissADME job submission”
object of study — evidence — “To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur. Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. In that context, computer models constitute valid alternatives to experiments. Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar. Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch . Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours”
research question — evidence — “Because most freely available in silico ADME tools focus on one specific property or model only, while generalist ADME packages are commercial software, we felt the need of gathering what we consider the most relevant computational methods to provide a global appraisal of the pharmacokinetics profile of small molecules. The methods were selected for robustness, speed, but also and importantly for ease of interpretation to enable efficient translation to medicinal chemistry through molecular design. Some of them were adapted with open-source algorithms to ensure freedom to operate for the global scientific community. Others are our own models developed and tested on purpose. When applicable, multiple predictions of the same parameter are provided to allow for a consensus view of a given property”
contribution — evidence — “To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur. Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. In that context, computer models constitute valid alternatives to experiments. Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar. Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch . Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours”
mechanismmolecular fingerprint Linear molecular paths are hashed into a bit string indicating feature presence or absence. — “Cheminformaticians developed different molecular descriptors mined from chemical structures. One of the most popular examples is the molecular fingerprint (FP), which consists in a sequence of bits defining the presence or absence of chemical features in a molecule. The FP2 method 9 is one archetype of topological (or path-based) FP, which considers all fragments of the molecular structure following a linear path up to a given number of bonds. Every possible path is hashed to generate the bit string (i.e. the FP). A major advantage of FP is the efficiency by which computers handle such bit strings 10 , allowing for instance large-scale virtual screening or the rapid estimation of synthetic accessibility of molecules 11 . FP are also employed in classification models for ADME behaviours built by support vector machine (SVM) or Bayesian techniques 12 . Remarkably, computer-aided drug design (CADD) has been a pioneer field for the application of such machine learning technologies”mechanisms[0]
mechanismconsensus log P o/w SwissADME averages the predictions from five diverse lipophilicity models. — “The partition coefficient between n -octanol and water (log P o/w ) is the classical descriptor for Lipophilicity . It has a dedicated section in SwissADME due to the critical importance of this physicochemical property for pharmacokinetics drug discovery 26 27 . Many computational methods for log P o/w estimation were developed with diverse performance on various chemical sets. Common practice is to use multiple predictors either to select the most accurate methods for a given chemical series or to generate consensus estimation. The models behind the predictors should be as diverse as possible to increase the prediction accuracy through consensus log P o/w 28 . In that regard, SwissADME gives access to five freely available predictive models; i.e. XLOGP3, an atomistic method including corrective factors and knowledge-based library 29 ; WLOGP, our own implementation of a purely atomistic method based on the fragmental system of Wildman and Crippen 30 ; MLOGP, an archetype of topological method relying on a linear relationship with 13 molecular descriptors implemented from refs 31 and 32 ; SILICOS-IT, an hybrid method relying on 27 fragments and 7 topological descriptors ( http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html , accessed June 2016); and finally iLOGP, our in-house physics-based method relying on free energies of solvation in n -octanol and water calculated by the Generalized-Born and solvent accessible surface area (GB/SA) model. iLOGP was benchmarked on two drug or drug-like external sets and performed equally as or better than six well-established predictors 16 . The consensus log P o/w is the arithmetic mean of the values predicted by the five proposed methods”mechanisms[1]
mechanismBioavailability Radar Six physicochemical descriptors are compared with optimal ranges; complete enclosure indicates drug-likeness. — “The Bioavailability Radar in the first section of the One-panel-per-molecule output complements the two-dimensional image from the JChem webserver and the canonical SMILES calculated by OpenBabel. We use the JpGraph PHP library (version 3.5.0b1, 2016, http://jpgraph.net ) to produce the radar plot, which bears six axes for six important properties for oral bioavailability. Each property is defined by a descriptor of SwissADME and a range of optimal values is depicted as a pink area. The latter is inspired from commonly accepted bioavailability and drug-likeness guidelines 23 24 . For saturation, the ratio of sp 3 hybridized carbons over the total carbon count of the molecule (Fraction Csp3) should be at least 0.25. For size, the molecular weight (MW calculated by OpenBabel) should be between 150 and 500 g/mol. For polarity, the TPSA 25 should be between 20 and 130Å 2 . For solubility, log S (calculated with the ESOL model 36 ) should not exceed 6. For lipophilicity, XLOGP3 29 should be in the range from −0.7 to +6.0. For flexibility, the molecule should not have more than 9 rotatable bonds. To be estimated as drug-like, the red line of the compound under study must be fully included in the pink area. Any deviation represents a suboptimal physicochemical property for oral bioavailability”mechanisms[2]
mechanismBOILED-Egg WLOGP and TPSA position molecules in passive HIA and BBB zones, with P-gp status added by colour. — “After all calculations completed, the “Show BOILED-Egg” red button appears below the sketcher to display the graphical output on the same page (as exemplify in Fig. 4 ). This consists primarily in the BOILED-Egg, an intuitive method to predict simultaneously two key ADME parameters, i.e. the passive gastrointestinal absorption (HIA) and brain access (BBB). Although conceptually very simple as it relies on two physicochemical descriptors only (WLOGP and TPSA, for lipophilicity and apparent polarity), this classification model was built with extreme care regarding statistical significance and robustness 17 . As shown in Fig. 4 , the egg-shaped classification plot includes the yolk (i.e. the physicochemical space for highly probable BBB permeation) and the white (i.e. the physicochemical space for highly probable HIA absorption). Both compartments are not mutually exclusive and the outside grey region stands for molecules with properties implying predicted low absorption and limited brain penetration. In practice, the BOILED-Egg has proven straightforward interpretation and efficient translation to molecular design in a variety of drug discovery settings. Whereas the predictive power of the BOILED-Egg is broad in term of chemical space, it is restricted to passive penetration through gastro-intestinal wall and BBB. We took benefit of its implementation within SwissADME to enrich the graphical output with the prediction of P-gp substrate, which is the most important active efflux mechanism involved in those biological barriers 40 (refer to the SVM model described in Pharmacokinetics ). As a result, the user conveniently obtains on the same graph a global evaluation about passive absorption (inside/outside the white), passive brain access (inside/outside the yolk) and active efflux from the CNS or to the gastrointestinal lumen by colour-coding”mechanisms[3]
mechanismSVM Balanced, cleansed descriptor datasets train binary substrate and inhibitor classifiers. — “Six other classification models are part of the Pharmacokinetics section to predict the propensity of the molecule under investigation to be substrate or inhibitor of important pharmacokinetics-related proteins, for which large diverse and balanced datasets were retrieved and meticulously cleansed. For P-glycoprotein1 (P-gp), the training set consists of 521 substrates and 512 non-substrates extracted from the Metrabase database 70 ( http://www-metrabase.ch.cam.ac.uk , accessed January 2016), whereas the test set was obtained from ref. 71 . To ensure truly external validation, molecules overlapping with the training set were removed from the test set, which finally includes 215 substrates and 200 non-substrates. For CYP major isoforms, all datasets were those of Veith et al . 50 and downloaded from the PubChem database 72 ( http://pubchem.ncbi.nlm.nih.gov , accessed February 2016). In case of unbalanced dataset (all except CYP1A2 and CYP2C19), sufficient chemical diversity was guaranteed by clustering with the Ward method and a reciprocal nearest neighbour (RNN) algorithm 73 , the more populated class to lessen. The number of molecules (described by circular fingerprints) of the large class is reduced by defining clusters with the JKlustor program (version 14.9.29, 2014, http://www.chemaxon.com ). Only the centre of each cluster (i.e. the molecule that has the smallest sum of dissimilarities to the other molecules in the cluster) is included in the training or test set to balance. As a result, the training sets involved respectively 4301 CYP1A2 inhibitors and 4844 CYP1A2 non-inhibitors; 4284 CYP2C19 inhibitors and 4988 CYP2C19 non-inhibitors; 2940 CYP2C9 inhibitors and 3000 CYP2C9 non-inhibitors; 1814 CYP2D6 inhibitors and 1850 CYP2D6 non-inhibitors; and 3758 CYP3A4 inhibitors and 3760 CYP3A4 non-inhibitors. The test sets involved respectively 1412 CYP1A2 inhibitors and 1588 CYP1A2 non-inhibitors; 1386 CYP2C19 inhibitors and 1614 CYP2C19 non-inhibitors; 1020 CYP2C9 inhibitors and 1055 CYP2C9 non-inhibitors; 528 CYP2D6 inhibitors and 540 CYP2D6 non-inhibitors; and 1289 CYP3A4 inhibitors and 1290 CYP3A4 non-inhibitors”mechanisms[4]
mechanismfeature selection Low-information and highly correlated descriptors are rejected before grid optimization of SVM coefficients. — “SwissADME’s backend calculations were ran to generate 50 molecular and physicochemical descriptors per molecule (described in the Supplementary Table S1 ). For a given model, a descriptor was rejected if non-zero values for all molecules in the training set are less than 20% or if the coefficient of variation is less than 3%. In case of correlation higher than 0.9 between remaining descriptors, a selection is made based on F-score. The selected descriptors for each model are shown in Supplementary Tables S2–S7 . These tables also include the minimum and maximum values for each descriptor among all molecules used in the training. This enables beholding the broadness of physicochemical space involved and the applicability domain of the SVM models. The predictive capability of each model can be further appraised on Supplementary Table S8 , where external accuracy was split in sensitivity and specificity to ensure that positive and negative molecules are predicted with the same level of robustness. The final training and test sets with selected descriptors were normalized and the respective model ready to be built. First, the libSVM support vector machine python library (version 3.20, 2015, https://www.csie.ntu.edu.tw/~cjlin/libsvm/ ) 74 was used for multi-step grid-based optimization of the best coefficients for the above-selected descriptors as well as for the soft-margin permissivity (C) and the hyper-parameter (ϒ) of the RBF Gaussian kernel function. The 10-fold crossvalidated accuracy (ACC CV ) for each model was so maximized and AUC CV was calculated. In a second step, the so-built models were used on the external test sets (normalized according to the training set) in order to evaluate predictive power in terms of external accuracy (ACC ext ) and AUC ext . All final SVM models were stored in separate files, which are read through the libSVM API upon SwissADME job submission”mechanisms[5]
mechanismsynthetic accessibility Frequent fragments contribute favourably, rare fragments unfavourably, followed by size and complexity penalties. — “SwissADME Synthetic Accessibility (SA) Score is based primarily on the assumption that the frequency of molecular fragments in ‘really’ obtainable molecules correlates with the ease of synthesis. The fragmental contribution to SA should be favourable for frequent chemical moieties and unfavourable for rare moieties. We examined the ‘All Now’ subset of ZINC database 76 (version 12, 2014, http://zinc.docking.org/subsets/all-now accessed April 2015) including 12′782′590 compounds immediately deliverable by vendors. This collection was not submitted to any other filter. FP2 fingerprints of all molecules were computed by OpenBabel 9 thus generating 12′782′590 bit strings (i.e. the fingerprints). The frequency of occupancy of each of the 1024 bits for the entire library was calculated and its contribution to SA obtained by applying natural logarithm to the normalized bit count. As a result, this fragmental system of bits allows extremely fast evaluation of any input molecule by reading its FP2 string. Fragmental contribution of bit occupancy is summed and linearly modulated by corrective factors, which are penalties for size (MW) and complexity. This latter is based on SMARTS recognition of chiral centres, spiro functions, bridged rings and macrocycles (more than 8-membered rings). The coefficients of the corrective terms are those defined by Ertl & Schuffenhauer 11 . Finally the score is normalized to range from 1 (very easy) to 10 (very difficult to synthetize). As crude as it may seem, SwissADME SA Score is extremely fast and performing slightly better than two similar methods previously published”mechanisms[6]
mechanismSMILES Input structures are canonicalized, standardized, neutralized, checked, and converted to 3D before calculation. — “The molecule inputted through the sketcher Marvin JS (version 16.4.18, 2016, www.chemaxon.com ) are converted into SMILES by JChem Web Services (version 14.9.29, 2013, www.chemaxon.com ) installed on one of our servers. This on-the-fly conversion allows seamless paste of SMILES in the input list. The user has the possibility to edit this list as a standard text, e.g. to modify SMILES or add a name to the molecule. Upon calculation submission by clicking the “Run” button, the SMILES of each molecule is canonicalised by OpenBabel (version 2.3.0, 2012, http://openbabel.org ) 9 and processed individually. Several actions are performed through JChem Web Services APIs. First hydrogen atoms are added to the molecular structure, which is dearomatised (i.e. kekulised), neutralised and checked by the Standardizer API. Then a tridimensional conformation is generated though the StringMolExport function with the Clean3D option and stored in MOL2 format. Besides, a two-dimensional image created through the MolConverter API is displayed on demand when scrolling the output web page”mechanisms[7]
mechanismrule-based filters Multiple pharmaceutical-company filters apply property thresholds to judge drug-likeness. — “As defined earlier, “drug-likeness” assesses qualitatively the chance for a molecule to become an oral drug with respect to bioavailability. Drug-likeness was established from structural or physicochemical inspections of development compounds advanced enough to be considered oral drug-candidates. This notion is routinely employed to perform filtering of chemical libraries to exclude molecules with properties most probably incompatible with an acceptable pharmacokinetics profile. This SwissADME section gives access to five different rule-based filters, with diverse ranges of properties inside of which the molecule is defined as drug-like. These filters often originate from analyses by major pharmaceutical companies aiming to improve the quality of their proprietary chemical collections. The Lipinski (Pfizer) filter is the pioneer rule-of-five implemented from ref. 4 . The Ghose (Amgen), Veber (GSK), Egan (Pharmacia) and Muegge (Bayer) methods were adapted from refs 58 , 59 , 60 , 61 , respectively. Multiple estimations allow consensus views or selection of methods best fitting the end-user’s specific needs in terms of chemical space or project-related demands. Any violation of any rule described here appears explicitly in the output panel. The Abbot Bioavailability Score 62 is similar but seeks to predict the probability of a compound to have at least 10% oral bioavailability in rat or measurable Caco-2 permeability. This semi-quantitative rule-based score relying on total charge, TPSA, and violation to the Lipinski filter defines four classes of compounds with probabilities of 11%, 17%, 56% or 85%. Like the other methods in this section, it primary focuses on the fast screening of chemical libraries, to select the best molecules to be purchased, synthetized or promoted at a further stage of a medicinal chemistry project”mechanisms[8]
mechanismPAINS SMARTS pattern matching flags recurrent fragments associated with target-independent assay activity. — “Both methods for identification of problematic fragments within the Medicinal Chemistry section, i.e. PAINS 6 and Brenk’s Structural Alert 5 , were implemented using the SMARTS recognition capability of OpenBabel API. The SMARTS definitions for PAINS were retrieved from the Filter-it distribution (version 1.0.2, 2013, http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html ). Little formatting and cleansing were needed to obtain a screenable collection of 481 fragments. Brenk provided directly the SMARTS descriptions of 105 unwanted chemical groups”mechanisms[9]
mechanismWater Solubility Three topological or fragmental models estimate log S and provide an averaged consensus value. — “Similarly to lipophilicity, the Water Solubility section includes multiple predictive methods for the user to choose between the most accurate model for a given chemical series and an averaged consensus value. The ESOL model 36 is a QSPR model establishing the linear relationship between log S and five molecular parameters, i.e. MW, the number of rotatable bonds, the fraction of aromatic heavy atoms and Daylight’s CLOGP. Because the lipophilicity descriptor is not freely available, the implementation of ESOL in SwissADME replaces CLOGP by XLOGP3 as parameter in the linear equation to predict log S . XLOGP3 is known to perform well on external datasets and to return similar predictions as CLOGP 28 . The other three parameters were computed with OpenBabel. Likewise, Ali et al . 37 linked log S with log P o/w and TPSA. The model implemented in SwissADME corresponds to the model 3 of the original publication, with XLOGP3 as lipophilicity descriptor. The third solubility method available in SwissADME is the log S estimated by the FILTER-IT program (version 1.0.2, 2013, http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html ). This prediction is based on a system of 16 fragmental contributions modulated by the squared root of MW. All three models are predicting log S values, which are also translated within SwissADME into solubility in mol/l and mg/ml. Finally a qualitative estimation of the solubility class is given according to the following log S scale: insoluble <−10 <poorly <−6 <moderately <−4 <soluble <−2 <very <0 <highly”mechanisms[10]
mechanisminteroperability One-click icons transfer molecules among SwissADME and other SwissDrugDesign tools. — “Moreover, SwissADME is an integral part of the SwissDrugDesign program, an ambitious initiative driven by the Molecular Modeling Group of the SIB Swiss Institute of Bioinformatics that aims at providing a collection of free Web-based tools covering many aspects of CADD. As such, SwissADME users can access the different Web sites, through the black toolbar at the top of the page. By clicking on the name of the tool, a new tab opens with the corresponding submission page. We have undertaken the implementation of more advanced interoperability capabilities. At the time of writing this manuscript, three icons were placed top left of the output panel (below the name of the molecule, see Fig. 2 ). They allow one-click submission of the molecule to SwissTargetPrediction (for reverse screening to predict protein target, by clicking on the red target), SwissSimilarity (for ligand-based virtual screening, by clicking on the red twins) and to re-submit the molecule to SwissADME (for instance to get a single compound graphical output, by clicking the red pill). Reversely, other SwissDrugDesign websites include the SwissADME pill icon”mechanisms[11]
extends free web-based tools for ADME and pharmacokinetics — “The SwissADME web tool presented here is freely accessible at http://www.swissadme.ch and meant for user-friendly submission and easy analysis of the results, also for nonexpert in CADD. Compared to the state-of-the art of free web-based tools for ADME and pharmacokinetics (e.g. pk-CSM 14 and admetSAR 15 ) and apart from unique access to proficient methods (e.g. iLOGP 16 or the BOILED-Egg 17 ), SwissADME strong points are, non-exhaustively: different input methods, computation for multiple molecules, and the possibility to display, save and share results per individual molecule or through global intuitive and interactive graphs”claim_relations[0]
builds-on published renowned approaches — “The SwissADME Web tool enables the computation of key physicochemical, pharmacokinetic, drug-like and related parameters for one or multiple molecules. In one hand, efforts were put in the backend to embed free open-access and fast predictive models showing statistical significance, predictive power, intuitive interpretation, and straightforward translation to molecular design. These models are adapted from published renowned approaches or in-house original methods, specially developed and thoroughly benchmarked. On the other hand, we focused on an ergonomic and user-friendly graphical interface for the cost- and login-free Web site http://www.swissadme.ch . The latter enables easy input and efficient analysis of the output through interactive capabilities, and does not require any prior knowledge in CADD. Moreover, interoperability allows for direct access to other SwissDrugDesign web tools, including SwissSimilarity 66 (virtual screening), SwissBioisostere 21 (ligand-based design), SwissTargetPrediction 19 (prediction of biotargets), SwissDock 20 (molecular docking), SwissSideChain 67 (protein modeling) and SwissParam 22 (molecular mechanics). As a result, SwissADME has been designed to support the entire community (specialists and nonexperts) in their drug discovery endeavours”claim_relations[1]
extends BOILED-Egg — “After all calculations completed, the “Show BOILED-Egg” red button appears below the sketcher to display the graphical output on the same page (as exemplify in Fig. 4 ). This consists primarily in the BOILED-Egg, an intuitive method to predict simultaneously two key ADME parameters, i.e. the passive gastrointestinal absorption (HIA) and brain access (BBB). Although conceptually very simple as it relies on two physicochemical descriptors only (WLOGP and TPSA, for lipophilicity and apparent polarity), this classification model was built with extreme care regarding statistical significance and robustness 17 . As shown in Fig. 4 , the egg-shaped classification plot includes the yolk (i.e. the physicochemical space for highly probable BBB permeation) and the white (i.e. the physicochemical space for highly probable HIA absorption). Both compartments are not mutually exclusive and the outside grey region stands for molecules with properties implying predicted low absorption and limited brain penetration. In practice, the BOILED-Egg has proven straightforward interpretation and efficient translation to molecular design in a variety of drug discovery settings. Whereas the predictive power of the BOILED-Egg is broad in term of chemical space, it is restricted to passive penetration through gastro-intestinal wall and BBB. We took benefit of its implementation within SwissADME to enrich the graphical output with the prediction of P-gp substrate, which is the most important active efflux mechanism involved in those biological barriers 40 (refer to the SVM model described in Pharmacokinetics ). As a result, the user conveniently obtains on the same graph a global evaluation about passive absorption (inside/outside the white), passive brain access (inside/outside the yolk) and active efflux from the CNS or to the gastrointestinal lumen by colour-coding”claim_relations[2]
builds-on Ertl & Schuffenhauer — “One of the key aspects of CADD activities is to help the selection of the most promising virtual molecules that will be synthetized and submitted to biological assays or other experiments. Synthetic accessibility (SA) is a major factor to consider in this selection process. Obviously, for a reasonable number of molecules, medicinal chemists are the best able to determine SA. However, when too many molecular structures prevent an expert evaluation, in silico estimation can be used for pre-filtering. Ertl & Schuffenhauer 11 proposed a fingerprint-based approach for SA estimation but including closed-source information about fingerprint definition that prevents a straightforward implementation in our tool open to the scientific community. As a consequence, we have built our own fragmental method by analysing more than 13 millions compounds immediately deliverable by vendors. We assumed that the most frequent molecular fragments (technically, FP2 bits, refer to Computational Methods ) in this large collection indicates a probably high SA, while rare fragments imply a difficult synthesis. For a given molecule, the fragmental contributions to SA are summed and corrected by the terms describing size and complexity, such as macrocycles, chiral centres, or spiro functions as defined by Ertl & Schuffenhauer 11 . After normalization, the SA Score ranges from 1 (very easy) to 10 (very difficult). To assess the performance of the method developed for SwissADME, we retrieved two test sets of SA previously published. Both sets involved external molecules, whose difficulty of synthesis was marked from 1 to 10 by nine 11 and four 65 medicinal chemists, respectively. The averaged expert score can then be compared to an in silico SA Score. As seen in Table 2 , the predictive capacity of all three methods appears very dependent of the test set. Indeed the SAs of set 1, smaller and evaluated by more chemists, turned out to be much more robustly predictable than set 2. Human evaluation of synthetic complexity is undeniably subjective and relies on individual chemist’s training and experience. However, significant linear correlation and small errors — especially with SwissADME SA Score that outperformed the reference methods on both sets with smaller errors, and equal or higher linear correlation coefficients — demonstrate how this simple and fast methodology can help prioritizing molecules to synthetize”claim_relations[3]
senseADME as absorption, distribution, metabolism, and excretion considered separately — “During the time- and resource-consuming processes of drug discovery and development, a large number of molecular structures are evaluated according to very diverse parameters in order to steer the selection of which chemicals to synthetize, test and promote, with the final goal to identify those with the best chance to become an effective medicine for the patients. The molecules must show high biological activity together with low toxicity. Equally important is the access to and concentration at the therapeutic target in the organism. The traditional way to consider pharmacokinetics (i.e. the fate of a therapeutic compound in the organism) is to break down the various effects that impact the access to the target into individual parameters. In turn, these ADME parameters (for Absorption, Distribution, Metabolism and Excretion) can be evaluated separately by dedicated methods. It has been demonstrated that early estimation of ADME in the discovery phase reduces drastically the fraction of pharmacokinetics-related failure in the clinical phases 1 . Computer models have been fostered as a valid alternative to experimental procedures for prediction of ADME, especially at initial steps, when investigated chemical structures are numerous but the availability of compounds is scarce”senses[0]
sensepharmacokinetics as the fate of a therapeutic compound in the organism — “During the time- and resource-consuming processes of drug discovery and development, a large number of molecular structures are evaluated according to very diverse parameters in order to steer the selection of which chemicals to synthetize, test and promote, with the final goal to identify those with the best chance to become an effective medicine for the patients. The molecules must show high biological activity together with low toxicity. Equally important is the access to and concentration at the therapeutic target in the organism. The traditional way to consider pharmacokinetics (i.e. the fate of a therapeutic compound in the organism) is to break down the various effects that impact the access to the target into individual parameters. In turn, these ADME parameters (for Absorption, Distribution, Metabolism and Excretion) can be evaluated separately by dedicated methods. It has been demonstrated that early estimation of ADME in the discovery phase reduces drastically the fraction of pharmacokinetics-related failure in the clinical phases 1 . Computer models have been fostered as a valid alternative to experimental procedures for prediction of ADME, especially at initial steps, when investigated chemical structures are numerous but the availability of compounds is scarce”senses[1]
sensemolecular fingerprint as a bit sequence encoding presence or absence of chemical features — “Cheminformaticians developed different molecular descriptors mined from chemical structures. One of the most popular examples is the molecular fingerprint (FP), which consists in a sequence of bits defining the presence or absence of chemical features in a molecule. The FP2 method 9 is one archetype of topological (or path-based) FP, which considers all fragments of the molecular structure following a linear path up to a given number of bonds. Every possible path is hashed to generate the bit string (i.e. the FP). A major advantage of FP is the efficiency by which computers handle such bit strings 10 , allowing for instance large-scale virtual screening or the rapid estimation of synthetic accessibility of molecules 11 . FP are also employed in classification models for ADME behaviours built by support vector machine (SVM) or Bayesian techniques 12 . Remarkably, computer-aided drug design (CADD) has been a pioneer field for the application of such machine learning technologies”senses[2]
senseFP2 as a topological fingerprint hashing linear molecular paths — “Cheminformaticians developed different molecular descriptors mined from chemical structures. One of the most popular examples is the molecular fingerprint (FP), which consists in a sequence of bits defining the presence or absence of chemical features in a molecule. The FP2 method 9 is one archetype of topological (or path-based) FP, which considers all fragments of the molecular structure following a linear path up to a given number of bonds. Every possible path is hashed to generate the bit string (i.e. the FP). A major advantage of FP is the efficiency by which computers handle such bit strings 10 , allowing for instance large-scale virtual screening or the rapid estimation of synthetic accessibility of molecules 11 . FP are also employed in classification models for ADME behaviours built by support vector machine (SVM) or Bayesian techniques 12 . Remarkably, computer-aided drug design (CADD) has been a pioneer field for the application of such machine learning technologies”senses[3]
senseSwissADME as a pooled, interpretable, free alternative to fragmented or commercial ADME software — “Because most freely available in silico ADME tools focus on one specific property or model only, while generalist ADME packages are commercial software, we felt the need of gathering what we consider the most relevant computational methods to provide a global appraisal of the pharmacokinetics profile of small molecules. The methods were selected for robustness, speed, but also and importantly for ease of interpretation to enable efficient translation to medicinal chemistry through molecular design. Some of them were adapted with open-source algorithms to ensure freedom to operate for the global scientific community. Others are our own models developed and tested on purpose. When applicable, multiple predictions of the same parameter are provided to allow for a consensus view of a given property”senses[4]
senseBioavailability Radar as six physicochemical ranges whose complete enclosure indicates drug-likeness — “The Bioavailability Radar in the first section of the One-panel-per-molecule output complements the two-dimensional image from the JChem webserver and the canonical SMILES calculated by OpenBabel. We use the JpGraph PHP library (version 3.5.0b1, 2016, http://jpgraph.net ) to produce the radar plot, which bears six axes for six important properties for oral bioavailability. Each property is defined by a descriptor of SwissADME and a range of optimal values is depicted as a pink area. The latter is inspired from commonly accepted bioavailability and drug-likeness guidelines 23 24 . For saturation, the ratio of sp 3 hybridized carbons over the total carbon count of the molecule (Fraction Csp3) should be at least 0.25. For size, the molecular weight (MW calculated by OpenBabel) should be between 150 and 500 g/mol. For polarity, the TPSA 25 should be between 20 and 130Å 2 . For solubility, log S (calculated with the ESOL model 36 ) should not exceed 6. For lipophilicity, XLOGP3 29 should be in the range from −0.7 to +6.0. For flexibility, the molecule should not have more than 9 rotatable bonds. To be estimated as drug-like, the red line of the compound under study must be fully included in the pink area. Any deviation represents a suboptimal physicochemical property for oral bioavailability”senses[5]
senseconsensus log P as the arithmetic mean of five diverse predictor outputs — “The partition coefficient between n -octanol and water (log P o/w ) is the classical descriptor for Lipophilicity . It has a dedicated section in SwissADME due to the critical importance of this physicochemical property for pharmacokinetics drug discovery 26 27 . Many computational methods for log P o/w estimation were developed with diverse performance on various chemical sets. Common practice is to use multiple predictors either to select the most accurate methods for a given chemical series or to generate consensus estimation. The models behind the predictors should be as diverse as possible to increase the prediction accuracy through consensus log P o/w 28 . In that regard, SwissADME gives access to five freely available predictive models; i.e. XLOGP3, an atomistic method including corrective factors and knowledge-based library 29 ; WLOGP, our own implementation of a purely atomistic method based on the fragmental system of Wildman and Crippen 30 ; MLOGP, an archetype of topological method relying on a linear relationship with 13 molecular descriptors implemented from refs 31 and 32 ; SILICOS-IT, an hybrid method relying on 27 fragments and 7 topological descriptors ( http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html , accessed June 2016); and finally iLOGP, our in-house physics-based method relying on free energies of solvation in n -octanol and water calculated by the Generalized-Born and solvent accessible surface area (GB/SA) model. iLOGP was benchmarked on two drug or drug-like external sets and performed equally as or better than six well-established predictors 16 . The consensus log P o/w is the arithmetic mean of the values predicted by the five proposed methods”senses[6]
sensedrug-likeness as qualitative oral-drug probability with respect to bioavailability — “As defined earlier, “drug-likeness” assesses qualitatively the chance for a molecule to become an oral drug with respect to bioavailability. Drug-likeness was established from structural or physicochemical inspections of development compounds advanced enough to be considered oral drug-candidates. This notion is routinely employed to perform filtering of chemical libraries to exclude molecules with properties most probably incompatible with an acceptable pharmacokinetics profile. This SwissADME section gives access to five different rule-based filters, with diverse ranges of properties inside of which the molecule is defined as drug-like. These filters often originate from analyses by major pharmaceutical companies aiming to improve the quality of their proprietary chemical collections. The Lipinski (Pfizer) filter is the pioneer rule-of-five implemented from ref. 4 . The Ghose (Amgen), Veber (GSK), Egan (Pharmacia) and Muegge (Bayer) methods were adapted from refs 58 , 59 , 60 , 61 , respectively. Multiple estimations allow consensus views or selection of methods best fitting the end-user’s specific needs in terms of chemical space or project-related demands. Any violation of any rule described here appears explicitly in the output panel. The Abbot Bioavailability Score 62 is similar but seeks to predict the probability of a compound to have at least 10% oral bioavailability in rat or measurable Caco-2 permeability. This semi-quantitative rule-based score relying on total charge, TPSA, and violation to the Lipinski filter defines four classes of compounds with probabilities of 11%, 17%, 56% or 85%. Like the other methods in this section, it primary focuses on the fast screening of chemical libraries, to select the best molecules to be purchased, synthetized or promoted at a further stage of a medicinal chemistry project”senses[7]
senseleadlikeness as suitability for optimization under smaller and less hydrophobic bounds — “The purpose of this section is to support medicinal chemists in their daily drug discovery endeavours. Two complementary pattern recognition methods allow for identification of potentially problematic fragments. PAINS (for pan assay interference compounds, a.k.a. frequent hitters or promiscuous compounds) are molecules containing substructures showing potent response in assays irrespective of the protein target. Such fragments, yielding false positive biological output, have been identified by Baell et al . 6 in analysing six orthogonal assays and breaking down the molecules active on 2 or more assays into 481 recurrent fragments, considered as potentially leading to promiscuous compounds. SwissADME returns warnings if such moieties are found in the molecule under evaluation. Besides, we implemented Structural Alert, which consists in a list of 105 fragments identified by Brenk et al . 5 to be putatively toxic, chemically reactive, metabolically unstable or to bear properties responsible for poor pharmacokinetics. In SwissADME, it is possible to have a chemical description of the problematic fragments found in a given molecule by flying over the “question mark” icon appearing after the fragment list. This is implemented for both PAINS and Brenk filters. By applying these and other physicochemical filters to design screening libraries, Brenk et al . 5 observed that most of the remaining compounds satisfy criteria for “leadlikeness”. This concept is similar to drug-likeness, yet focusing on physicochemical boundaries defining a good lead, i.e. a molecular entity suitable for optimization. By definition, leads are subjected to chemical modifications that will most likely increase size and lipophilicity 63 . As a consequence, leads are required to be smaller and less hydrophobic than drug-like molecules. Since it is crucial for a chemist to judge whether a given molecule is suitable to initiate lead optimization, in addition to structural filters, we implemented a rule-based method for leadlikeness”senses[8]
sensesynthetic accessibility as fragment-frequency evidence corrected for size and complexity — “SwissADME Synthetic Accessibility (SA) Score is based primarily on the assumption that the frequency of molecular fragments in ‘really’ obtainable molecules correlates with the ease of synthesis. The fragmental contribution to SA should be favourable for frequent chemical moieties and unfavourable for rare moieties. We examined the ‘All Now’ subset of ZINC database 76 (version 12, 2014, http://zinc.docking.org/subsets/all-now accessed April 2015) including 12′782′590 compounds immediately deliverable by vendors. This collection was not submitted to any other filter. FP2 fingerprints of all molecules were computed by OpenBabel 9 thus generating 12′782′590 bit strings (i.e. the fingerprints). The frequency of occupancy of each of the 1024 bits for the entire library was calculated and its contribution to SA obtained by applying natural logarithm to the normalized bit count. As a result, this fragmental system of bits allows extremely fast evaluation of any input molecule by reading its FP2 string. Fragmental contribution of bit occupancy is summed and linearly modulated by corrective factors, which are penalties for size (MW) and complexity. This latter is based on SMARTS recognition of chiral centres, spiro functions, bridged rings and macrocycles (more than 8-membered rings). The coefficients of the corrective terms are those defined by Ertl & Schuffenhauer 11 . Finally the score is normalized to range from 1 (very easy) to 10 (very difficult to synthetize). As crude as it may seem, SwissADME SA Score is extremely fast and performing slightly better than two similar methods previously published”senses[9]
senseBOILED-Egg as WLOGP-TPSA zones for passive gut and brain penetration enriched with P-gp efflux — “After all calculations completed, the “Show BOILED-Egg” red button appears below the sketcher to display the graphical output on the same page (as exemplify in Fig. 4 ). This consists primarily in the BOILED-Egg, an intuitive method to predict simultaneously two key ADME parameters, i.e. the passive gastrointestinal absorption (HIA) and brain access (BBB). Although conceptually very simple as it relies on two physicochemical descriptors only (WLOGP and TPSA, for lipophilicity and apparent polarity), this classification model was built with extreme care regarding statistical significance and robustness 17 . As shown in Fig. 4 , the egg-shaped classification plot includes the yolk (i.e. the physicochemical space for highly probable BBB permeation) and the white (i.e. the physicochemical space for highly probable HIA absorption). Both compartments are not mutually exclusive and the outside grey region stands for molecules with properties implying predicted low absorption and limited brain penetration. In practice, the BOILED-Egg has proven straightforward interpretation and efficient translation to molecular design in a variety of drug discovery settings. Whereas the predictive power of the BOILED-Egg is broad in term of chemical space, it is restricted to passive penetration through gastro-intestinal wall and BBB. We took benefit of its implementation within SwissADME to enrich the graphical output with the prediction of P-gp substrate, which is the most important active efflux mechanism involved in those biological barriers 40 (refer to the SVM model described in Pharmacokinetics ). As a result, the user conveniently obtains on the same graph a global evaluation about passive absorption (inside/outside the white), passive brain access (inside/outside the yolk) and active efflux from the CNS or to the gastrointestinal lumen by colour-coding”senses[10]
senseclassifier robustness as balanced data, cross-validation, external validation, and applicability-domain breadth — “The quantification of the models performance is not straightforwardly comparable, because the training sets are different, most of the published models are less than 10-fold cross-validated and some statistical parameters are missing. Nevertheless, the SwissADME classifiers are competitive with previous models in term of robustness, with cross-validation accuracy (ACC CV ) grossly at the same level. Furthermore, cross-validated areas under receiver operating characteristic (ROC) curves (AUC CV ) are equal to the corresponding values found in the literature. Likewise, external prediction power is difficult to compare, as each test set includes different molecules. However, the predictive capacity of SwissADME classifiers is grossly equivalent to the related SVM methods, both in terms of external accuracy (ACC ext ) and external area under ROC curve (AUC ext ). The models for which external validation was not found (P-gp of refs 15 and 53 ) have to be taken with extreme caution since they possibly suffer from overfitting biases. Noteworthy, some of the published models (e.g. CYP2C9 and CYP3A4 of ref. 54 or CYP2C9 of ref. 55 ) were built on severely unbalanced training sets and tested on clearly unbalanced external sets. As demonstrated by Carbon-Mangels et al . 56 the relevance of machine-learning classification methods, and especially SVM, are negatively impacted by datasets with one significantly more populated class. In that case, accuracy measurements are overestimated and prone to mislead the construction and the evaluation of the model. Moreover, some SVM models were published with small training and test sets (P-gp of refs 15 and 57 ), which imply questionable capacity of generalization and broadness of applicability domains. We emphasize that for SwissADME classifiers, both training and test sets were carefully cleansed and checked for size, diversity and balance between classes. Furthermore, our SVM models rely merely on molecular and physicochemical descriptors generated by SwissADME. We believe that this improves robustness and sustainability of the underlying methodologies. In particular, not using molecular fingerprints, molecular graphs or other structural descriptions can be an handicap to generate high statistical values but should also limit overfitting biases and yield more generalist predictive models, not necessarily influenced by specific chemical scaffolds or moieties. In our practice, these well-performing models able to estimate important ADME behaviours are of great support for pharmacokinetics optimization and evaluation of small molecules”senses[11]
senseinteroperability as one-click molecule transfer among SwissDrugDesign prediction and design tools — “Moreover, SwissADME is an integral part of the SwissDrugDesign program, an ambitious initiative driven by the Molecular Modeling Group of the SIB Swiss Institute of Bioinformatics that aims at providing a collection of free Web-based tools covering many aspects of CADD. As such, SwissADME users can access the different Web sites, through the black toolbar at the top of the page. By clicking on the name of the tool, a new tab opens with the corresponding submission page. We have undertaken the implementation of more advanced interoperability capabilities. At the time of writing this manuscript, three icons were placed top left of the output panel (below the name of the molecule, see Fig. 2 ). They allow one-click submission of the molecule to SwissTargetPrediction (for reverse screening to predict protein target, by clicking on the red target), SwissSimilarity (for ligand-based virtual screening, by clicking on the red twins) and to re-submit the molecule to SwissADME (for instance to get a single compound graphical output, by clicking the red pill). Reversely, other SwissDrugDesign websites include the SwissADME pill icon”senses[12]
notefree web-based tools for ADME and pharmacokinetics — SwissADME adds multi-molecule input, per-molecule and global outputs, and integrated CADD tools. — “The SwissADME web tool presented here is freely accessible at http://www.swissadme.ch and meant for user-friendly submission and easy analysis of the results, also for nonexpert in CADD. Compared to the state-of-the art of free web-based tools for ADME and pharmacokinetics (e.g. pk-CSM 14 and admetSAR 15 ) and apart from unique access to proficient methods (e.g. iLOGP 16 or the BOILED-Egg 17 ), SwissADME strong points are, non-exhaustively: different input methods, computation for multiple molecules, and the possibility to display, save and share results per individual molecule or through global intuitive and interactive graphs”claim_relations[0]
weightfree web-based tools for ADME and pharmacokinetics — 0.95 — “The SwissADME web tool presented here is freely accessible at http://www.swissadme.ch and meant for user-friendly submission and easy analysis of the results, also for nonexpert in CADD. Compared to the state-of-the art of free web-based tools for ADME and pharmacokinetics (e.g. pk-CSM 14 and admetSAR 15 ) and apart from unique access to proficient methods (e.g. iLOGP 16 or the BOILED-Egg 17 ), SwissADME strong points are, non-exhaustively: different input methods, computation for multiple molecules, and the possibility to display, save and share results per individual molecule or through global intuitive and interactive graphs”claim_relations[0]
notepublished renowned approaches — The backend adapts published approaches alongside purpose-built in-house models. — “The SwissADME Web tool enables the computation of key physicochemical, pharmacokinetic, drug-like and related parameters for one or multiple molecules. In one hand, efforts were put in the backend to embed free open-access and fast predictive models showing statistical significance, predictive power, intuitive interpretation, and straightforward translation to molecular design. These models are adapted from published renowned approaches or in-house original methods, specially developed and thoroughly benchmarked. On the other hand, we focused on an ergonomic and user-friendly graphical interface for the cost- and login-free Web site http://www.swissadme.ch . The latter enables easy input and efficient analysis of the output through interactive capabilities, and does not require any prior knowledge in CADD. Moreover, interoperability allows for direct access to other SwissDrugDesign web tools, including SwissSimilarity 66 (virtual screening), SwissBioisostere 21 (ligand-based design), SwissTargetPrediction 19 (prediction of biotargets), SwissDock 20 (molecular docking), SwissSideChain 67 (protein modeling) and SwissParam 22 (molecular mechanics). As a result, SwissADME has been designed to support the entire community (specialists and nonexperts) in their drug discovery endeavours”claim_relations[1]
noteBOILED-Egg — SwissADME enriches passive HIA/BBB zones with P-gp active-efflux classification. — “After all calculations completed, the “Show BOILED-Egg” red button appears below the sketcher to display the graphical output on the same page (as exemplify in Fig. 4 ). This consists primarily in the BOILED-Egg, an intuitive method to predict simultaneously two key ADME parameters, i.e. the passive gastrointestinal absorption (HIA) and brain access (BBB). Although conceptually very simple as it relies on two physicochemical descriptors only (WLOGP and TPSA, for lipophilicity and apparent polarity), this classification model was built with extreme care regarding statistical significance and robustness 17 . As shown in Fig. 4 , the egg-shaped classification plot includes the yolk (i.e. the physicochemical space for highly probable BBB permeation) and the white (i.e. the physicochemical space for highly probable HIA absorption). Both compartments are not mutually exclusive and the outside grey region stands for molecules with properties implying predicted low absorption and limited brain penetration. In practice, the BOILED-Egg has proven straightforward interpretation and efficient translation to molecular design in a variety of drug discovery settings. Whereas the predictive power of the BOILED-Egg is broad in term of chemical space, it is restricted to passive penetration through gastro-intestinal wall and BBB. We took benefit of its implementation within SwissADME to enrich the graphical output with the prediction of P-gp substrate, which is the most important active efflux mechanism involved in those biological barriers 40 (refer to the SVM model described in Pharmacokinetics ). As a result, the user conveniently obtains on the same graph a global evaluation about passive absorption (inside/outside the white), passive brain access (inside/outside the yolk) and active efflux from the CNS or to the gastrointestinal lumen by colour-coding”claim_relations[2]
noteErtl & Schuffenhauer — The paper develops an open fragment-frequency SA method from the prior approach and benchmarks against it. — “One of the key aspects of CADD activities is to help the selection of the most promising virtual molecules that will be synthetized and submitted to biological assays or other experiments. Synthetic accessibility (SA) is a major factor to consider in this selection process. Obviously, for a reasonable number of molecules, medicinal chemists are the best able to determine SA. However, when too many molecular structures prevent an expert evaluation, in silico estimation can be used for pre-filtering. Ertl & Schuffenhauer 11 proposed a fingerprint-based approach for SA estimation but including closed-source information about fingerprint definition that prevents a straightforward implementation in our tool open to the scientific community. As a consequence, we have built our own fragmental method by analysing more than 13 millions compounds immediately deliverable by vendors. We assumed that the most frequent molecular fragments (technically, FP2 bits, refer to Computational Methods ) in this large collection indicates a probably high SA, while rare fragments imply a difficult synthesis. For a given molecule, the fragmental contributions to SA are summed and corrected by the terms describing size and complexity, such as macrocycles, chiral centres, or spiro functions as defined by Ertl & Schuffenhauer 11 . After normalization, the SA Score ranges from 1 (very easy) to 10 (very difficult). To assess the performance of the method developed for SwissADME, we retrieved two test sets of SA previously published. Both sets involved external molecules, whose difficulty of synthesis was marked from 1 to 10 by nine 11 and four 65 medicinal chemists, respectively. The averaged expert score can then be compared to an in silico SA Score. As seen in Table 2 , the predictive capacity of all three methods appears very dependent of the test set. Indeed the SAs of set 1, smaller and evaluated by more chemists, turned out to be much more robustly predictable than set 2. Human evaluation of synthetic complexity is undeniably subjective and relies on individual chemist’s training and experience. However, significant linear correlation and small errors — especially with SwissADME SA Score that outperformed the reference methods on both sets with smaller errors, and equal or higher linear correlation coefficients — demonstrate how this simple and fast methodology can help prioritizing molecules to synthetize”claim_relations[3]
weightErtl & Schuffenhauer — 0.95 — “One of the key aspects of CADD activities is to help the selection of the most promising virtual molecules that will be synthetized and submitted to biological assays or other experiments. Synthetic accessibility (SA) is a major factor to consider in this selection process. Obviously, for a reasonable number of molecules, medicinal chemists are the best able to determine SA. However, when too many molecular structures prevent an expert evaluation, in silico estimation can be used for pre-filtering. Ertl & Schuffenhauer 11 proposed a fingerprint-based approach for SA estimation but including closed-source information about fingerprint definition that prevents a straightforward implementation in our tool open to the scientific community. As a consequence, we have built our own fragmental method by analysing more than 13 millions compounds immediately deliverable by vendors. We assumed that the most frequent molecular fragments (technically, FP2 bits, refer to Computational Methods ) in this large collection indicates a probably high SA, while rare fragments imply a difficult synthesis. For a given molecule, the fragmental contributions to SA are summed and corrected by the terms describing size and complexity, such as macrocycles, chiral centres, or spiro functions as defined by Ertl & Schuffenhauer 11 . After normalization, the SA Score ranges from 1 (very easy) to 10 (very difficult). To assess the performance of the method developed for SwissADME, we retrieved two test sets of SA previously published. Both sets involved external molecules, whose difficulty of synthesis was marked from 1 to 10 by nine 11 and four 65 medicinal chemists, respectively. The averaged expert score can then be compared to an in silico SA Score. As seen in Table 2 , the predictive capacity of all three methods appears very dependent of the test set. Indeed the SAs of set 1, smaller and evaluated by more chemists, turned out to be much more robustly predictable than set 2. Human evaluation of synthetic complexity is undeniably subjective and relies on individual chemist’s training and experience. However, significant linear correlation and small errors — especially with SwissADME SA Score that outperformed the reference methods on both sets with smaller errors, and equal or higher linear correlation coefficients — demonstrate how this simple and fast methodology can help prioritizing molecules to synthetize”claim_relations[3]
auditSwissADME web tool —part-of→ predictive models — Audit 2026-09-28: DOUBTFUL - read against its span and kept, but the tool GIVES ACCESS to predictive models; part-of runs the wrong way. — “To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur. Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. In that context, computer models constitute valid alternatives to experiments. Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar. Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch . Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours”concept_edges[0]
noteSwissADME web tool —part-of→ predictive models — Categorical tool composition stated by 'pool of'. — “To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur. Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. In that context, computer models constitute valid alternatives to experiments. Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar. Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch . Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours”concept_edges[0]
relationSwissADME web tool —part-of→ predictive models — SwissADME gives access to a pool of predictive models. — “To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur. Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. In that context, computer models constitute valid alternatives to experiments. Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar. Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch . Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours”concept_edges[0]
notesequence of bits —part-of→ molecular fingerprint — Direct categorical composition; the bit sequence is the fingerprint's representation. — “Cheminformaticians developed different molecular descriptors mined from chemical structures. One of the most popular examples is the molecular fingerprint (FP), which consists in a sequence of bits defining the presence or absence of chemical features in a molecule. The FP2 method 9 is one archetype of topological (or path-based) FP, which considers all fragments of the molecular structure following a linear path up to a given number of bonds. Every possible path is hashed to generate the bit string (i.e. the FP). A major advantage of FP is the efficiency by which computers handle such bit strings 10 , allowing for instance large-scale virtual screening or the rapid estimation of synthetic accessibility of molecules 11 . FP are also employed in classification models for ADME behaviours built by support vector machine (SVM) or Bayesian techniques 12 . Remarkably, computer-aided drug design (CADD) has been a pioneer field for the application of such machine learning technologies”concept_edges[1]
relationsequence of bits —part-of→ molecular fingerprint — A molecular fingerprint consists in a sequence of bits. — “Cheminformaticians developed different molecular descriptors mined from chemical structures. One of the most popular examples is the molecular fingerprint (FP), which consists in a sequence of bits defining the presence or absence of chemical features in a molecule. The FP2 method 9 is one archetype of topological (or path-based) FP, which considers all fragments of the molecular structure following a linear path up to a given number of bonds. Every possible path is hashed to generate the bit string (i.e. the FP). A major advantage of FP is the efficiency by which computers handle such bit strings 10 , allowing for instance large-scale virtual screening or the rapid estimation of synthetic accessibility of molecules 11 . FP are also employed in classification models for ADME behaviours built by support vector machine (SVM) or Bayesian techniques 12 . Remarkably, computer-aided drug design (CADD) has been a pioneer field for the application of such machine learning technologies”concept_edges[1]
notephysicochemical parameters —contrasted-with→ substructure searches — Explicit Whereas contrast. — “Whereas physicochemical parameters give a global description of the structure, molecules can be directly described by substructure searches. These techniques are at the root of Structural Alert 5 , the PAINS 6 or the Lilly MedChem 7 filters applied to cleanse chemical libraries from compounds most likely unstable, reactive, toxic, or prone to interfere with biological assays because unspecific frequent hitters, dyes or aggregators”concept_edges[2]
relationphysicochemical parameters —contrasted-with→ substructure searches — Global physicochemical description is contrasted with direct substructure search. — “Whereas physicochemical parameters give a global description of the structure, molecules can be directly described by substructure searches. These techniques are at the root of Structural Alert 5 , the PAINS 6 or the Lilly MedChem 7 filters applied to cleanse chemical libraries from compounds most likely unstable, reactive, toxic, or prone to interfere with biological assays because unspecific frequent hitters, dyes or aggregators”concept_edges[2]
weightphysicochemical parameters —contrasted-with→ substructure searches — 0.95 — “Whereas physicochemical parameters give a global description of the structure, molecules can be directly described by substructure searches. These techniques are at the root of Structural Alert 5 , the PAINS 6 or the Lilly MedChem 7 filters applied to cleanse chemical libraries from compounds most likely unstable, reactive, toxic, or prone to interfere with biological assays because unspecific frequent hitters, dyes or aggregators”concept_edges[2]
notefreely available in silico ADME tools —contrasted-with→ generalist ADME packages — Explicit while contrast. — “Because most freely available in silico ADME tools focus on one specific property or model only, while generalist ADME packages are commercial software, we felt the need of gathering what we consider the most relevant computational methods to provide a global appraisal of the pharmacokinetics profile of small molecules. The methods were selected for robustness, speed, but also and importantly for ease of interpretation to enable efficient translation to medicinal chemistry through molecular design. Some of them were adapted with open-source algorithms to ensure freedom to operate for the global scientific community. Others are our own models developed and tested on purpose. When applicable, multiple predictions of the same parameter are provided to allow for a consensus view of a given property”concept_edges[3]
relationfreely available in silico ADME tools —contrasted-with→ generalist ADME packages — Single-property free tools are contrasted with commercial generalist packages. — “Because most freely available in silico ADME tools focus on one specific property or model only, while generalist ADME packages are commercial software, we felt the need of gathering what we consider the most relevant computational methods to provide a global appraisal of the pharmacokinetics profile of small molecules. The methods were selected for robustness, speed, but also and importantly for ease of interpretation to enable efficient translation to medicinal chemistry through molecular design. Some of them were adapted with open-source algorithms to ensure freedom to operate for the global scientific community. Others are our own models developed and tested on purpose. When applicable, multiple predictions of the same parameter are provided to allow for a consensus view of a given property”concept_edges[3]
weightfreely available in silico ADME tools —contrasted-with→ generalist ADME packages — 0.95 — “Because most freely available in silico ADME tools focus on one specific property or model only, while generalist ADME packages are commercial software, we felt the need of gathering what we consider the most relevant computational methods to provide a global appraisal of the pharmacokinetics profile of small molecules. The methods were selected for robustness, speed, but also and importantly for ease of interpretation to enable efficient translation to medicinal chemistry through molecular design. Some of them were adapted with open-source algorithms to ensure freedom to operate for the global scientific community. Others are our own models developed and tested on purpose. When applicable, multiple predictions of the same parameter are provided to allow for a consensus view of a given property”concept_edges[3]
noteabsorption, distribution, metabolism and excretion —same-as→ ADME — Parenthetical abbreviation equivalence. — “To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur. Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. In that context, computer models constitute valid alternatives to experiments. Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar. Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch . Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours”concept_edges[4]
relationabsorption, distribution, metabolism and excretion —same-as→ ADME — Absorption, distribution, metabolism and excretion are abbreviated ADME. — “To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur. Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. In that context, computer models constitute valid alternatives to experiments. Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar. Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch . Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours”concept_edges[4]
notemolecular fingerprint —same-as→ FP — Parenthetical abbreviation equivalence. — “Cheminformaticians developed different molecular descriptors mined from chemical structures. One of the most popular examples is the molecular fingerprint (FP), which consists in a sequence of bits defining the presence or absence of chemical features in a molecule. The FP2 method 9 is one archetype of topological (or path-based) FP, which considers all fragments of the molecular structure following a linear path up to a given number of bonds. Every possible path is hashed to generate the bit string (i.e. the FP). A major advantage of FP is the efficiency by which computers handle such bit strings 10 , allowing for instance large-scale virtual screening or the rapid estimation of synthetic accessibility of molecules 11 . FP are also employed in classification models for ADME behaviours built by support vector machine (SVM) or Bayesian techniques 12 . Remarkably, computer-aided drug design (CADD) has been a pioneer field for the application of such machine learning technologies”concept_edges[5]
relationmolecular fingerprint —same-as→ FP — Molecular fingerprint is abbreviated FP. — “Cheminformaticians developed different molecular descriptors mined from chemical structures. One of the most popular examples is the molecular fingerprint (FP), which consists in a sequence of bits defining the presence or absence of chemical features in a molecule. The FP2 method 9 is one archetype of topological (or path-based) FP, which considers all fragments of the molecular structure following a linear path up to a given number of bonds. Every possible path is hashed to generate the bit string (i.e. the FP). A major advantage of FP is the efficiency by which computers handle such bit strings 10 , allowing for instance large-scale virtual screening or the rapid estimation of synthetic accessibility of molecules 11 . FP are also employed in classification models for ADME behaviours built by support vector machine (SVM) or Bayesian techniques 12 . Remarkably, computer-aided drug design (CADD) has been a pioneer field for the application of such machine learning technologies”concept_edges[5]
notesupport vector machine —same-as→ SVM — Parenthetical abbreviation equivalence. — “SwissADME enables the estimation for a chemical to be substrate of P-gp or inhibitor of the most important CYP isoenzymes. We applied the support vector machine algorithm (SVM) 51 on meticulously cleansed large datasets of known substrates/non-substrates or inhibitors/non-inhibitors (for details, see Computational Methods ). In similar contexts, SVM was found to perform better than other machine-learning algorithms for binary classification 40 52 . The models return “Yes” or “No” if the molecule under investigation has higher probability to be substrate or non-substrate of P-gp (respectively inhibitor or non-inhibitor of a given CYP). The statistical performance of the classification models is given in Table 1 , in comparison with previous SVM models on the same targets. We restricted the benchmark to state-of-the-art methods, published after 2010”concept_edges[6]
relationsupport vector machine —same-as→ SVM — Support vector machine is abbreviated SVM. — “SwissADME enables the estimation for a chemical to be substrate of P-gp or inhibitor of the most important CYP isoenzymes. We applied the support vector machine algorithm (SVM) 51 on meticulously cleansed large datasets of known substrates/non-substrates or inhibitors/non-inhibitors (for details, see Computational Methods ). In similar contexts, SVM was found to perform better than other machine-learning algorithms for binary classification 40 52 . The models return “Yes” or “No” if the molecule under investigation has higher probability to be substrate or non-substrate of P-gp (respectively inhibitor or non-inhibitor of a given CYP). The statistical performance of the classification models is given in Table 1 , in comparison with previous SVM models on the same targets. We restricted the benchmark to state-of-the-art methods, published after 2010”concept_edges[6]
notecomputer-aided drug design —same-as→ CADD — Parenthetical abbreviation equivalence. — “Cheminformaticians developed different molecular descriptors mined from chemical structures. One of the most popular examples is the molecular fingerprint (FP), which consists in a sequence of bits defining the presence or absence of chemical features in a molecule. The FP2 method 9 is one archetype of topological (or path-based) FP, which considers all fragments of the molecular structure following a linear path up to a given number of bonds. Every possible path is hashed to generate the bit string (i.e. the FP). A major advantage of FP is the efficiency by which computers handle such bit strings 10 , allowing for instance large-scale virtual screening or the rapid estimation of synthetic accessibility of molecules 11 . FP are also employed in classification models for ADME behaviours built by support vector machine (SVM) or Bayesian techniques 12 . Remarkably, computer-aided drug design (CADD) has been a pioneer field for the application of such machine learning technologies”concept_edges[7]
relationcomputer-aided drug design —same-as→ CADD — Computer-aided drug design is abbreviated CADD. — “Cheminformaticians developed different molecular descriptors mined from chemical structures. One of the most popular examples is the molecular fingerprint (FP), which consists in a sequence of bits defining the presence or absence of chemical features in a molecule. The FP2 method 9 is one archetype of topological (or path-based) FP, which considers all fragments of the molecular structure following a linear path up to a given number of bonds. Every possible path is hashed to generate the bit string (i.e. the FP). A major advantage of FP is the efficiency by which computers handle such bit strings 10 , allowing for instance large-scale virtual screening or the rapid estimation of synthetic accessibility of molecules 11 . FP are also employed in classification models for ADME behaviours built by support vector machine (SVM) or Bayesian techniques 12 . Remarkably, computer-aided drug design (CADD) has been a pioneer field for the application of such machine learning technologies”concept_edges[7]
notepolar surface area —same-as→ PSA — Parenthetical abbreviation equivalence. — “Simple molecular and physicochemical descriptors like molecular weight (MW), molecular refractivity (MR), count of specific atom types and polar surface area (PSA) are compiled in this section. The values are computed with OpenBabel 9 , version 2.3.0. The PSA is calculated using the fragmental technique called topological polar surface area (TPSA), considering sulfur and phosphorus as polar atoms 25 . This has proven a useful descriptor in many models and rules to quickly estimate some ADME properties, especially with regards to biological barrier crossing such as absorption and brain access”concept_edges[8]
relationpolar surface area —same-as→ PSA — Polar surface area is abbreviated PSA. — “Simple molecular and physicochemical descriptors like molecular weight (MW), molecular refractivity (MR), count of specific atom types and polar surface area (PSA) are compiled in this section. The values are computed with OpenBabel 9 , version 2.3.0. The PSA is calculated using the fragmental technique called topological polar surface area (TPSA), considering sulfur and phosphorus as polar atoms 25 . This has proven a useful descriptor in many models and rules to quickly estimate some ADME properties, especially with regards to biological barrier crossing such as absorption and brain access”concept_edges[8]
notehuman gastrointestinal absorption —same-as→ HIA — Parenthetical abbreviation equivalence. — “The predictions for passive human gastrointestinal absorption (HIA) and blood-brain barrier (BBB) permeation both consist in the readout of the BOILED-Egg model 17 , an intuitive graphical classification model, which can be displayed in the SwissADME result page by clicking the red button appearing below the sketcher when all input molecules have been processed (refer to Graphical Output ). Other binary classification models are included, which focus on the propensity for a given small molecule to be substrate or inhibitor of proteins governing important pharmacokinetic behaviours”concept_edges[9]
relationhuman gastrointestinal absorption —same-as→ HIA — Human gastrointestinal absorption is abbreviated HIA. — “The predictions for passive human gastrointestinal absorption (HIA) and blood-brain barrier (BBB) permeation both consist in the readout of the BOILED-Egg model 17 , an intuitive graphical classification model, which can be displayed in the SwissADME result page by clicking the red button appearing below the sketcher when all input molecules have been processed (refer to Graphical Output ). Other binary classification models are included, which focus on the propensity for a given small molecule to be substrate or inhibitor of proteins governing important pharmacokinetic behaviours”concept_edges[9]
noteblood-brain barrier —same-as→ BBB — Parenthetical abbreviation equivalence. — “The predictions for passive human gastrointestinal absorption (HIA) and blood-brain barrier (BBB) permeation both consist in the readout of the BOILED-Egg model 17 , an intuitive graphical classification model, which can be displayed in the SwissADME result page by clicking the red button appearing below the sketcher when all input molecules have been processed (refer to Graphical Output ). Other binary classification models are included, which focus on the propensity for a given small molecule to be substrate or inhibitor of proteins governing important pharmacokinetic behaviours”concept_edges[10]
relationblood-brain barrier —same-as→ BBB — Blood-brain barrier is abbreviated BBB. — “The predictions for passive human gastrointestinal absorption (HIA) and blood-brain barrier (BBB) permeation both consist in the readout of the BOILED-Egg model 17 , an intuitive graphical classification model, which can be displayed in the SwissADME result page by clicking the red button appearing below the sketcher when all input molecules have been processed (refer to Graphical Output ). Other binary classification models are included, which focus on the propensity for a given small molecule to be substrate or inhibitor of proteins governing important pharmacokinetic behaviours”concept_edges[10]
notecytochromes P450 —same-as→ CYP — Parenthetical abbreviation equivalence. — “Also essential is the knowledge about interaction of molecules with cytochromes P450 (CYP). This superfamily of isoenzymes is a key player in drug elimination through metabolic biotransformation 43 . It has been suggested that CYP and P-gp can process small molecules synergistically to improve protection of tissues and organisms 44 . One can estimate that 50 to 90% (depending on the authors) of therapeutic molecules are substrate of five major isoforms (CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4) 45 46 . Inhibition of these isoenzymes is certainly one major cause of pharmacokinetics-related drug-drug interactions 47 48 leading to toxic or other unwanted adverse effects due to the lower clearance and accumulation of the drug or its metabolites 49 . Numerous inhibitors of the CYP isoforms have been identified. Some are affecting different CYP isoforms, while other compounds show selectivity for specific isoenzymes 50 . It is therefore of great importance for drug discovery to predict the propensity with which the molecule will cause significant drug interactions through inhibition of CYPs, and to determine which isoforms are affected”concept_edges[11]
relationcytochromes P450 —same-as→ CYP — Cytochromes P450 are abbreviated CYP. — “Also essential is the knowledge about interaction of molecules with cytochromes P450 (CYP). This superfamily of isoenzymes is a key player in drug elimination through metabolic biotransformation 43 . It has been suggested that CYP and P-gp can process small molecules synergistically to improve protection of tissues and organisms 44 . One can estimate that 50 to 90% (depending on the authors) of therapeutic molecules are substrate of five major isoforms (CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4) 45 46 . Inhibition of these isoenzymes is certainly one major cause of pharmacokinetics-related drug-drug interactions 47 48 leading to toxic or other unwanted adverse effects due to the lower clearance and accumulation of the drug or its metabolites 49 . Numerous inhibitors of the CYP isoforms have been identified. Some are affecting different CYP isoforms, while other compounds show selectivity for specific isoenzymes 50 . It is therefore of great importance for drug discovery to predict the propensity with which the molecule will cause significant drug interactions through inhibition of CYPs, and to determine which isoforms are affected”concept_edges[11]
noteiLOGP —is-a→ in-house physics-based methods — Explicit categorical classification. — “iLOGP (for implicit log P ) is an in-house physics-based methods relying on Gibbs free energy of solvation calculated by GB/SA in water and n -octanol”concept_edges[12]
relationiLOGP —is-a→ in-house physics-based methods — iLOGP is an in-house physics-based method. — “iLOGP (for implicit log P ) is an in-house physics-based methods relying on Gibbs free energy of solvation calculated by GB/SA in water and n -octanol”concept_edges[12]
noteESOL model —is-a→ QSPR model — Explicit categorical classification. — “Similarly to lipophilicity, the Water Solubility section includes multiple predictive methods for the user to choose between the most accurate model for a given chemical series and an averaged consensus value. The ESOL model 36 is a QSPR model establishing the linear relationship between log S and five molecular parameters, i.e. MW, the number of rotatable bonds, the fraction of aromatic heavy atoms and Daylight’s CLOGP. Because the lipophilicity descriptor is not freely available, the implementation of ESOL in SwissADME replaces CLOGP by XLOGP3 as parameter in the linear equation to predict log S . XLOGP3 is known to perform well on external datasets and to return similar predictions as CLOGP 28 . The other three parameters were computed with OpenBabel. Likewise, Ali et al . 37 linked log S with log P o/w and TPSA. The model implemented in SwissADME corresponds to the model 3 of the original publication, with XLOGP3 as lipophilicity descriptor. The third solubility method available in SwissADME is the log S estimated by the FILTER-IT program (version 1.0.2, 2013, http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html ). This prediction is based on a system of 16 fragmental contributions modulated by the squared root of MW. All three models are predicting log S values, which are also translated within SwissADME into solubility in mol/l and mg/ml. Finally a qualitative estimation of the solubility class is given according to the following log S scale: insoluble <−10 <poorly <−6 <moderately <−4 <soluble <−2 <very <0 <highly”concept_edges[13]
relationESOL model —is-a→ QSPR model — The ESOL model is a QSPR model. — “Similarly to lipophilicity, the Water Solubility section includes multiple predictive methods for the user to choose between the most accurate model for a given chemical series and an averaged consensus value. The ESOL model 36 is a QSPR model establishing the linear relationship between log S and five molecular parameters, i.e. MW, the number of rotatable bonds, the fraction of aromatic heavy atoms and Daylight’s CLOGP. Because the lipophilicity descriptor is not freely available, the implementation of ESOL in SwissADME replaces CLOGP by XLOGP3 as parameter in the linear equation to predict log S . XLOGP3 is known to perform well on external datasets and to return similar predictions as CLOGP 28 . The other three parameters were computed with OpenBabel. Likewise, Ali et al . 37 linked log S with log P o/w and TPSA. The model implemented in SwissADME corresponds to the model 3 of the original publication, with XLOGP3 as lipophilicity descriptor. The third solubility method available in SwissADME is the log S estimated by the FILTER-IT program (version 1.0.2, 2013, http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html ). This prediction is based on a system of 16 fragmental contributions modulated by the squared root of MW. All three models are predicting log S values, which are also translated within SwissADME into solubility in mol/l and mg/ml. Finally a qualitative estimation of the solubility class is given according to the following log S scale: insoluble <−10 <poorly <−6 <moderately <−4 <soluble <−2 <very <0 <highly”concept_edges[13]
effect directionInhibition of these isoenzymes —causes→ pharmacokinetics-related drug-drug interactions — increases — “Also essential is the knowledge about interaction of molecules with cytochromes P450 (CYP). This superfamily of isoenzymes is a key player in drug elimination through metabolic biotransformation 43 . It has been suggested that CYP and P-gp can process small molecules synergistically to improve protection of tissues and organisms 44 . One can estimate that 50 to 90% (depending on the authors) of therapeutic molecules are substrate of five major isoforms (CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4) 45 46 . Inhibition of these isoenzymes is certainly one major cause of pharmacokinetics-related drug-drug interactions 47 48 leading to toxic or other unwanted adverse effects due to the lower clearance and accumulation of the drug or its metabolites 49 . Numerous inhibitors of the CYP isoforms have been identified. Some are affecting different CYP isoforms, while other compounds show selectivity for specific isoenzymes 50 . It is therefore of great importance for drug discovery to predict the propensity with which the molecule will cause significant drug interactions through inhibition of CYPs, and to determine which isoforms are affected”concept_edges[14]
noteInhibition of these isoenzymes —causes→ pharmacokinetics-related drug-drug interactions — Flat causal assertion; weight below 1.0 because causation is gradable. — “Also essential is the knowledge about interaction of molecules with cytochromes P450 (CYP). This superfamily of isoenzymes is a key player in drug elimination through metabolic biotransformation 43 . It has been suggested that CYP and P-gp can process small molecules synergistically to improve protection of tissues and organisms 44 . One can estimate that 50 to 90% (depending on the authors) of therapeutic molecules are substrate of five major isoforms (CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4) 45 46 . Inhibition of these isoenzymes is certainly one major cause of pharmacokinetics-related drug-drug interactions 47 48 leading to toxic or other unwanted adverse effects due to the lower clearance and accumulation of the drug or its metabolites 49 . Numerous inhibitors of the CYP isoforms have been identified. Some are affecting different CYP isoforms, while other compounds show selectivity for specific isoenzymes 50 . It is therefore of great importance for drug discovery to predict the propensity with which the molecule will cause significant drug interactions through inhibition of CYPs, and to determine which isoforms are affected”concept_edges[14]
relationInhibition of these isoenzymes —causes→ pharmacokinetics-related drug-drug interactions — CYP inhibition is stated to be a major cause of pharmacokinetics-related drug-drug interactions. — “Also essential is the knowledge about interaction of molecules with cytochromes P450 (CYP). This superfamily of isoenzymes is a key player in drug elimination through metabolic biotransformation 43 . It has been suggested that CYP and P-gp can process small molecules synergistically to improve protection of tissues and organisms 44 . One can estimate that 50 to 90% (depending on the authors) of therapeutic molecules are substrate of five major isoforms (CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4) 45 46 . Inhibition of these isoenzymes is certainly one major cause of pharmacokinetics-related drug-drug interactions 47 48 leading to toxic or other unwanted adverse effects due to the lower clearance and accumulation of the drug or its metabolites 49 . Numerous inhibitors of the CYP isoforms have been identified. Some are affecting different CYP isoforms, while other compounds show selectivity for specific isoenzymes 50 . It is therefore of great importance for drug discovery to predict the propensity with which the molecule will cause significant drug interactions through inhibition of CYPs, and to determine which isoforms are affected”concept_edges[14]
weightInhibition of these isoenzymes —causes→ pharmacokinetics-related drug-drug interactions — 0.95 — “Also essential is the knowledge about interaction of molecules with cytochromes P450 (CYP). This superfamily of isoenzymes is a key player in drug elimination through metabolic biotransformation 43 . It has been suggested that CYP and P-gp can process small molecules synergistically to improve protection of tissues and organisms 44 . One can estimate that 50 to 90% (depending on the authors) of therapeutic molecules are substrate of five major isoforms (CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4) 45 46 . Inhibition of these isoenzymes is certainly one major cause of pharmacokinetics-related drug-drug interactions 47 48 leading to toxic or other unwanted adverse effects due to the lower clearance and accumulation of the drug or its metabolites 49 . Numerous inhibitors of the CYP isoforms have been identified. Some are affecting different CYP isoforms, while other compounds show selectivity for specific isoenzymes 50 . It is therefore of great importance for drug discovery to predict the propensity with which the molecule will cause significant drug interactions through inhibition of CYPs, and to determine which isoforms are affected”concept_edges[14]
effect directionpharmacokinetics-related drug-drug interactions —causes→ toxic or other unwanted adverse effects — increases — “Also essential is the knowledge about interaction of molecules with cytochromes P450 (CYP). This superfamily of isoenzymes is a key player in drug elimination through metabolic biotransformation 43 . It has been suggested that CYP and P-gp can process small molecules synergistically to improve protection of tissues and organisms 44 . One can estimate that 50 to 90% (depending on the authors) of therapeutic molecules are substrate of five major isoforms (CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4) 45 46 . Inhibition of these isoenzymes is certainly one major cause of pharmacokinetics-related drug-drug interactions 47 48 leading to toxic or other unwanted adverse effects due to the lower clearance and accumulation of the drug or its metabolites 49 . Numerous inhibitors of the CYP isoforms have been identified. Some are affecting different CYP isoforms, while other compounds show selectivity for specific isoenzymes 50 . It is therefore of great importance for drug discovery to predict the propensity with which the molecule will cause significant drug interactions through inhibition of CYPs, and to determine which isoforms are affected”concept_edges[15]
notepharmacokinetics-related drug-drug interactions —causes→ toxic or other unwanted adverse effects — Direct leading-to clause; positive causal sign checked. — “Also essential is the knowledge about interaction of molecules with cytochromes P450 (CYP). This superfamily of isoenzymes is a key player in drug elimination through metabolic biotransformation 43 . It has been suggested that CYP and P-gp can process small molecules synergistically to improve protection of tissues and organisms 44 . One can estimate that 50 to 90% (depending on the authors) of therapeutic molecules are substrate of five major isoforms (CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4) 45 46 . Inhibition of these isoenzymes is certainly one major cause of pharmacokinetics-related drug-drug interactions 47 48 leading to toxic or other unwanted adverse effects due to the lower clearance and accumulation of the drug or its metabolites 49 . Numerous inhibitors of the CYP isoforms have been identified. Some are affecting different CYP isoforms, while other compounds show selectivity for specific isoenzymes 50 . It is therefore of great importance for drug discovery to predict the propensity with which the molecule will cause significant drug interactions through inhibition of CYPs, and to determine which isoforms are affected”concept_edges[15]
relationpharmacokinetics-related drug-drug interactions —causes→ toxic or other unwanted adverse effects — Drug-drug interactions lead to toxic or other unwanted adverse effects. — “Also essential is the knowledge about interaction of molecules with cytochromes P450 (CYP). This superfamily of isoenzymes is a key player in drug elimination through metabolic biotransformation 43 . It has been suggested that CYP and P-gp can process small molecules synergistically to improve protection of tissues and organisms 44 . One can estimate that 50 to 90% (depending on the authors) of therapeutic molecules are substrate of five major isoforms (CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4) 45 46 . Inhibition of these isoenzymes is certainly one major cause of pharmacokinetics-related drug-drug interactions 47 48 leading to toxic or other unwanted adverse effects due to the lower clearance and accumulation of the drug or its metabolites 49 . Numerous inhibitors of the CYP isoforms have been identified. Some are affecting different CYP isoforms, while other compounds show selectivity for specific isoenzymes 50 . It is therefore of great importance for drug discovery to predict the propensity with which the molecule will cause significant drug interactions through inhibition of CYPs, and to determine which isoforms are affected”concept_edges[15]
weightpharmacokinetics-related drug-drug interactions —causes→ toxic or other unwanted adverse effects — 0.95 — “Also essential is the knowledge about interaction of molecules with cytochromes P450 (CYP). This superfamily of isoenzymes is a key player in drug elimination through metabolic biotransformation 43 . It has been suggested that CYP and P-gp can process small molecules synergistically to improve protection of tissues and organisms 44 . One can estimate that 50 to 90% (depending on the authors) of therapeutic molecules are substrate of five major isoforms (CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4) 45 46 . Inhibition of these isoenzymes is certainly one major cause of pharmacokinetics-related drug-drug interactions 47 48 leading to toxic or other unwanted adverse effects due to the lower clearance and accumulation of the drug or its metabolites 49 . Numerous inhibitors of the CYP isoforms have been identified. Some are affecting different CYP isoforms, while other compounds show selectivity for specific isoenzymes 50 . It is therefore of great importance for drug discovery to predict the propensity with which the molecule will cause significant drug interactions through inhibition of CYPs, and to determine which isoforms are affected”concept_edges[15]
noteleads —contrasted-with→ drug-like molecules — Direct comparative contrast. — “The purpose of this section is to support medicinal chemists in their daily drug discovery endeavours. Two complementary pattern recognition methods allow for identification of potentially problematic fragments. PAINS (for pan assay interference compounds, a.k.a. frequent hitters or promiscuous compounds) are molecules containing substructures showing potent response in assays irrespective of the protein target. Such fragments, yielding false positive biological output, have been identified by Baell et al . 6 in analysing six orthogonal assays and breaking down the molecules active on 2 or more assays into 481 recurrent fragments, considered as potentially leading to promiscuous compounds. SwissADME returns warnings if such moieties are found in the molecule under evaluation. Besides, we implemented Structural Alert, which consists in a list of 105 fragments identified by Brenk et al . 5 to be putatively toxic, chemically reactive, metabolically unstable or to bear properties responsible for poor pharmacokinetics. In SwissADME, it is possible to have a chemical description of the problematic fragments found in a given molecule by flying over the “question mark” icon appearing after the fragment list. This is implemented for both PAINS and Brenk filters. By applying these and other physicochemical filters to design screening libraries, Brenk et al . 5 observed that most of the remaining compounds satisfy criteria for “leadlikeness”. This concept is similar to drug-likeness, yet focusing on physicochemical boundaries defining a good lead, i.e. a molecular entity suitable for optimization. By definition, leads are subjected to chemical modifications that will most likely increase size and lipophilicity 63 . As a consequence, leads are required to be smaller and less hydrophobic than drug-like molecules. Since it is crucial for a chemist to judge whether a given molecule is suitable to initiate lead optimization, in addition to structural filters, we implemented a rule-based method for leadlikeness”concept_edges[16]
relationleads —contrasted-with→ drug-like molecules — Leads are required to be smaller and less hydrophobic than drug-like molecules. — “The purpose of this section is to support medicinal chemists in their daily drug discovery endeavours. Two complementary pattern recognition methods allow for identification of potentially problematic fragments. PAINS (for pan assay interference compounds, a.k.a. frequent hitters or promiscuous compounds) are molecules containing substructures showing potent response in assays irrespective of the protein target. Such fragments, yielding false positive biological output, have been identified by Baell et al . 6 in analysing six orthogonal assays and breaking down the molecules active on 2 or more assays into 481 recurrent fragments, considered as potentially leading to promiscuous compounds. SwissADME returns warnings if such moieties are found in the molecule under evaluation. Besides, we implemented Structural Alert, which consists in a list of 105 fragments identified by Brenk et al . 5 to be putatively toxic, chemically reactive, metabolically unstable or to bear properties responsible for poor pharmacokinetics. In SwissADME, it is possible to have a chemical description of the problematic fragments found in a given molecule by flying over the “question mark” icon appearing after the fragment list. This is implemented for both PAINS and Brenk filters. By applying these and other physicochemical filters to design screening libraries, Brenk et al . 5 observed that most of the remaining compounds satisfy criteria for “leadlikeness”. This concept is similar to drug-likeness, yet focusing on physicochemical boundaries defining a good lead, i.e. a molecular entity suitable for optimization. By definition, leads are subjected to chemical modifications that will most likely increase size and lipophilicity 63 . As a consequence, leads are required to be smaller and less hydrophobic than drug-like molecules. Since it is crucial for a chemist to judge whether a given molecule is suitable to initiate lead optimization, in addition to structural filters, we implemented a rule-based method for leadlikeness”concept_edges[16]
weightleads —contrasted-with→ drug-like molecules — 0.95 — “The purpose of this section is to support medicinal chemists in their daily drug discovery endeavours. Two complementary pattern recognition methods allow for identification of potentially problematic fragments. PAINS (for pan assay interference compounds, a.k.a. frequent hitters or promiscuous compounds) are molecules containing substructures showing potent response in assays irrespective of the protein target. Such fragments, yielding false positive biological output, have been identified by Baell et al . 6 in analysing six orthogonal assays and breaking down the molecules active on 2 or more assays into 481 recurrent fragments, considered as potentially leading to promiscuous compounds. SwissADME returns warnings if such moieties are found in the molecule under evaluation. Besides, we implemented Structural Alert, which consists in a list of 105 fragments identified by Brenk et al . 5 to be putatively toxic, chemically reactive, metabolically unstable or to bear properties responsible for poor pharmacokinetics. In SwissADME, it is possible to have a chemical description of the problematic fragments found in a given molecule by flying over the “question mark” icon appearing after the fragment list. This is implemented for both PAINS and Brenk filters. By applying these and other physicochemical filters to design screening libraries, Brenk et al . 5 observed that most of the remaining compounds satisfy criteria for “leadlikeness”. This concept is similar to drug-likeness, yet focusing on physicochemical boundaries defining a good lead, i.e. a molecular entity suitable for optimization. By definition, leads are subjected to chemical modifications that will most likely increase size and lipophilicity 63 . As a consequence, leads are required to be smaller and less hydrophobic than drug-like molecules. Since it is crucial for a chemist to judge whether a given molecule is suitable to initiate lead optimization, in addition to structural filters, we implemented a rule-based method for leadlikeness”concept_edges[16]
noteSwissADME —part-of→ SwissDrugDesign program — Explicit categorical part-of statement. — “Moreover, SwissADME is an integral part of the SwissDrugDesign program, an ambitious initiative driven by the Molecular Modeling Group of the SIB Swiss Institute of Bioinformatics that aims at providing a collection of free Web-based tools covering many aspects of CADD. As such, SwissADME users can access the different Web sites, through the black toolbar at the top of the page. By clicking on the name of the tool, a new tab opens with the corresponding submission page. We have undertaken the implementation of more advanced interoperability capabilities. At the time of writing this manuscript, three icons were placed top left of the output panel (below the name of the molecule, see Fig. 2 ). They allow one-click submission of the molecule to SwissTargetPrediction (for reverse screening to predict protein target, by clicking on the red target), SwissSimilarity (for ligand-based virtual screening, by clicking on the red twins) and to re-submit the molecule to SwissADME (for instance to get a single compound graphical output, by clicking the red pill). Reversely, other SwissDrugDesign websites include the SwissADME pill icon”concept_edges[17]
relationSwissADME —part-of→ SwissDrugDesign program — SwissADME is an integral part of the SwissDrugDesign program. — “Moreover, SwissADME is an integral part of the SwissDrugDesign program, an ambitious initiative driven by the Molecular Modeling Group of the SIB Swiss Institute of Bioinformatics that aims at providing a collection of free Web-based tools covering many aspects of CADD. As such, SwissADME users can access the different Web sites, through the black toolbar at the top of the page. By clicking on the name of the tool, a new tab opens with the corresponding submission page. We have undertaken the implementation of more advanced interoperability capabilities. At the time of writing this manuscript, three icons were placed top left of the output panel (below the name of the molecule, see Fig. 2 ). They allow one-click submission of the molecule to SwissTargetPrediction (for reverse screening to predict protein target, by clicking on the red target), SwissSimilarity (for ligand-based virtual screening, by clicking on the red twins) and to re-submit the molecule to SwissADME (for instance to get a single compound graphical output, by clicking the red pill). Reversely, other SwissDrugDesign websites include the SwissADME pill icon”concept_edges[17]
relationcomputer models → experiments — Computer models are presented as valid alternatives to experiments. — “To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur. Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. In that context, computer models constitute valid alternatives to experiments. Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar. Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch . Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours”unhoused_relations[0]
weightcomputer models → experiments — 0.95 — “To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur. Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. In that context, computer models constitute valid alternatives to experiments. Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar. Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch . Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours”unhoused_relations[0]
relationpermeability glycoprotein → P-gp — Permeability glycoprotein is abbreviated P-gp. — “The knowledge about compounds being substrate or non-substrate of the permeability glycoprotein (P-gp, suggested the most important member among ATP-binding cassette transporters or ABC-transporters) is key to appraise active efflux through biological membranes, for instance from the gastrointestinal wall to the lumen or from the brain 40 . One major role of P-gp is to protect the central nervous system (CNS) from xenobiotics 41 . Importantly as well, P-gp is overexpressed in some tumour cells and leads to multidrug-resistant cancers”unhoused_relations[1]
relationADME → pharmacokinetics-related failure — Early ADME estimation drastically reduces pharmacokinetics-related failure in clinical phases. — “During the time- and resource-consuming processes of drug discovery and development, a large number of molecular structures are evaluated according to very diverse parameters in order to steer the selection of which chemicals to synthetize, test and promote, with the final goal to identify those with the best chance to become an effective medicine for the patients. The molecules must show high biological activity together with low toxicity. Equally important is the access to and concentration at the therapeutic target in the organism. The traditional way to consider pharmacokinetics (i.e. the fate of a therapeutic compound in the organism) is to break down the various effects that impact the access to the target into individual parameters. In turn, these ADME parameters (for Absorption, Distribution, Metabolism and Excretion) can be evaluated separately by dedicated methods. It has been demonstrated that early estimation of ADME in the discovery phase reduces drastically the fraction of pharmacokinetics-related failure in the clinical phases 1 . Computer models have been fostered as a valid alternative to experimental procedures for prediction of ADME, especially at initial steps, when investigated chemical structures are numerous but the availability of compounds is scarce”unhoused_relations[2]
weightADME → pharmacokinetics-related failure — 0.95 — “During the time- and resource-consuming processes of drug discovery and development, a large number of molecular structures are evaluated according to very diverse parameters in order to steer the selection of which chemicals to synthetize, test and promote, with the final goal to identify those with the best chance to become an effective medicine for the patients. The molecules must show high biological activity together with low toxicity. Equally important is the access to and concentration at the therapeutic target in the organism. The traditional way to consider pharmacokinetics (i.e. the fate of a therapeutic compound in the organism) is to break down the various effects that impact the access to the target into individual parameters. In turn, these ADME parameters (for Absorption, Distribution, Metabolism and Excretion) can be evaluated separately by dedicated methods. It has been demonstrated that early estimation of ADME in the discovery phase reduces drastically the fraction of pharmacokinetics-related failure in the clinical phases 1 . Computer models have been fostered as a valid alternative to experimental procedures for prediction of ADME, especially at initial steps, when investigated chemical structures are numerous but the availability of compounds is scarce”unhoused_relations[2]
relationsubstructure searches → Structural Alert — Substructure searches are the methodological root of Structural Alert filters. — “Whereas physicochemical parameters give a global description of the structure, molecules can be directly described by substructure searches. These techniques are at the root of Structural Alert 5 , the PAINS 6 or the Lilly MedChem 7 filters applied to cleanse chemical libraries from compounds most likely unstable, reactive, toxic, or prone to interfere with biological assays because unspecific frequent hitters, dyes or aggregators”unhoused_relations[3]
weightsubstructure searches → Structural Alert — 0.95 — “Whereas physicochemical parameters give a global description of the structure, molecules can be directly described by substructure searches. These techniques are at the root of Structural Alert 5 , the PAINS 6 or the Lilly MedChem 7 filters applied to cleanse chemical libraries from compounds most likely unstable, reactive, toxic, or prone to interfere with biological assays because unspecific frequent hitters, dyes or aggregators”unhoused_relations[3]
relationmolecular fingerprint → virtual screening — Efficient bit-string handling enables large-scale virtual screening. — “Cheminformaticians developed different molecular descriptors mined from chemical structures. One of the most popular examples is the molecular fingerprint (FP), which consists in a sequence of bits defining the presence or absence of chemical features in a molecule. The FP2 method 9 is one archetype of topological (or path-based) FP, which considers all fragments of the molecular structure following a linear path up to a given number of bonds. Every possible path is hashed to generate the bit string (i.e. the FP). A major advantage of FP is the efficiency by which computers handle such bit strings 10 , allowing for instance large-scale virtual screening or the rapid estimation of synthetic accessibility of molecules 11 . FP are also employed in classification models for ADME behaviours built by support vector machine (SVM) or Bayesian techniques 12 . Remarkably, computer-aided drug design (CADD) has been a pioneer field for the application of such machine learning technologies”unhoused_relations[4]
weightmolecular fingerprint → virtual screening — 0.95 — “Cheminformaticians developed different molecular descriptors mined from chemical structures. One of the most popular examples is the molecular fingerprint (FP), which consists in a sequence of bits defining the presence or absence of chemical features in a molecule. The FP2 method 9 is one archetype of topological (or path-based) FP, which considers all fragments of the molecular structure following a linear path up to a given number of bonds. Every possible path is hashed to generate the bit string (i.e. the FP). A major advantage of FP is the efficiency by which computers handle such bit strings 10 , allowing for instance large-scale virtual screening or the rapid estimation of synthetic accessibility of molecules 11 . FP are also employed in classification models for ADME behaviours built by support vector machine (SVM) or Bayesian techniques 12 . Remarkably, computer-aided drug design (CADD) has been a pioneer field for the application of such machine learning technologies”unhoused_relations[4]
relationmultiple predictions → consensus view — Multiple predictions support a consensus view of a property. — “Because most freely available in silico ADME tools focus on one specific property or model only, while generalist ADME packages are commercial software, we felt the need of gathering what we consider the most relevant computational methods to provide a global appraisal of the pharmacokinetics profile of small molecules. The methods were selected for robustness, speed, but also and importantly for ease of interpretation to enable efficient translation to medicinal chemistry through molecular design. Some of them were adapted with open-source algorithms to ensure freedom to operate for the global scientific community. Others are our own models developed and tested on purpose. When applicable, multiple predictions of the same parameter are provided to allow for a consensus view of a given property”unhoused_relations[5]
weightmultiple predictions → consensus view — 0.95 — “Because most freely available in silico ADME tools focus on one specific property or model only, while generalist ADME packages are commercial software, we felt the need of gathering what we consider the most relevant computational methods to provide a global appraisal of the pharmacokinetics profile of small molecules. The methods were selected for robustness, speed, but also and importantly for ease of interpretation to enable efficient translation to medicinal chemistry through molecular design. Some of them were adapted with open-source algorithms to ensure freedom to operate for the global scientific community. Others are our own models developed and tested on purpose. When applicable, multiple predictions of the same parameter are provided to allow for a consensus view of a given property”unhoused_relations[5]
relationhuman gastrointestinal absorption → BOILED-Egg — Human gastrointestinal absorption is predicted by reading the BOILED-Egg model. — “The predictions for passive human gastrointestinal absorption (HIA) and blood-brain barrier (BBB) permeation both consist in the readout of the BOILED-Egg model 17 , an intuitive graphical classification model, which can be displayed in the SwissADME result page by clicking the red button appearing below the sketcher when all input molecules have been processed (refer to Graphical Output ). Other binary classification models are included, which focus on the propensity for a given small molecule to be substrate or inhibitor of proteins governing important pharmacokinetic behaviours”unhoused_relations[6]
relationP-gp → central nervous system — P-gp protects the central nervous system from xenobiotics. — “The knowledge about compounds being substrate or non-substrate of the permeability glycoprotein (P-gp, suggested the most important member among ATP-binding cassette transporters or ABC-transporters) is key to appraise active efflux through biological membranes, for instance from the gastrointestinal wall to the lumen or from the brain 40 . One major role of P-gp is to protect the central nervous system (CNS) from xenobiotics 41 . Importantly as well, P-gp is overexpressed in some tumour cells and leads to multidrug-resistant cancers”unhoused_relations[7]
relationCYP → P-gp — CYP and P-gp may process small molecules synergistically. — “Also essential is the knowledge about interaction of molecules with cytochromes P450 (CYP). This superfamily of isoenzymes is a key player in drug elimination through metabolic biotransformation 43 . It has been suggested that CYP and P-gp can process small molecules synergistically to improve protection of tissues and organisms 44 . One can estimate that 50 to 90% (depending on the authors) of therapeutic molecules are substrate of five major isoforms (CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4) 45 46 . Inhibition of these isoenzymes is certainly one major cause of pharmacokinetics-related drug-drug interactions 47 48 leading to toxic or other unwanted adverse effects due to the lower clearance and accumulation of the drug or its metabolites 49 . Numerous inhibitors of the CYP isoforms have been identified. Some are affecting different CYP isoforms, while other compounds show selectivity for specific isoenzymes 50 . It is therefore of great importance for drug discovery to predict the propensity with which the molecule will cause significant drug interactions through inhibition of CYPs, and to determine which isoforms are affected”unhoused_relations[8]
weightCYP → P-gp — 0.6 — “Also essential is the knowledge about interaction of molecules with cytochromes P450 (CYP). This superfamily of isoenzymes is a key player in drug elimination through metabolic biotransformation 43 . It has been suggested that CYP and P-gp can process small molecules synergistically to improve protection of tissues and organisms 44 . One can estimate that 50 to 90% (depending on the authors) of therapeutic molecules are substrate of five major isoforms (CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4) 45 46 . Inhibition of these isoenzymes is certainly one major cause of pharmacokinetics-related drug-drug interactions 47 48 leading to toxic or other unwanted adverse effects due to the lower clearance and accumulation of the drug or its metabolites 49 . Numerous inhibitors of the CYP isoforms have been identified. Some are affecting different CYP isoforms, while other compounds show selectivity for specific isoenzymes 50 . It is therefore of great importance for drug discovery to predict the propensity with which the molecule will cause significant drug interactions through inhibition of CYPs, and to determine which isoforms are affected”unhoused_relations[8]
relationtraining and test sets → cross-validation accuracy — Class-imbalanced training and test sets can overestimate accuracy measurements. — “The quantification of the models performance is not straightforwardly comparable, because the training sets are different, most of the published models are less than 10-fold cross-validated and some statistical parameters are missing. Nevertheless, the SwissADME classifiers are competitive with previous models in term of robustness, with cross-validation accuracy (ACC CV ) grossly at the same level. Furthermore, cross-validated areas under receiver operating characteristic (ROC) curves (AUC CV ) are equal to the corresponding values found in the literature. Likewise, external prediction power is difficult to compare, as each test set includes different molecules. However, the predictive capacity of SwissADME classifiers is grossly equivalent to the related SVM methods, both in terms of external accuracy (ACC ext ) and external area under ROC curve (AUC ext ). The models for which external validation was not found (P-gp of refs 15 and 53 ) have to be taken with extreme caution since they possibly suffer from overfitting biases. Noteworthy, some of the published models (e.g. CYP2C9 and CYP3A4 of ref. 54 or CYP2C9 of ref. 55 ) were built on severely unbalanced training sets and tested on clearly unbalanced external sets. As demonstrated by Carbon-Mangels et al . 56 the relevance of machine-learning classification methods, and especially SVM, are negatively impacted by datasets with one significantly more populated class. In that case, accuracy measurements are overestimated and prone to mislead the construction and the evaluation of the model. Moreover, some SVM models were published with small training and test sets (P-gp of refs 15 and 57 ), which imply questionable capacity of generalization and broadness of applicability domains. We emphasize that for SwissADME classifiers, both training and test sets were carefully cleansed and checked for size, diversity and balance between classes. Furthermore, our SVM models rely merely on molecular and physicochemical descriptors generated by SwissADME. We believe that this improves robustness and sustainability of the underlying methodologies. In particular, not using molecular fingerprints, molecular graphs or other structural descriptions can be an handicap to generate high statistical values but should also limit overfitting biases and yield more generalist predictive models, not necessarily influenced by specific chemical scaffolds or moieties. In our practice, these well-performing models able to estimate important ADME behaviours are of great support for pharmacokinetics optimization and evaluation of small molecules”unhoused_relations[9]
weighttraining and test sets → cross-validation accuracy — 0.95 — “The quantification of the models performance is not straightforwardly comparable, because the training sets are different, most of the published models are less than 10-fold cross-validated and some statistical parameters are missing. Nevertheless, the SwissADME classifiers are competitive with previous models in term of robustness, with cross-validation accuracy (ACC CV ) grossly at the same level. Furthermore, cross-validated areas under receiver operating characteristic (ROC) curves (AUC CV ) are equal to the corresponding values found in the literature. Likewise, external prediction power is difficult to compare, as each test set includes different molecules. However, the predictive capacity of SwissADME classifiers is grossly equivalent to the related SVM methods, both in terms of external accuracy (ACC ext ) and external area under ROC curve (AUC ext ). The models for which external validation was not found (P-gp of refs 15 and 53 ) have to be taken with extreme caution since they possibly suffer from overfitting biases. Noteworthy, some of the published models (e.g. CYP2C9 and CYP3A4 of ref. 54 or CYP2C9 of ref. 55 ) were built on severely unbalanced training sets and tested on clearly unbalanced external sets. As demonstrated by Carbon-Mangels et al . 56 the relevance of machine-learning classification methods, and especially SVM, are negatively impacted by datasets with one significantly more populated class. In that case, accuracy measurements are overestimated and prone to mislead the construction and the evaluation of the model. Moreover, some SVM models were published with small training and test sets (P-gp of refs 15 and 57 ), which imply questionable capacity of generalization and broadness of applicability domains. We emphasize that for SwissADME classifiers, both training and test sets were carefully cleansed and checked for size, diversity and balance between classes. Furthermore, our SVM models rely merely on molecular and physicochemical descriptors generated by SwissADME. We believe that this improves robustness and sustainability of the underlying methodologies. In particular, not using molecular fingerprints, molecular graphs or other structural descriptions can be an handicap to generate high statistical values but should also limit overfitting biases and yield more generalist predictive models, not necessarily influenced by specific chemical scaffolds or moieties. In our practice, these well-performing models able to estimate important ADME behaviours are of great support for pharmacokinetics optimization and evaluation of small molecules”unhoused_relations[9]
relationmolecular fingerprints → overfitting biases — Not using molecular fingerprints may limit overfitting biases. — “The quantification of the models performance is not straightforwardly comparable, because the training sets are different, most of the published models are less than 10-fold cross-validated and some statistical parameters are missing. Nevertheless, the SwissADME classifiers are competitive with previous models in term of robustness, with cross-validation accuracy (ACC CV ) grossly at the same level. Furthermore, cross-validated areas under receiver operating characteristic (ROC) curves (AUC CV ) are equal to the corresponding values found in the literature. Likewise, external prediction power is difficult to compare, as each test set includes different molecules. However, the predictive capacity of SwissADME classifiers is grossly equivalent to the related SVM methods, both in terms of external accuracy (ACC ext ) and external area under ROC curve (AUC ext ). The models for which external validation was not found (P-gp of refs 15 and 53 ) have to be taken with extreme caution since they possibly suffer from overfitting biases. Noteworthy, some of the published models (e.g. CYP2C9 and CYP3A4 of ref. 54 or CYP2C9 of ref. 55 ) were built on severely unbalanced training sets and tested on clearly unbalanced external sets. As demonstrated by Carbon-Mangels et al . 56 the relevance of machine-learning classification methods, and especially SVM, are negatively impacted by datasets with one significantly more populated class. In that case, accuracy measurements are overestimated and prone to mislead the construction and the evaluation of the model. Moreover, some SVM models were published with small training and test sets (P-gp of refs 15 and 57 ), which imply questionable capacity of generalization and broadness of applicability domains. We emphasize that for SwissADME classifiers, both training and test sets were carefully cleansed and checked for size, diversity and balance between classes. Furthermore, our SVM models rely merely on molecular and physicochemical descriptors generated by SwissADME. We believe that this improves robustness and sustainability of the underlying methodologies. In particular, not using molecular fingerprints, molecular graphs or other structural descriptions can be an handicap to generate high statistical values but should also limit overfitting biases and yield more generalist predictive models, not necessarily influenced by specific chemical scaffolds or moieties. In our practice, these well-performing models able to estimate important ADME behaviours are of great support for pharmacokinetics optimization and evaluation of small molecules”unhoused_relations[10]
weightmolecular fingerprints → overfitting biases — 0.6 — “The quantification of the models performance is not straightforwardly comparable, because the training sets are different, most of the published models are less than 10-fold cross-validated and some statistical parameters are missing. Nevertheless, the SwissADME classifiers are competitive with previous models in term of robustness, with cross-validation accuracy (ACC CV ) grossly at the same level. Furthermore, cross-validated areas under receiver operating characteristic (ROC) curves (AUC CV ) are equal to the corresponding values found in the literature. Likewise, external prediction power is difficult to compare, as each test set includes different molecules. However, the predictive capacity of SwissADME classifiers is grossly equivalent to the related SVM methods, both in terms of external accuracy (ACC ext ) and external area under ROC curve (AUC ext ). The models for which external validation was not found (P-gp of refs 15 and 53 ) have to be taken with extreme caution since they possibly suffer from overfitting biases. Noteworthy, some of the published models (e.g. CYP2C9 and CYP3A4 of ref. 54 or CYP2C9 of ref. 55 ) were built on severely unbalanced training sets and tested on clearly unbalanced external sets. As demonstrated by Carbon-Mangels et al . 56 the relevance of machine-learning classification methods, and especially SVM, are negatively impacted by datasets with one significantly more populated class. In that case, accuracy measurements are overestimated and prone to mislead the construction and the evaluation of the model. Moreover, some SVM models were published with small training and test sets (P-gp of refs 15 and 57 ), which imply questionable capacity of generalization and broadness of applicability domains. We emphasize that for SwissADME classifiers, both training and test sets were carefully cleansed and checked for size, diversity and balance between classes. Furthermore, our SVM models rely merely on molecular and physicochemical descriptors generated by SwissADME. We believe that this improves robustness and sustainability of the underlying methodologies. In particular, not using molecular fingerprints, molecular graphs or other structural descriptions can be an handicap to generate high statistical values but should also limit overfitting biases and yield more generalist predictive models, not necessarily influenced by specific chemical scaffolds or moieties. In our practice, these well-performing models able to estimate important ADME behaviours are of great support for pharmacokinetics optimization and evaluation of small molecules”unhoused_relations[10]
relationOpenBabel → physicochemical descriptors — OpenBabel computes molecular and physicochemical descriptor values. — “Simple molecular and physicochemical descriptors like molecular weight (MW), molecular refractivity (MR), count of specific atom types and polar surface area (PSA) are compiled in this section. The values are computed with OpenBabel 9 , version 2.3.0. The PSA is calculated using the fragmental technique called topological polar surface area (TPSA), considering sulfur and phosphorus as polar atoms 25 . This has proven a useful descriptor in many models and rules to quickly estimate some ADME properties, especially with regards to biological barrier crossing such as absorption and brain access”unhoused_relations[11]
relationinteroperability → SwissDrugDesign web tools — Interoperability gives direct access to other SwissDrugDesign tools. — “The SwissADME Web tool enables the computation of key physicochemical, pharmacokinetic, drug-like and related parameters for one or multiple molecules. In one hand, efforts were put in the backend to embed free open-access and fast predictive models showing statistical significance, predictive power, intuitive interpretation, and straightforward translation to molecular design. These models are adapted from published renowned approaches or in-house original methods, specially developed and thoroughly benchmarked. On the other hand, we focused on an ergonomic and user-friendly graphical interface for the cost- and login-free Web site http://www.swissadme.ch . The latter enables easy input and efficient analysis of the output through interactive capabilities, and does not require any prior knowledge in CADD. Moreover, interoperability allows for direct access to other SwissDrugDesign web tools, including SwissSimilarity 66 (virtual screening), SwissBioisostere 21 (ligand-based design), SwissTargetPrediction 19 (prediction of biotargets), SwissDock 20 (molecular docking), SwissSideChain 67 (protein modeling) and SwissParam 22 (molecular mechanics). As a result, SwissADME has been designed to support the entire community (specialists and nonexperts) in their drug discovery endeavours”unhoused_relations[12]
no type for thiscomputer models → experiments — Computer models are presented as valid alternatives to experiments. — “To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur. Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. In that context, computer models constitute valid alternatives to experiments. Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar. Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch . Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours”unhoused_relations[0]
no type for thispermeability glycoprotein → P-gp — Permeability glycoprotein is abbreviated P-gp. — “The knowledge about compounds being substrate or non-substrate of the permeability glycoprotein (P-gp, suggested the most important member among ATP-binding cassette transporters or ABC-transporters) is key to appraise active efflux through biological membranes, for instance from the gastrointestinal wall to the lumen or from the brain 40 . One major role of P-gp is to protect the central nervous system (CNS) from xenobiotics 41 . Importantly as well, P-gp is overexpressed in some tumour cells and leads to multidrug-resistant cancers”unhoused_relations[1]
no type for thisADME → pharmacokinetics-related failure — Early ADME estimation drastically reduces pharmacokinetics-related failure in clinical phases. — “During the time- and resource-consuming processes of drug discovery and development, a large number of molecular structures are evaluated according to very diverse parameters in order to steer the selection of which chemicals to synthetize, test and promote, with the final goal to identify those with the best chance to become an effective medicine for the patients. The molecules must show high biological activity together with low toxicity. Equally important is the access to and concentration at the therapeutic target in the organism. The traditional way to consider pharmacokinetics (i.e. the fate of a therapeutic compound in the organism) is to break down the various effects that impact the access to the target into individual parameters. In turn, these ADME parameters (for Absorption, Distribution, Metabolism and Excretion) can be evaluated separately by dedicated methods. It has been demonstrated that early estimation of ADME in the discovery phase reduces drastically the fraction of pharmacokinetics-related failure in the clinical phases 1 . Computer models have been fostered as a valid alternative to experimental procedures for prediction of ADME, especially at initial steps, when investigated chemical structures are numerous but the availability of compounds is scarce”unhoused_relations[2]
no type for thissubstructure searches → Structural Alert — Substructure searches are the methodological root of Structural Alert filters. — “Whereas physicochemical parameters give a global description of the structure, molecules can be directly described by substructure searches. These techniques are at the root of Structural Alert 5 , the PAINS 6 or the Lilly MedChem 7 filters applied to cleanse chemical libraries from compounds most likely unstable, reactive, toxic, or prone to interfere with biological assays because unspecific frequent hitters, dyes or aggregators”unhoused_relations[3]
no type for thismolecular fingerprint → virtual screening — Efficient bit-string handling enables large-scale virtual screening. — “Cheminformaticians developed different molecular descriptors mined from chemical structures. One of the most popular examples is the molecular fingerprint (FP), which consists in a sequence of bits defining the presence or absence of chemical features in a molecule. The FP2 method 9 is one archetype of topological (or path-based) FP, which considers all fragments of the molecular structure following a linear path up to a given number of bonds. Every possible path is hashed to generate the bit string (i.e. the FP). A major advantage of FP is the efficiency by which computers handle such bit strings 10 , allowing for instance large-scale virtual screening or the rapid estimation of synthetic accessibility of molecules 11 . FP are also employed in classification models for ADME behaviours built by support vector machine (SVM) or Bayesian techniques 12 . Remarkably, computer-aided drug design (CADD) has been a pioneer field for the application of such machine learning technologies”unhoused_relations[4]
no type for thismultiple predictions → consensus view — Multiple predictions support a consensus view of a property. — “Because most freely available in silico ADME tools focus on one specific property or model only, while generalist ADME packages are commercial software, we felt the need of gathering what we consider the most relevant computational methods to provide a global appraisal of the pharmacokinetics profile of small molecules. The methods were selected for robustness, speed, but also and importantly for ease of interpretation to enable efficient translation to medicinal chemistry through molecular design. Some of them were adapted with open-source algorithms to ensure freedom to operate for the global scientific community. Others are our own models developed and tested on purpose. When applicable, multiple predictions of the same parameter are provided to allow for a consensus view of a given property”unhoused_relations[5]
no type for thishuman gastrointestinal absorption → BOILED-Egg — Human gastrointestinal absorption is predicted by reading the BOILED-Egg model. — “The predictions for passive human gastrointestinal absorption (HIA) and blood-brain barrier (BBB) permeation both consist in the readout of the BOILED-Egg model 17 , an intuitive graphical classification model, which can be displayed in the SwissADME result page by clicking the red button appearing below the sketcher when all input molecules have been processed (refer to Graphical Output ). Other binary classification models are included, which focus on the propensity for a given small molecule to be substrate or inhibitor of proteins governing important pharmacokinetic behaviours”unhoused_relations[6]
no type for thisP-gp → central nervous system — P-gp protects the central nervous system from xenobiotics. — “The knowledge about compounds being substrate or non-substrate of the permeability glycoprotein (P-gp, suggested the most important member among ATP-binding cassette transporters or ABC-transporters) is key to appraise active efflux through biological membranes, for instance from the gastrointestinal wall to the lumen or from the brain 40 . One major role of P-gp is to protect the central nervous system (CNS) from xenobiotics 41 . Importantly as well, P-gp is overexpressed in some tumour cells and leads to multidrug-resistant cancers”unhoused_relations[7]
no type for thisCYP → P-gp — CYP and P-gp may process small molecules synergistically. — “Also essential is the knowledge about interaction of molecules with cytochromes P450 (CYP). This superfamily of isoenzymes is a key player in drug elimination through metabolic biotransformation 43 . It has been suggested that CYP and P-gp can process small molecules synergistically to improve protection of tissues and organisms 44 . One can estimate that 50 to 90% (depending on the authors) of therapeutic molecules are substrate of five major isoforms (CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4) 45 46 . Inhibition of these isoenzymes is certainly one major cause of pharmacokinetics-related drug-drug interactions 47 48 leading to toxic or other unwanted adverse effects due to the lower clearance and accumulation of the drug or its metabolites 49 . Numerous inhibitors of the CYP isoforms have been identified. Some are affecting different CYP isoforms, while other compounds show selectivity for specific isoenzymes 50 . It is therefore of great importance for drug discovery to predict the propensity with which the molecule will cause significant drug interactions through inhibition of CYPs, and to determine which isoforms are affected”unhoused_relations[8]
no type for thistraining and test sets → cross-validation accuracy — Class-imbalanced training and test sets can overestimate accuracy measurements. — “The quantification of the models performance is not straightforwardly comparable, because the training sets are different, most of the published models are less than 10-fold cross-validated and some statistical parameters are missing. Nevertheless, the SwissADME classifiers are competitive with previous models in term of robustness, with cross-validation accuracy (ACC CV ) grossly at the same level. Furthermore, cross-validated areas under receiver operating characteristic (ROC) curves (AUC CV ) are equal to the corresponding values found in the literature. Likewise, external prediction power is difficult to compare, as each test set includes different molecules. However, the predictive capacity of SwissADME classifiers is grossly equivalent to the related SVM methods, both in terms of external accuracy (ACC ext ) and external area under ROC curve (AUC ext ). The models for which external validation was not found (P-gp of refs 15 and 53 ) have to be taken with extreme caution since they possibly suffer from overfitting biases. Noteworthy, some of the published models (e.g. CYP2C9 and CYP3A4 of ref. 54 or CYP2C9 of ref. 55 ) were built on severely unbalanced training sets and tested on clearly unbalanced external sets. As demonstrated by Carbon-Mangels et al . 56 the relevance of machine-learning classification methods, and especially SVM, are negatively impacted by datasets with one significantly more populated class. In that case, accuracy measurements are overestimated and prone to mislead the construction and the evaluation of the model. Moreover, some SVM models were published with small training and test sets (P-gp of refs 15 and 57 ), which imply questionable capacity of generalization and broadness of applicability domains. We emphasize that for SwissADME classifiers, both training and test sets were carefully cleansed and checked for size, diversity and balance between classes. Furthermore, our SVM models rely merely on molecular and physicochemical descriptors generated by SwissADME. We believe that this improves robustness and sustainability of the underlying methodologies. In particular, not using molecular fingerprints, molecular graphs or other structural descriptions can be an handicap to generate high statistical values but should also limit overfitting biases and yield more generalist predictive models, not necessarily influenced by specific chemical scaffolds or moieties. In our practice, these well-performing models able to estimate important ADME behaviours are of great support for pharmacokinetics optimization and evaluation of small molecules”unhoused_relations[9]
no type for thismolecular fingerprints → overfitting biases — Not using molecular fingerprints may limit overfitting biases. — “The quantification of the models performance is not straightforwardly comparable, because the training sets are different, most of the published models are less than 10-fold cross-validated and some statistical parameters are missing. Nevertheless, the SwissADME classifiers are competitive with previous models in term of robustness, with cross-validation accuracy (ACC CV ) grossly at the same level. Furthermore, cross-validated areas under receiver operating characteristic (ROC) curves (AUC CV ) are equal to the corresponding values found in the literature. Likewise, external prediction power is difficult to compare, as each test set includes different molecules. However, the predictive capacity of SwissADME classifiers is grossly equivalent to the related SVM methods, both in terms of external accuracy (ACC ext ) and external area under ROC curve (AUC ext ). The models for which external validation was not found (P-gp of refs 15 and 53 ) have to be taken with extreme caution since they possibly suffer from overfitting biases. Noteworthy, some of the published models (e.g. CYP2C9 and CYP3A4 of ref. 54 or CYP2C9 of ref. 55 ) were built on severely unbalanced training sets and tested on clearly unbalanced external sets. As demonstrated by Carbon-Mangels et al . 56 the relevance of machine-learning classification methods, and especially SVM, are negatively impacted by datasets with one significantly more populated class. In that case, accuracy measurements are overestimated and prone to mislead the construction and the evaluation of the model. Moreover, some SVM models were published with small training and test sets (P-gp of refs 15 and 57 ), which imply questionable capacity of generalization and broadness of applicability domains. We emphasize that for SwissADME classifiers, both training and test sets were carefully cleansed and checked for size, diversity and balance between classes. Furthermore, our SVM models rely merely on molecular and physicochemical descriptors generated by SwissADME. We believe that this improves robustness and sustainability of the underlying methodologies. In particular, not using molecular fingerprints, molecular graphs or other structural descriptions can be an handicap to generate high statistical values but should also limit overfitting biases and yield more generalist predictive models, not necessarily influenced by specific chemical scaffolds or moieties. In our practice, these well-performing models able to estimate important ADME behaviours are of great support for pharmacokinetics optimization and evaluation of small molecules”unhoused_relations[10]
no type for thisOpenBabel → physicochemical descriptors — OpenBabel computes molecular and physicochemical descriptor values. — “Simple molecular and physicochemical descriptors like molecular weight (MW), molecular refractivity (MR), count of specific atom types and polar surface area (PSA) are compiled in this section. The values are computed with OpenBabel 9 , version 2.3.0. The PSA is calculated using the fragmental technique called topological polar surface area (TPSA), considering sulfur and phosphorus as polar atoms 25 . This has proven a useful descriptor in many models and rules to quickly estimate some ADME properties, especially with regards to biological barrier crossing such as absorption and brain access”unhoused_relations[11]
no type for thisinteroperability → SwissDrugDesign web tools — Interoperability gives direct access to other SwissDrugDesign tools. — “The SwissADME Web tool enables the computation of key physicochemical, pharmacokinetic, drug-like and related parameters for one or multiple molecules. In one hand, efforts were put in the backend to embed free open-access and fast predictive models showing statistical significance, predictive power, intuitive interpretation, and straightforward translation to molecular design. These models are adapted from published renowned approaches or in-house original methods, specially developed and thoroughly benchmarked. On the other hand, we focused on an ergonomic and user-friendly graphical interface for the cost- and login-free Web site http://www.swissadme.ch . The latter enables easy input and efficient analysis of the output through interactive capabilities, and does not require any prior knowledge in CADD. Moreover, interoperability allows for direct access to other SwissDrugDesign web tools, including SwissSimilarity 66 (virtual screening), SwissBioisostere 21 (ligand-based design), SwissTargetPrediction 19 (prediction of biotargets), SwissDock 20 (molecular docking), SwissSideChain 67 (protein modeling) and SwissParam 22 (molecular mechanics). As a result, SwissADME has been designed to support the entire community (specialists and nonexperts) in their drug discovery endeavours”unhoused_relations[12]
limitationAt early discovery stages, compounds are numerous while physical samples are scarce. — “To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur. Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. In that context, computer models constitute valid alternatives to experiments. Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar. Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch . Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours”limitations[0]
limitationMost free in-silico ADME tools cover one property or model, while generalist packages are commercial. — “Because most freely available in silico ADME tools focus on one specific property or model only, while generalist ADME packages are commercial software, we felt the need of gathering what we consider the most relevant computational methods to provide a global appraisal of the pharmacokinetics profile of small molecules. The methods were selected for robustness, speed, but also and importantly for ease of interpretation to enable efficient translation to medicinal chemistry through molecular design. Some of them were adapted with open-source algorithms to ensure freedom to operate for the global scientific community. Others are our own models developed and tested on purpose. When applicable, multiple predictions of the same parameter are provided to allow for a consensus view of a given property”limitations[1]
limitationClassifier performance is difficult to compare when studies use different training and external test sets or omit statistics. — “The quantification of the models performance is not straightforwardly comparable, because the training sets are different, most of the published models are less than 10-fold cross-validated and some statistical parameters are missing. Nevertheless, the SwissADME classifiers are competitive with previous models in term of robustness, with cross-validation accuracy (ACC CV ) grossly at the same level. Furthermore, cross-validated areas under receiver operating characteristic (ROC) curves (AUC CV ) are equal to the corresponding values found in the literature. Likewise, external prediction power is difficult to compare, as each test set includes different molecules. However, the predictive capacity of SwissADME classifiers is grossly equivalent to the related SVM methods, both in terms of external accuracy (ACC ext ) and external area under ROC curve (AUC ext ). The models for which external validation was not found (P-gp of refs 15 and 53 ) have to be taken with extreme caution since they possibly suffer from overfitting biases. Noteworthy, some of the published models (e.g. CYP2C9 and CYP3A4 of ref. 54 or CYP2C9 of ref. 55 ) were built on severely unbalanced training sets and tested on clearly unbalanced external sets. As demonstrated by Carbon-Mangels et al . 56 the relevance of machine-learning classification methods, and especially SVM, are negatively impacted by datasets with one significantly more populated class. In that case, accuracy measurements are overestimated and prone to mislead the construction and the evaluation of the model. Moreover, some SVM models were published with small training and test sets (P-gp of refs 15 and 57 ), which imply questionable capacity of generalization and broadness of applicability domains. We emphasize that for SwissADME classifiers, both training and test sets were carefully cleansed and checked for size, diversity and balance between classes. Furthermore, our SVM models rely merely on molecular and physicochemical descriptors generated by SwissADME. We believe that this improves robustness and sustainability of the underlying methodologies. In particular, not using molecular fingerprints, molecular graphs or other structural descriptions can be an handicap to generate high statistical values but should also limit overfitting biases and yield more generalist predictive models, not necessarily influenced by specific chemical scaffolds or moieties. In our practice, these well-performing models able to estimate important ADME behaviours are of great support for pharmacokinetics optimization and evaluation of small molecules”limitations[2]
limitationModels without external validation may suffer from overfitting. — “The quantification of the models performance is not straightforwardly comparable, because the training sets are different, most of the published models are less than 10-fold cross-validated and some statistical parameters are missing. Nevertheless, the SwissADME classifiers are competitive with previous models in term of robustness, with cross-validation accuracy (ACC CV ) grossly at the same level. Furthermore, cross-validated areas under receiver operating characteristic (ROC) curves (AUC CV ) are equal to the corresponding values found in the literature. Likewise, external prediction power is difficult to compare, as each test set includes different molecules. However, the predictive capacity of SwissADME classifiers is grossly equivalent to the related SVM methods, both in terms of external accuracy (ACC ext ) and external area under ROC curve (AUC ext ). The models for which external validation was not found (P-gp of refs 15 and 53 ) have to be taken with extreme caution since they possibly suffer from overfitting biases. Noteworthy, some of the published models (e.g. CYP2C9 and CYP3A4 of ref. 54 or CYP2C9 of ref. 55 ) were built on severely unbalanced training sets and tested on clearly unbalanced external sets. As demonstrated by Carbon-Mangels et al . 56 the relevance of machine-learning classification methods, and especially SVM, are negatively impacted by datasets with one significantly more populated class. In that case, accuracy measurements are overestimated and prone to mislead the construction and the evaluation of the model. Moreover, some SVM models were published with small training and test sets (P-gp of refs 15 and 57 ), which imply questionable capacity of generalization and broadness of applicability domains. We emphasize that for SwissADME classifiers, both training and test sets were carefully cleansed and checked for size, diversity and balance between classes. Furthermore, our SVM models rely merely on molecular and physicochemical descriptors generated by SwissADME. We believe that this improves robustness and sustainability of the underlying methodologies. In particular, not using molecular fingerprints, molecular graphs or other structural descriptions can be an handicap to generate high statistical values but should also limit overfitting biases and yield more generalist predictive models, not necessarily influenced by specific chemical scaffolds or moieties. In our practice, these well-performing models able to estimate important ADME behaviours are of great support for pharmacokinetics optimization and evaluation of small molecules”limitations[3]
limitationClass imbalance can overestimate accuracy and mislead model construction and evaluation. — “The quantification of the models performance is not straightforwardly comparable, because the training sets are different, most of the published models are less than 10-fold cross-validated and some statistical parameters are missing. Nevertheless, the SwissADME classifiers are competitive with previous models in term of robustness, with cross-validation accuracy (ACC CV ) grossly at the same level. Furthermore, cross-validated areas under receiver operating characteristic (ROC) curves (AUC CV ) are equal to the corresponding values found in the literature. Likewise, external prediction power is difficult to compare, as each test set includes different molecules. However, the predictive capacity of SwissADME classifiers is grossly equivalent to the related SVM methods, both in terms of external accuracy (ACC ext ) and external area under ROC curve (AUC ext ). The models for which external validation was not found (P-gp of refs 15 and 53 ) have to be taken with extreme caution since they possibly suffer from overfitting biases. Noteworthy, some of the published models (e.g. CYP2C9 and CYP3A4 of ref. 54 or CYP2C9 of ref. 55 ) were built on severely unbalanced training sets and tested on clearly unbalanced external sets. As demonstrated by Carbon-Mangels et al . 56 the relevance of machine-learning classification methods, and especially SVM, are negatively impacted by datasets with one significantly more populated class. In that case, accuracy measurements are overestimated and prone to mislead the construction and the evaluation of the model. Moreover, some SVM models were published with small training and test sets (P-gp of refs 15 and 57 ), which imply questionable capacity of generalization and broadness of applicability domains. We emphasize that for SwissADME classifiers, both training and test sets were carefully cleansed and checked for size, diversity and balance between classes. Furthermore, our SVM models rely merely on molecular and physicochemical descriptors generated by SwissADME. We believe that this improves robustness and sustainability of the underlying methodologies. In particular, not using molecular fingerprints, molecular graphs or other structural descriptions can be an handicap to generate high statistical values but should also limit overfitting biases and yield more generalist predictive models, not necessarily influenced by specific chemical scaffolds or moieties. In our practice, these well-performing models able to estimate important ADME behaviours are of great support for pharmacokinetics optimization and evaluation of small molecules”limitations[4]
limitationOmitting fingerprints or molecular graphs can handicap headline statistical values even while limiting scaffold-specific overfitting. — “The quantification of the models performance is not straightforwardly comparable, because the training sets are different, most of the published models are less than 10-fold cross-validated and some statistical parameters are missing. Nevertheless, the SwissADME classifiers are competitive with previous models in term of robustness, with cross-validation accuracy (ACC CV ) grossly at the same level. Furthermore, cross-validated areas under receiver operating characteristic (ROC) curves (AUC CV ) are equal to the corresponding values found in the literature. Likewise, external prediction power is difficult to compare, as each test set includes different molecules. However, the predictive capacity of SwissADME classifiers is grossly equivalent to the related SVM methods, both in terms of external accuracy (ACC ext ) and external area under ROC curve (AUC ext ). The models for which external validation was not found (P-gp of refs 15 and 53 ) have to be taken with extreme caution since they possibly suffer from overfitting biases. Noteworthy, some of the published models (e.g. CYP2C9 and CYP3A4 of ref. 54 or CYP2C9 of ref. 55 ) were built on severely unbalanced training sets and tested on clearly unbalanced external sets. As demonstrated by Carbon-Mangels et al . 56 the relevance of machine-learning classification methods, and especially SVM, are negatively impacted by datasets with one significantly more populated class. In that case, accuracy measurements are overestimated and prone to mislead the construction and the evaluation of the model. Moreover, some SVM models were published with small training and test sets (P-gp of refs 15 and 57 ), which imply questionable capacity of generalization and broadness of applicability domains. We emphasize that for SwissADME classifiers, both training and test sets were carefully cleansed and checked for size, diversity and balance between classes. Furthermore, our SVM models rely merely on molecular and physicochemical descriptors generated by SwissADME. We believe that this improves robustness and sustainability of the underlying methodologies. In particular, not using molecular fingerprints, molecular graphs or other structural descriptions can be an handicap to generate high statistical values but should also limit overfitting biases and yield more generalist predictive models, not necessarily influenced by specific chemical scaffolds or moieties. In our practice, these well-performing models able to estimate important ADME behaviours are of great support for pharmacokinetics optimization and evaluation of small molecules”limitations[5]
limitationThe BOILED-Egg is restricted to passive penetration through the gastrointestinal wall and blood-brain barrier. — “After all calculations completed, the “Show BOILED-Egg” red button appears below the sketcher to display the graphical output on the same page (as exemplify in Fig. 4 ). This consists primarily in the BOILED-Egg, an intuitive method to predict simultaneously two key ADME parameters, i.e. the passive gastrointestinal absorption (HIA) and brain access (BBB). Although conceptually very simple as it relies on two physicochemical descriptors only (WLOGP and TPSA, for lipophilicity and apparent polarity), this classification model was built with extreme care regarding statistical significance and robustness 17 . As shown in Fig. 4 , the egg-shaped classification plot includes the yolk (i.e. the physicochemical space for highly probable BBB permeation) and the white (i.e. the physicochemical space for highly probable HIA absorption). Both compartments are not mutually exclusive and the outside grey region stands for molecules with properties implying predicted low absorption and limited brain penetration. In practice, the BOILED-Egg has proven straightforward interpretation and efficient translation to molecular design in a variety of drug discovery settings. Whereas the predictive power of the BOILED-Egg is broad in term of chemical space, it is restricted to passive penetration through gastro-intestinal wall and BBB. We took benefit of its implementation within SwissADME to enrich the graphical output with the prediction of P-gp substrate, which is the most important active efflux mechanism involved in those biological barriers 40 (refer to the SVM model described in Pharmacokinetics ). As a result, the user conveniently obtains on the same graph a global evaluation about passive absorption (inside/outside the white), passive brain access (inside/outside the yolk) and active efflux from the CNS or to the gastrointestinal lumen by colour-coding”limitations[6]
limitationClosed-source fingerprint information prevented straightforward implementation of a prior synthetic-accessibility method. — “One of the key aspects of CADD activities is to help the selection of the most promising virtual molecules that will be synthetized and submitted to biological assays or other experiments. Synthetic accessibility (SA) is a major factor to consider in this selection process. Obviously, for a reasonable number of molecules, medicinal chemists are the best able to determine SA. However, when too many molecular structures prevent an expert evaluation, in silico estimation can be used for pre-filtering. Ertl & Schuffenhauer 11 proposed a fingerprint-based approach for SA estimation but including closed-source information about fingerprint definition that prevents a straightforward implementation in our tool open to the scientific community. As a consequence, we have built our own fragmental method by analysing more than 13 millions compounds immediately deliverable by vendors. We assumed that the most frequent molecular fragments (technically, FP2 bits, refer to Computational Methods ) in this large collection indicates a probably high SA, while rare fragments imply a difficult synthesis. For a given molecule, the fragmental contributions to SA are summed and corrected by the terms describing size and complexity, such as macrocycles, chiral centres, or spiro functions as defined by Ertl & Schuffenhauer 11 . After normalization, the SA Score ranges from 1 (very easy) to 10 (very difficult). To assess the performance of the method developed for SwissADME, we retrieved two test sets of SA previously published. Both sets involved external molecules, whose difficulty of synthesis was marked from 1 to 10 by nine 11 and four 65 medicinal chemists, respectively. The averaged expert score can then be compared to an in silico SA Score. As seen in Table 2 , the predictive capacity of all three methods appears very dependent of the test set. Indeed the SAs of set 1, smaller and evaluated by more chemists, turned out to be much more robustly predictable than set 2. Human evaluation of synthetic complexity is undeniably subjective and relies on individual chemist’s training and experience. However, significant linear correlation and small errors — especially with SwissADME SA Score that outperformed the reference methods on both sets with smaller errors, and equal or higher linear correlation coefficients — demonstrate how this simple and fast methodology can help prioritizing molecules to synthetize”limitations[7]
limitationSynthetic-accessibility performance depends strongly on the test set, while human complexity ratings are subjective. — “One of the key aspects of CADD activities is to help the selection of the most promising virtual molecules that will be synthetized and submitted to biological assays or other experiments. Synthetic accessibility (SA) is a major factor to consider in this selection process. Obviously, for a reasonable number of molecules, medicinal chemists are the best able to determine SA. However, when too many molecular structures prevent an expert evaluation, in silico estimation can be used for pre-filtering. Ertl & Schuffenhauer 11 proposed a fingerprint-based approach for SA estimation but including closed-source information about fingerprint definition that prevents a straightforward implementation in our tool open to the scientific community. As a consequence, we have built our own fragmental method by analysing more than 13 millions compounds immediately deliverable by vendors. We assumed that the most frequent molecular fragments (technically, FP2 bits, refer to Computational Methods ) in this large collection indicates a probably high SA, while rare fragments imply a difficult synthesis. For a given molecule, the fragmental contributions to SA are summed and corrected by the terms describing size and complexity, such as macrocycles, chiral centres, or spiro functions as defined by Ertl & Schuffenhauer 11 . After normalization, the SA Score ranges from 1 (very easy) to 10 (very difficult). To assess the performance of the method developed for SwissADME, we retrieved two test sets of SA previously published. Both sets involved external molecules, whose difficulty of synthesis was marked from 1 to 10 by nine 11 and four 65 medicinal chemists, respectively. The averaged expert score can then be compared to an in silico SA Score. As seen in Table 2 , the predictive capacity of all three methods appears very dependent of the test set. Indeed the SAs of set 1, smaller and evaluated by more chemists, turned out to be much more robustly predictable than set 2. Human evaluation of synthetic complexity is undeniably subjective and relies on individual chemist’s training and experience. However, significant linear correlation and small errors — especially with SwissADME SA Score that outperformed the reference methods on both sets with smaller errors, and equal or higher linear correlation coefficients — demonstrate how this simple and fast methodology can help prioritizing molecules to synthetize”limitations[8]
Content tags
content-observations: finding · quantity · variable · definition · key-term — grounded in the full text
findingSwissADME provides fast predictive models for physicochemical, pharmacokinetic, drug-likeness, and medicinal-chemistry properties. — “To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur. Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. In that context, computer models constitute valid alternatives to experiments. Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar. Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch . Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours”content_tags.findings[0]
findingThe interface permits rapid multi-molecule prediction for specialists and nonexperts. — “To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur. Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. In that context, computer models constitute valid alternatives to experiments. Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar. Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch . Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours”content_tags.findings[1]
findingMultiple predictions of one property are supplied where possible to support a consensus view. — “Because most freely available in silico ADME tools focus on one specific property or model only, while generalist ADME packages are commercial software, we felt the need of gathering what we consider the most relevant computational methods to provide a global appraisal of the pharmacokinetics profile of small molecules. The methods were selected for robustness, speed, but also and importantly for ease of interpretation to enable efficient translation to medicinal chemistry through molecular design. Some of them were adapted with open-source algorithms to ensure freedom to operate for the global scientific community. Others are our own models developed and tested on purpose. When applicable, multiple predictions of the same parameter are provided to allow for a consensus view of a given property”content_tags.findings[2]
findingA drug-like molecule typically returns a result in one to five seconds at the time reported. — “The input zone itself comprises a molecular sketcher based on ChemAxon’s Marvin JS ( http://www.chemaxon.com ) that enables the user to import (from a file or an external database), draw, and edit a 2D chemical structure, and to transfer it to a list of molecules. This list, on the right-hand side of the submission page, is the actual input for computation. It can be edited as a standard text, allowing for typing or pasting SMILES. The list is made to contain one input molecule per line, defined by a SMILES and optionally a name separated by a space. If name is omitted, SwissADME will automatically provide an identifier. Noteworthy, both buttons for transferring the sketch to SMILES list and for running the computation are dynamic, in the sense that they are active only if the action is possible. At the time of writing, one can expect a result in 1 to 5 seconds for a drug-like molecule”content_tags.findings[3]
findingThe Bioavailability Radar assesses six properties against optimal oral-drug ranges. — “The first section, including two-dimensional chemical structure and canonical SMILES, is located below the title ( Fig. 2 ). It shows on which chemical form the predictions were calculated (refer to Computational Methods ). Moreover, our Bioavailability Radar is displayed for a rapid appraisal of drug-likeness (refer to Fig. 3 ). Six physicochemical properties are taken into account: lipophilicity, size, polarity, solubility, flexibility and saturation. A physicochemical range on each axis was defined by descriptors adapted from refs 23 and 24 and depicted as a pink area in which the radar plot of the molecule has to fall entirely to be considered drug-like. Leaving the mouse over the radar gives further information about the descriptors”content_tags.findings[4]
findingFive lipophilicity predictors are averaged into a consensus log P value. — “The partition coefficient between n -octanol and water (log P o/w ) is the classical descriptor for Lipophilicity . It has a dedicated section in SwissADME due to the critical importance of this physicochemical property for pharmacokinetics drug discovery 26 27 . Many computational methods for log P o/w estimation were developed with diverse performance on various chemical sets. Common practice is to use multiple predictors either to select the most accurate methods for a given chemical series or to generate consensus estimation. The models behind the predictors should be as diverse as possible to increase the prediction accuracy through consensus log P o/w 28 . In that regard, SwissADME gives access to five freely available predictive models; i.e. XLOGP3, an atomistic method including corrective factors and knowledge-based library 29 ; WLOGP, our own implementation of a purely atomistic method based on the fragmental system of Wildman and Crippen 30 ; MLOGP, an archetype of topological method relying on a linear relationship with 13 molecular descriptors implemented from refs 31 and 32 ; SILICOS-IT, an hybrid method relying on 27 fragments and 7 topological descriptors ( http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html , accessed June 2016); and finally iLOGP, our in-house physics-based method relying on free energies of solvation in n -octanol and water calculated by the Generalized-Born and solvent accessible surface area (GB/SA) model. iLOGP was benchmarked on two drug or drug-like external sets and performed equally as or better than six well-established predictors 16 . The consensus log P o/w is the arithmetic mean of the values predicted by the five proposed methods”content_tags.findings[5]
findingSwissADME supplies three water-solubility predictions and qualitative solubility classes. — “Having a soluble molecule greatly facilitates many drug development activities, primarily the ease of handling and formulation 33 . Moreover, for discovery projects targeting oral administration, solubility is one major property influencing absorption 34 . As well, a drug meant for parenteral usage has to be highly soluble in water to deliver a sufficient quantity of active ingredient in the small volume of such pharmaceutical dosage 35 . Two topological methods to predict Water Solubility are included in SwissADME. The first one is an implementation of the ESOL model 36 and the second one is adapted from Ali et al . 37 . Both differ from the seminal general solubility equation 38 since they avoid the melting point parameter; the latter being challenging to predict. Moreover they demonstrate strong linear correlation between predicted and experimental values (R 2 = 0.69 and 0.81, respectively). SwissADME third predictor for solubility was developed by SILICOS-IT. The linear correlation coefficient of this fragmental method corrected by molecular weight is R 2 = 0.75 ( http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html , accessed June 2016). All predicted values are the decimal logarithm of the molar solubility in water (log S ). SwissADME also provides solubility in mol/l and mg/ml along with qualitative solubility classes”content_tags.findings[6]
findingSwissADME predicts P-gp substrate status and inhibition of five major CYP isoenzymes. — “SwissADME enables the estimation for a chemical to be substrate of P-gp or inhibitor of the most important CYP isoenzymes. We applied the support vector machine algorithm (SVM) 51 on meticulously cleansed large datasets of known substrates/non-substrates or inhibitors/non-inhibitors (for details, see Computational Methods ). In similar contexts, SVM was found to perform better than other machine-learning algorithms for binary classification 40 52 . The models return “Yes” or “No” if the molecule under investigation has higher probability to be substrate or non-substrate of P-gp (respectively inhibitor or non-inhibitor of a given CYP). The statistical performance of the classification models is given in Table 1 , in comparison with previous SVM models on the same targets. We restricted the benchmark to state-of-the-art methods, published after 2010”content_tags.findings[7]
findingSwissADME classifiers show roughly comparable robustness and predictive power to prior SVM models. — “The quantification of the models performance is not straightforwardly comparable, because the training sets are different, most of the published models are less than 10-fold cross-validated and some statistical parameters are missing. Nevertheless, the SwissADME classifiers are competitive with previous models in term of robustness, with cross-validation accuracy (ACC CV ) grossly at the same level. Furthermore, cross-validated areas under receiver operating characteristic (ROC) curves (AUC CV ) are equal to the corresponding values found in the literature. Likewise, external prediction power is difficult to compare, as each test set includes different molecules. However, the predictive capacity of SwissADME classifiers is grossly equivalent to the related SVM methods, both in terms of external accuracy (ACC ext ) and external area under ROC curve (AUC ext ). The models for which external validation was not found (P-gp of refs 15 and 53 ) have to be taken with extreme caution since they possibly suffer from overfitting biases. Noteworthy, some of the published models (e.g. CYP2C9 and CYP3A4 of ref. 54 or CYP2C9 of ref. 55 ) were built on severely unbalanced training sets and tested on clearly unbalanced external sets. As demonstrated by Carbon-Mangels et al . 56 the relevance of machine-learning classification methods, and especially SVM, are negatively impacted by datasets with one significantly more populated class. In that case, accuracy measurements are overestimated and prone to mislead the construction and the evaluation of the model. Moreover, some SVM models were published with small training and test sets (P-gp of refs 15 and 57 ), which imply questionable capacity of generalization and broadness of applicability domains. We emphasize that for SwissADME classifiers, both training and test sets were carefully cleansed and checked for size, diversity and balance between classes. Furthermore, our SVM models rely merely on molecular and physicochemical descriptors generated by SwissADME. We believe that this improves robustness and sustainability of the underlying methodologies. In particular, not using molecular fingerprints, molecular graphs or other structural descriptions can be an handicap to generate high statistical values but should also limit overfitting biases and yield more generalist predictive models, not necessarily influenced by specific chemical scaffolds or moieties. In our practice, these well-performing models able to estimate important ADME behaviours are of great support for pharmacokinetics optimization and evaluation of small molecules”content_tags.findings[8]
findingCareful data cleansing, diversity, and balance are used to support classifier robustness. — “The quantification of the models performance is not straightforwardly comparable, because the training sets are different, most of the published models are less than 10-fold cross-validated and some statistical parameters are missing. Nevertheless, the SwissADME classifiers are competitive with previous models in term of robustness, with cross-validation accuracy (ACC CV ) grossly at the same level. Furthermore, cross-validated areas under receiver operating characteristic (ROC) curves (AUC CV ) are equal to the corresponding values found in the literature. Likewise, external prediction power is difficult to compare, as each test set includes different molecules. However, the predictive capacity of SwissADME classifiers is grossly equivalent to the related SVM methods, both in terms of external accuracy (ACC ext ) and external area under ROC curve (AUC ext ). The models for which external validation was not found (P-gp of refs 15 and 53 ) have to be taken with extreme caution since they possibly suffer from overfitting biases. Noteworthy, some of the published models (e.g. CYP2C9 and CYP3A4 of ref. 54 or CYP2C9 of ref. 55 ) were built on severely unbalanced training sets and tested on clearly unbalanced external sets. As demonstrated by Carbon-Mangels et al . 56 the relevance of machine-learning classification methods, and especially SVM, are negatively impacted by datasets with one significantly more populated class. In that case, accuracy measurements are overestimated and prone to mislead the construction and the evaluation of the model. Moreover, some SVM models were published with small training and test sets (P-gp of refs 15 and 57 ), which imply questionable capacity of generalization and broadness of applicability domains. We emphasize that for SwissADME classifiers, both training and test sets were carefully cleansed and checked for size, diversity and balance between classes. Furthermore, our SVM models rely merely on molecular and physicochemical descriptors generated by SwissADME. We believe that this improves robustness and sustainability of the underlying methodologies. In particular, not using molecular fingerprints, molecular graphs or other structural descriptions can be an handicap to generate high statistical values but should also limit overfitting biases and yield more generalist predictive models, not necessarily influenced by specific chemical scaffolds or moieties. In our practice, these well-performing models able to estimate important ADME behaviours are of great support for pharmacokinetics optimization and evaluation of small molecules”content_tags.findings[9]
findingThe SwissADME SA Score outperformed two reference methods on both external sets by errors and correlation. — “One of the key aspects of CADD activities is to help the selection of the most promising virtual molecules that will be synthetized and submitted to biological assays or other experiments. Synthetic accessibility (SA) is a major factor to consider in this selection process. Obviously, for a reasonable number of molecules, medicinal chemists are the best able to determine SA. However, when too many molecular structures prevent an expert evaluation, in silico estimation can be used for pre-filtering. Ertl & Schuffenhauer 11 proposed a fingerprint-based approach for SA estimation but including closed-source information about fingerprint definition that prevents a straightforward implementation in our tool open to the scientific community. As a consequence, we have built our own fragmental method by analysing more than 13 millions compounds immediately deliverable by vendors. We assumed that the most frequent molecular fragments (technically, FP2 bits, refer to Computational Methods ) in this large collection indicates a probably high SA, while rare fragments imply a difficult synthesis. For a given molecule, the fragmental contributions to SA are summed and corrected by the terms describing size and complexity, such as macrocycles, chiral centres, or spiro functions as defined by Ertl & Schuffenhauer 11 . After normalization, the SA Score ranges from 1 (very easy) to 10 (very difficult). To assess the performance of the method developed for SwissADME, we retrieved two test sets of SA previously published. Both sets involved external molecules, whose difficulty of synthesis was marked from 1 to 10 by nine 11 and four 65 medicinal chemists, respectively. The averaged expert score can then be compared to an in silico SA Score. As seen in Table 2 , the predictive capacity of all three methods appears very dependent of the test set. Indeed the SAs of set 1, smaller and evaluated by more chemists, turned out to be much more robustly predictable than set 2. Human evaluation of synthetic complexity is undeniably subjective and relies on individual chemist’s training and experience. However, significant linear correlation and small errors — especially with SwissADME SA Score that outperformed the reference methods on both sets with smaller errors, and equal or higher linear correlation coefficients — demonstrate how this simple and fast methodology can help prioritizing molecules to synthetize”content_tags.findings[10]
findingThe BOILED-Egg combines passive HIA and BBB predictions with active P-gp efflux status. — “After all calculations completed, the “Show BOILED-Egg” red button appears below the sketcher to display the graphical output on the same page (as exemplify in Fig. 4 ). This consists primarily in the BOILED-Egg, an intuitive method to predict simultaneously two key ADME parameters, i.e. the passive gastrointestinal absorption (HIA) and brain access (BBB). Although conceptually very simple as it relies on two physicochemical descriptors only (WLOGP and TPSA, for lipophilicity and apparent polarity), this classification model was built with extreme care regarding statistical significance and robustness 17 . As shown in Fig. 4 , the egg-shaped classification plot includes the yolk (i.e. the physicochemical space for highly probable BBB permeation) and the white (i.e. the physicochemical space for highly probable HIA absorption). Both compartments are not mutually exclusive and the outside grey region stands for molecules with properties implying predicted low absorption and limited brain penetration. In practice, the BOILED-Egg has proven straightforward interpretation and efficient translation to molecular design in a variety of drug discovery settings. Whereas the predictive power of the BOILED-Egg is broad in term of chemical space, it is restricted to passive penetration through gastro-intestinal wall and BBB. We took benefit of its implementation within SwissADME to enrich the graphical output with the prediction of P-gp substrate, which is the most important active efflux mechanism involved in those biological barriers 40 (refer to the SVM model described in Pharmacokinetics ). As a result, the user conveniently obtains on the same graph a global evaluation about passive absorption (inside/outside the white), passive brain access (inside/outside the yolk) and active efflux from the CNS or to the gastrointestinal lumen by colour-coding”content_tags.findings[11]
findingResults can be saved or shared as CSV or clipboard data. — “SwissADME is user-friendly and has been conceived for a variety of users, including nonexpert in cheminformatics or computational chemistry. Efforts were put to insure ease of input and interpretability of output. These aspects are supported by the Help page, which provides technical guidance on the usage of the website and by the FAQ , where we collected not only technical but also scientific and general questions. Contextual help about specific items can be displayed by leaving the mouse over question marks or some boxes on the pages. Moreover, SwissADME is an integral part of the SwissDrugDesign program, an ambitious initiative driven by the Molecular Modeling Group of the SIB Swiss Institute of Bioinformatics that aims at providing a collection of free Web-based tools covering many aspects of CADD. As such, SwissADME users can access the different Web sites, through the black toolbar at the top of the page. By clicking on the name of the tool, a new tab opens with the corresponding submission page. We have undertaken the implementation of more advanced interoperability capabilities. At the time of writing this manuscript, three icons were placed top left of the output panel (below the name of the molecule, see Fig. 2 ). They allow one-click submission of the molecule to SwissTargetPrediction (for reverse screening to predict protein target, by clicking on the red target), SwissSimilarity (for ligand-based virtual screening, by clicking on the red twins) and to re-submit the molecule to SwissADME (for instance to get a single compound graphical output, by clicking the red pill). Reversely, other SwissDrugDesign websites include the SwissADME pill icon for estimation of ADME, pharmacokinetics, drug-likeness and medicinal chemistry friendliness regarding a small molecule output of any CADD process. Importantly, the user has the opportunity to save or share SwissADME results in files (CSV) or by copying the values in the clipboard of the local computer and pasting in text or spreadsheet applications for further processing”content_tags.findings[12]
findingSwissADME supports one-click transfer to other SwissDrugDesign tools. — “Moreover, SwissADME is an integral part of the SwissDrugDesign program, an ambitious initiative driven by the Molecular Modeling Group of the SIB Swiss Institute of Bioinformatics that aims at providing a collection of free Web-based tools covering many aspects of CADD. As such, SwissADME users can access the different Web sites, through the black toolbar at the top of the page. By clicking on the name of the tool, a new tab opens with the corresponding submission page. We have undertaken the implementation of more advanced interoperability capabilities. At the time of writing this manuscript, three icons were placed top left of the output panel (below the name of the molecule, see Fig. 2 ). They allow one-click submission of the molecule to SwissTargetPrediction (for reverse screening to predict protein target, by clicking on the red target), SwissSimilarity (for ligand-based virtual screening, by clicking on the red twins) and to re-submit the molecule to SwissADME (for instance to get a single compound graphical output, by clicking the red pill). Reversely, other SwissDrugDesign websites include the SwissADME pill icon”content_tags.findings[13]
quantity1 to 5 seconds — expected result time for one drug-like molecule — “The input zone itself comprises a molecular sketcher based on ChemAxon’s Marvin JS ( http://www.chemaxon.com ) that enables the user to import (from a file or an external database), draw, and edit a 2D chemical structure, and to transfer it to a list of molecules. This list, on the right-hand side of the submission page, is the actual input for computation. It can be edited as a standard text, allowing for typing or pasting SMILES. The list is made to contain one input molecule per line, defined by a SMILES and optionally a name separated by a space. If name is omitted, SwissADME will automatically provide an identifier. Noteworthy, both buttons for transferring the sketch to SMILES list and for running the computation are dynamic, in the sense that they are active only if the action is possible. At the time of writing, one can expect a result in 1 to 5 seconds for a drug-like molecule”content_tags.quantities[0]
quantitysix — physicochemical axes in the Bioavailability Radar — “The Bioavailability Radar in the first section of the One-panel-per-molecule output complements the two-dimensional image from the JChem webserver and the canonical SMILES calculated by OpenBabel. We use the JpGraph PHP library (version 3.5.0b1, 2016, http://jpgraph.net ) to produce the radar plot, which bears six axes for six important properties for oral bioavailability. Each property is defined by a descriptor of SwissADME and a range of optimal values is depicted as a pink area. The latter is inspired from commonly accepted bioavailability and drug-likeness guidelines 23 24 . For saturation, the ratio of sp 3 hybridized carbons over the total carbon count of the molecule (Fraction Csp3) should be at least 0.25. For size, the molecular weight (MW calculated by OpenBabel) should be between 150 and 500 g/mol. For polarity, the TPSA 25 should be between 20 and 130Å 2 . For solubility, log S (calculated with the ESOL model 36 ) should not exceed 6. For lipophilicity, XLOGP3 29 should be in the range from −0.7 to +6.0. For flexibility, the molecule should not have more than 9 rotatable bonds. To be estimated as drug-like, the red line of the compound under study must be fully included in the pink area. Any deviation represents a suboptimal physicochemical property for oral bioavailability”content_tags.quantities[1]
quantity150 and 500 g/mol — optimal molecular-weight range in the radar — “The Bioavailability Radar in the first section of the One-panel-per-molecule output complements the two-dimensional image from the JChem webserver and the canonical SMILES calculated by OpenBabel. We use the JpGraph PHP library (version 3.5.0b1, 2016, http://jpgraph.net ) to produce the radar plot, which bears six axes for six important properties for oral bioavailability. Each property is defined by a descriptor of SwissADME and a range of optimal values is depicted as a pink area. The latter is inspired from commonly accepted bioavailability and drug-likeness guidelines 23 24 . For saturation, the ratio of sp 3 hybridized carbons over the total carbon count of the molecule (Fraction Csp3) should be at least 0.25. For size, the molecular weight (MW calculated by OpenBabel) should be between 150 and 500 g/mol. For polarity, the TPSA 25 should be between 20 and 130Å 2 . For solubility, log S (calculated with the ESOL model 36 ) should not exceed 6. For lipophilicity, XLOGP3 29 should be in the range from −0.7 to +6.0. For flexibility, the molecule should not have more than 9 rotatable bonds. To be estimated as drug-like, the red line of the compound under study must be fully included in the pink area. Any deviation represents a suboptimal physicochemical property for oral bioavailability”content_tags.quantities[2]
quantity20 and 130Å 2 — optimal TPSA range in the radar — “The Bioavailability Radar in the first section of the One-panel-per-molecule output complements the two-dimensional image from the JChem webserver and the canonical SMILES calculated by OpenBabel. We use the JpGraph PHP library (version 3.5.0b1, 2016, http://jpgraph.net ) to produce the radar plot, which bears six axes for six important properties for oral bioavailability. Each property is defined by a descriptor of SwissADME and a range of optimal values is depicted as a pink area. The latter is inspired from commonly accepted bioavailability and drug-likeness guidelines 23 24 . For saturation, the ratio of sp 3 hybridized carbons over the total carbon count of the molecule (Fraction Csp3) should be at least 0.25. For size, the molecular weight (MW calculated by OpenBabel) should be between 150 and 500 g/mol. For polarity, the TPSA 25 should be between 20 and 130Å 2 . For solubility, log S (calculated with the ESOL model 36 ) should not exceed 6. For lipophilicity, XLOGP3 29 should be in the range from −0.7 to +6.0. For flexibility, the molecule should not have more than 9 rotatable bonds. To be estimated as drug-like, the red line of the compound under study must be fully included in the pink area. Any deviation represents a suboptimal physicochemical property for oral bioavailability”content_tags.quantities[3]
quantity−0.7 to +6.0 — optimal XLOGP3 range in the radar — “The Bioavailability Radar in the first section of the One-panel-per-molecule output complements the two-dimensional image from the JChem webserver and the canonical SMILES calculated by OpenBabel. We use the JpGraph PHP library (version 3.5.0b1, 2016, http://jpgraph.net ) to produce the radar plot, which bears six axes for six important properties for oral bioavailability. Each property is defined by a descriptor of SwissADME and a range of optimal values is depicted as a pink area. The latter is inspired from commonly accepted bioavailability and drug-likeness guidelines 23 24 . For saturation, the ratio of sp 3 hybridized carbons over the total carbon count of the molecule (Fraction Csp3) should be at least 0.25. For size, the molecular weight (MW calculated by OpenBabel) should be between 150 and 500 g/mol. For polarity, the TPSA 25 should be between 20 and 130Å 2 . For solubility, log S (calculated with the ESOL model 36 ) should not exceed 6. For lipophilicity, XLOGP3 29 should be in the range from −0.7 to +6.0. For flexibility, the molecule should not have more than 9 rotatable bonds. To be estimated as drug-like, the red line of the compound under study must be fully included in the pink area. Any deviation represents a suboptimal physicochemical property for oral bioavailability”content_tags.quantities[4]
quantity9 rotatable bonds — maximum flexibility threshold in the radar — “The Bioavailability Radar in the first section of the One-panel-per-molecule output complements the two-dimensional image from the JChem webserver and the canonical SMILES calculated by OpenBabel. We use the JpGraph PHP library (version 3.5.0b1, 2016, http://jpgraph.net ) to produce the radar plot, which bears six axes for six important properties for oral bioavailability. Each property is defined by a descriptor of SwissADME and a range of optimal values is depicted as a pink area. The latter is inspired from commonly accepted bioavailability and drug-likeness guidelines 23 24 . For saturation, the ratio of sp 3 hybridized carbons over the total carbon count of the molecule (Fraction Csp3) should be at least 0.25. For size, the molecular weight (MW calculated by OpenBabel) should be between 150 and 500 g/mol. For polarity, the TPSA 25 should be between 20 and 130Å 2 . For solubility, log S (calculated with the ESOL model 36 ) should not exceed 6. For lipophilicity, XLOGP3 29 should be in the range from −0.7 to +6.0. For flexibility, the molecule should not have more than 9 rotatable bonds. To be estimated as drug-like, the red line of the compound under study must be fully included in the pink area. Any deviation represents a suboptimal physicochemical property for oral bioavailability”content_tags.quantities[5]
quantity0.69 and 0.81 — linear-correlation R-squared values for two solubility predictors — “Having a soluble molecule greatly facilitates many drug development activities, primarily the ease of handling and formulation 33 . Moreover, for discovery projects targeting oral administration, solubility is one major property influencing absorption 34 . As well, a drug meant for parenteral usage has to be highly soluble in water to deliver a sufficient quantity of active ingredient in the small volume of such pharmaceutical dosage 35 . Two topological methods to predict Water Solubility are included in SwissADME. The first one is an implementation of the ESOL model 36 and the second one is adapted from Ali et al . 37 . Both differ from the seminal general solubility equation 38 since they avoid the melting point parameter; the latter being challenging to predict. Moreover they demonstrate strong linear correlation between predicted and experimental values (R 2 = 0.69 and 0.81, respectively). SwissADME third predictor for solubility was developed by SILICOS-IT. The linear correlation coefficient of this fragmental method corrected by molecular weight is R 2 = 0.75 ( http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html , accessed June 2016). All predicted values are the decimal logarithm of the molar solubility in water (log S ). SwissADME also provides solubility in mol/l and mg/ml along with qualitative solubility classes”content_tags.quantities[6]
quantity50 to 90% — estimated fraction of therapeutic molecules handled by five major CYP isoforms — “Also essential is the knowledge about interaction of molecules with cytochromes P450 (CYP). This superfamily of isoenzymes is a key player in drug elimination through metabolic biotransformation 43 . It has been suggested that CYP and P-gp can process small molecules synergistically to improve protection of tissues and organisms 44 . One can estimate that 50 to 90% (depending on the authors) of therapeutic molecules are substrate of five major isoforms (CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4) 45 46 . Inhibition of these isoenzymes is certainly one major cause of pharmacokinetics-related drug-drug interactions 47 48 leading to toxic or other unwanted adverse effects due to the lower clearance and accumulation of the drug or its metabolites 49 . Numerous inhibitors of the CYP isoforms have been identified. Some are affecting different CYP isoforms, while other compounds show selectivity for specific isoenzymes 50 . It is therefore of great importance for drug discovery to predict the propensity with which the molecule will cause significant drug interactions through inhibition of CYPs, and to determine which isoforms are affected”content_tags.quantities[7]
quantity11%, 17%, 56% or 85% — Bioavailability Score class probabilities — “As defined earlier, “drug-likeness” assesses qualitatively the chance for a molecule to become an oral drug with respect to bioavailability. Drug-likeness was established from structural or physicochemical inspections of development compounds advanced enough to be considered oral drug-candidates. This notion is routinely employed to perform filtering of chemical libraries to exclude molecules with properties most probably incompatible with an acceptable pharmacokinetics profile. This SwissADME section gives access to five different rule-based filters, with diverse ranges of properties inside of which the molecule is defined as drug-like. These filters often originate from analyses by major pharmaceutical companies aiming to improve the quality of their proprietary chemical collections. The Lipinski (Pfizer) filter is the pioneer rule-of-five implemented from ref. 4 . The Ghose (Amgen), Veber (GSK), Egan (Pharmacia) and Muegge (Bayer) methods were adapted from refs 58 , 59 , 60 , 61 , respectively. Multiple estimations allow consensus views or selection of methods best fitting the end-user’s specific needs in terms of chemical space or project-related demands. Any violation of any rule described here appears explicitly in the output panel. The Abbot Bioavailability Score 62 is similar but seeks to predict the probability of a compound to have at least 10% oral bioavailability in rat or measurable Caco-2 permeability. This semi-quantitative rule-based score relying on total charge, TPSA, and violation to the Lipinski filter defines four classes of compounds with probabilities of 11%, 17%, 56% or 85%. Like the other methods in this section, it primary focuses on the fast screening of chemical libraries, to select the best molecules to be purchased, synthetized or promoted at a further stage of a medicinal chemistry project”content_tags.quantities[8]
quantity481 recurrent fragments — PAINS fragments derived from assay analysis — “The purpose of this section is to support medicinal chemists in their daily drug discovery endeavours. Two complementary pattern recognition methods allow for identification of potentially problematic fragments. PAINS (for pan assay interference compounds, a.k.a. frequent hitters or promiscuous compounds) are molecules containing substructures showing potent response in assays irrespective of the protein target. Such fragments, yielding false positive biological output, have been identified by Baell et al . 6 in analysing six orthogonal assays and breaking down the molecules active on 2 or more assays into 481 recurrent fragments, considered as potentially leading to promiscuous compounds. SwissADME returns warnings if such moieties are found in the molecule under evaluation. Besides, we implemented Structural Alert, which consists in a list of 105 fragments identified by Brenk et al . 5 to be putatively toxic, chemically reactive, metabolically unstable or to bear properties responsible for poor pharmacokinetics. In SwissADME, it is possible to have a chemical description of the problematic fragments found in a given molecule by flying over the “question mark” icon appearing after the fragment list. This is implemented for both PAINS and Brenk filters. By applying these and other physicochemical filters to design screening libraries, Brenk et al . 5 observed that most of the remaining compounds satisfy criteria for “leadlikeness”. This concept is similar to drug-likeness, yet focusing on physicochemical boundaries defining a good lead, i.e. a molecular entity suitable for optimization. By definition, leads are subjected to chemical modifications that will most likely increase size and lipophilicity 63 . As a consequence, leads are required to be smaller and less hydrophobic than drug-like molecules. Since it is crucial for a chemist to judge whether a given molecule is suitable to initiate lead optimization, in addition to structural filters, we implemented a rule-based method for leadlikeness”content_tags.quantities[9]
quantity105 fragments — Brenk Structural Alert fragments — “The purpose of this section is to support medicinal chemists in their daily drug discovery endeavours. Two complementary pattern recognition methods allow for identification of potentially problematic fragments. PAINS (for pan assay interference compounds, a.k.a. frequent hitters or promiscuous compounds) are molecules containing substructures showing potent response in assays irrespective of the protein target. Such fragments, yielding false positive biological output, have been identified by Baell et al . 6 in analysing six orthogonal assays and breaking down the molecules active on 2 or more assays into 481 recurrent fragments, considered as potentially leading to promiscuous compounds. SwissADME returns warnings if such moieties are found in the molecule under evaluation. Besides, we implemented Structural Alert, which consists in a list of 105 fragments identified by Brenk et al . 5 to be putatively toxic, chemically reactive, metabolically unstable or to bear properties responsible for poor pharmacokinetics. In SwissADME, it is possible to have a chemical description of the problematic fragments found in a given molecule by flying over the “question mark” icon appearing after the fragment list. This is implemented for both PAINS and Brenk filters. By applying these and other physicochemical filters to design screening libraries, Brenk et al . 5 observed that most of the remaining compounds satisfy criteria for “leadlikeness”. This concept is similar to drug-likeness, yet focusing on physicochemical boundaries defining a good lead, i.e. a molecular entity suitable for optimization. By definition, leads are subjected to chemical modifications that will most likely increase size and lipophilicity 63 . As a consequence, leads are required to be smaller and less hydrophobic than drug-like molecules. Since it is crucial for a chemist to judge whether a given molecule is suitable to initiate lead optimization, in addition to structural filters, we implemented a rule-based method for leadlikeness”content_tags.quantities[10]
quantitymore than 13 millions compounds — vendor-available collection used to derive fragment frequencies — “One of the key aspects of CADD activities is to help the selection of the most promising virtual molecules that will be synthetized and submitted to biological assays or other experiments. Synthetic accessibility (SA) is a major factor to consider in this selection process. Obviously, for a reasonable number of molecules, medicinal chemists are the best able to determine SA. However, when too many molecular structures prevent an expert evaluation, in silico estimation can be used for pre-filtering. Ertl & Schuffenhauer 11 proposed a fingerprint-based approach for SA estimation but including closed-source information about fingerprint definition that prevents a straightforward implementation in our tool open to the scientific community. As a consequence, we have built our own fragmental method by analysing more than 13 millions compounds immediately deliverable by vendors. We assumed that the most frequent molecular fragments (technically, FP2 bits, refer to Computational Methods ) in this large collection indicates a probably high SA, while rare fragments imply a difficult synthesis. For a given molecule, the fragmental contributions to SA are summed and corrected by the terms describing size and complexity, such as macrocycles, chiral centres, or spiro functions as defined by Ertl & Schuffenhauer 11 . After normalization, the SA Score ranges from 1 (very easy) to 10 (very difficult). To assess the performance of the method developed for SwissADME, we retrieved two test sets of SA previously published. Both sets involved external molecules, whose difficulty of synthesis was marked from 1 to 10 by nine 11 and four 65 medicinal chemists, respectively. The averaged expert score can then be compared to an in silico SA Score. As seen in Table 2 , the predictive capacity of all three methods appears very dependent of the test set. Indeed the SAs of set 1, smaller and evaluated by more chemists, turned out to be much more robustly predictable than set 2. Human evaluation of synthetic complexity is undeniably subjective and relies on individual chemist’s training and experience. However, significant linear correlation and small errors — especially with SwissADME SA Score that outperformed the reference methods on both sets with smaller errors, and equal or higher linear correlation coefficients — demonstrate how this simple and fast methodology can help prioritizing molecules to synthetize”content_tags.quantities[11]
quantity1 to 10 — normalized range of the SwissADME SA Score — “One of the key aspects of CADD activities is to help the selection of the most promising virtual molecules that will be synthetized and submitted to biological assays or other experiments. Synthetic accessibility (SA) is a major factor to consider in this selection process. Obviously, for a reasonable number of molecules, medicinal chemists are the best able to determine SA. However, when too many molecular structures prevent an expert evaluation, in silico estimation can be used for pre-filtering. Ertl & Schuffenhauer 11 proposed a fingerprint-based approach for SA estimation but including closed-source information about fingerprint definition that prevents a straightforward implementation in our tool open to the scientific community. As a consequence, we have built our own fragmental method by analysing more than 13 millions compounds immediately deliverable by vendors. We assumed that the most frequent molecular fragments (technically, FP2 bits, refer to Computational Methods ) in this large collection indicates a probably high SA, while rare fragments imply a difficult synthesis. For a given molecule, the fragmental contributions to SA are summed and corrected by the terms describing size and complexity, such as macrocycles, chiral centres, or spiro functions as defined by Ertl & Schuffenhauer 11 . After normalization, the SA Score ranges from 1 (very easy) to 10 (very difficult). To assess the performance of the method developed for SwissADME, we retrieved two test sets of SA previously published. Both sets involved external molecules, whose difficulty of synthesis was marked from 1 to 10 by nine 11 and four 65 medicinal chemists, respectively. The averaged expert score can then be compared to an in silico SA Score. As seen in Table 2 , the predictive capacity of all three methods appears very dependent of the test set. Indeed the SAs of set 1, smaller and evaluated by more chemists, turned out to be much more robustly predictable than set 2. Human evaluation of synthetic complexity is undeniably subjective and relies on individual chemist’s training and experience. However, significant linear correlation and small errors — especially with SwissADME SA Score that outperformed the reference methods on both sets with smaller errors, and equal or higher linear correlation coefficients — demonstrate how this simple and fast methodology can help prioritizing molecules to synthetize”content_tags.quantities[12]
quantity92% and 88% — ten-fold cross-validation accuracy for BBB and HIA BOILED-Egg models — “The Pharmacokinetics section proposes one linear method for skin permeation, which relies on the simple QSPR model by Potts and Guy 39 linking the decimal logarithm of the skin permeability coefficient (log K p in cm/s) with MW and log P o/w . The model implemented in SwissADME uses XLOGP3 as lipophilicity descriptor. Besides, most of the models in this section are machine-learning binary classifiers for important ADME behaviours. Passive gastro-intestinal (HIA) absorption and blood-brain barrier (BBB) permeation are predicted with the BOILED-Egg model, which defines favourable and unfavourable zones in the log P o/w versus PSA physicochemical space for passive diffusion through both physiological barriers 17 . The classification showed 10-fold cross-validation accuracy of 92% and 88% for BBB and HIA, respectively”content_tags.quantities[13]
quantity50 — molecular and physicochemical descriptors generated per molecule for SVM feature selection — “SwissADME’s backend calculations were ran to generate 50 molecular and physicochemical descriptors per molecule (described in the Supplementary Table S1 ). For a given model, a descriptor was rejected if non-zero values for all molecules in the training set are less than 20% or if the coefficient of variation is less than 3%. In case of correlation higher than 0.9 between remaining descriptors, a selection is made based on F-score. The selected descriptors for each model are shown in Supplementary Tables S2–S7 . These tables also include the minimum and maximum values for each descriptor among all molecules used in the training. This enables beholding the broadness of physicochemical space involved and the applicability domain of the SVM models. The predictive capability of each model can be further appraised on Supplementary Table S8 , where external accuracy was split in sensitivity and specificity to ensure that positive and negative molecules are predicted with the same level of robustness. The final training and test sets with selected descriptors were normalized and the respective model ready to be built. First, the libSVM support vector machine python library (version 3.20, 2015, https://www.csie.ntu.edu.tw/~cjlin/libsvm/ ) 74 was used for multi-step grid-based optimization of the best coefficients for the above-selected descriptors as well as for the soft-margin permissivity (C) and the hyper-parameter (ϒ) of the RBF Gaussian kernel function. The 10-fold crossvalidated accuracy (ACC CV ) for each model was so maximized and AUC CV was calculated. In a second step, the so-built models were used on the external test sets (normalized according to the training set) in order to evaluate predictive power in terms of external accuracy (ACC ext ) and AUC ext . All final SVM models were stored in separate files, which are read through the libSVM API upon SwissADME job submission”content_tags.quantities[14]
variablelipophilicity (Bioavailability Radar axis and pharmacokinetic predictor) — “The first section, including two-dimensional chemical structure and canonical SMILES, is located below the title ( Fig. 2 ). It shows on which chemical form the predictions were calculated (refer to Computational Methods ). Moreover, our Bioavailability Radar is displayed for a rapid appraisal of drug-likeness (refer to Fig. 3 ). Six physicochemical properties are taken into account: lipophilicity, size, polarity, solubility, flexibility and saturation. A physicochemical range on each axis was defined by descriptors adapted from refs 23 and 24 and depicted as a pink area in which the radar plot of the molecule has to fall entirely to be considered drug-like. Leaving the mouse over the radar gives further information about the descriptors”content_tags.variables[0]
variablesize (Bioavailability Radar axis and SA correction) — “The first section, including two-dimensional chemical structure and canonical SMILES, is located below the title ( Fig. 2 ). It shows on which chemical form the predictions were calculated (refer to Computational Methods ). Moreover, our Bioavailability Radar is displayed for a rapid appraisal of drug-likeness (refer to Fig. 3 ). Six physicochemical properties are taken into account: lipophilicity, size, polarity, solubility, flexibility and saturation. A physicochemical range on each axis was defined by descriptors adapted from refs 23 and 24 and depicted as a pink area in which the radar plot of the molecule has to fall entirely to be considered drug-like. Leaving the mouse over the radar gives further information about the descriptors”content_tags.variables[1]
variablepolarity (Bioavailability Radar axis represented by TPSA) — “The first section, including two-dimensional chemical structure and canonical SMILES, is located below the title ( Fig. 2 ). It shows on which chemical form the predictions were calculated (refer to Computational Methods ). Moreover, our Bioavailability Radar is displayed for a rapid appraisal of drug-likeness (refer to Fig. 3 ). Six physicochemical properties are taken into account: lipophilicity, size, polarity, solubility, flexibility and saturation. A physicochemical range on each axis was defined by descriptors adapted from refs 23 and 24 and depicted as a pink area in which the radar plot of the molecule has to fall entirely to be considered drug-like. Leaving the mouse over the radar gives further information about the descriptors”content_tags.variables[2]
variablesolubility (Bioavailability Radar axis and predicted drug-development property) — “The first section, including two-dimensional chemical structure and canonical SMILES, is located below the title ( Fig. 2 ). It shows on which chemical form the predictions were calculated (refer to Computational Methods ). Moreover, our Bioavailability Radar is displayed for a rapid appraisal of drug-likeness (refer to Fig. 3 ). Six physicochemical properties are taken into account: lipophilicity, size, polarity, solubility, flexibility and saturation. A physicochemical range on each axis was defined by descriptors adapted from refs 23 and 24 and depicted as a pink area in which the radar plot of the molecule has to fall entirely to be considered drug-like. Leaving the mouse over the radar gives further information about the descriptors”content_tags.variables[3]
variableflexibility (Bioavailability Radar axis represented by rotatable bonds) — “The first section, including two-dimensional chemical structure and canonical SMILES, is located below the title ( Fig. 2 ). It shows on which chemical form the predictions were calculated (refer to Computational Methods ). Moreover, our Bioavailability Radar is displayed for a rapid appraisal of drug-likeness (refer to Fig. 3 ). Six physicochemical properties are taken into account: lipophilicity, size, polarity, solubility, flexibility and saturation. A physicochemical range on each axis was defined by descriptors adapted from refs 23 and 24 and depicted as a pink area in which the radar plot of the molecule has to fall entirely to be considered drug-like. Leaving the mouse over the radar gives further information about the descriptors”content_tags.variables[4]
variablesaturation (Bioavailability Radar axis represented by carbon hybridization) — “The first section, including two-dimensional chemical structure and canonical SMILES, is located below the title ( Fig. 2 ). It shows on which chemical form the predictions were calculated (refer to Computational Methods ). Moreover, our Bioavailability Radar is displayed for a rapid appraisal of drug-likeness (refer to Fig. 3 ). Six physicochemical properties are taken into account: lipophilicity, size, polarity, solubility, flexibility and saturation. A physicochemical range on each axis was defined by descriptors adapted from refs 23 and 24 and depicted as a pink area in which the radar plot of the molecule has to fall entirely to be considered drug-like. Leaving the mouse over the radar gives further information about the descriptors”content_tags.variables[5]
variableWLOGP (lipophilicity coordinate of the BOILED-Egg) — “After all calculations completed, the “Show BOILED-Egg” red button appears below the sketcher to display the graphical output on the same page (as exemplify in Fig. 4 ). This consists primarily in the BOILED-Egg, an intuitive method to predict simultaneously two key ADME parameters, i.e. the passive gastrointestinal absorption (HIA) and brain access (BBB). Although conceptually very simple as it relies on two physicochemical descriptors only (WLOGP and TPSA, for lipophilicity and apparent polarity), this classification model was built with extreme care regarding statistical significance and robustness 17 . As shown in Fig. 4 , the egg-shaped classification plot includes the yolk (i.e. the physicochemical space for highly probable BBB permeation) and the white (i.e. the physicochemical space for highly probable HIA absorption). Both compartments are not mutually exclusive and the outside grey region stands for molecules with properties implying predicted low absorption and limited brain penetration. In practice, the BOILED-Egg has proven straightforward interpretation and efficient translation to molecular design in a variety of drug discovery settings. Whereas the predictive power of the BOILED-Egg is broad in term of chemical space, it is restricted to passive penetration through gastro-intestinal wall and BBB. We took benefit of its implementation within SwissADME to enrich the graphical output with the prediction of P-gp substrate, which is the most important active efflux mechanism involved in those biological barriers 40 (refer to the SVM model described in Pharmacokinetics ). As a result, the user conveniently obtains on the same graph a global evaluation about passive absorption (inside/outside the white), passive brain access (inside/outside the yolk) and active efflux from the CNS or to the gastrointestinal lumen by colour-coding”content_tags.variables[6]
variableTPSA (apparent-polarity coordinate of the BOILED-Egg) — “After all calculations completed, the “Show BOILED-Egg” red button appears below the sketcher to display the graphical output on the same page (as exemplify in Fig. 4 ). This consists primarily in the BOILED-Egg, an intuitive method to predict simultaneously two key ADME parameters, i.e. the passive gastrointestinal absorption (HIA) and brain access (BBB). Although conceptually very simple as it relies on two physicochemical descriptors only (WLOGP and TPSA, for lipophilicity and apparent polarity), this classification model was built with extreme care regarding statistical significance and robustness 17 . As shown in Fig. 4 , the egg-shaped classification plot includes the yolk (i.e. the physicochemical space for highly probable BBB permeation) and the white (i.e. the physicochemical space for highly probable HIA absorption). Both compartments are not mutually exclusive and the outside grey region stands for molecules with properties implying predicted low absorption and limited brain penetration. In practice, the BOILED-Egg has proven straightforward interpretation and efficient translation to molecular design in a variety of drug discovery settings. Whereas the predictive power of the BOILED-Egg is broad in term of chemical space, it is restricted to passive penetration through gastro-intestinal wall and BBB. We took benefit of its implementation within SwissADME to enrich the graphical output with the prediction of P-gp substrate, which is the most important active efflux mechanism involved in those biological barriers 40 (refer to the SVM model described in Pharmacokinetics ). As a result, the user conveniently obtains on the same graph a global evaluation about passive absorption (inside/outside the white), passive brain access (inside/outside the yolk) and active efflux from the CNS or to the gastrointestinal lumen by colour-coding”content_tags.variables[7]
variablecross-validation accuracy (internal classifier-robustness outcome) — “The quantification of the models performance is not straightforwardly comparable, because the training sets are different, most of the published models are less than 10-fold cross-validated and some statistical parameters are missing. Nevertheless, the SwissADME classifiers are competitive with previous models in term of robustness, with cross-validation accuracy (ACC CV ) grossly at the same level. Furthermore, cross-validated areas under receiver operating characteristic (ROC) curves (AUC CV ) are equal to the corresponding values found in the literature. Likewise, external prediction power is difficult to compare, as each test set includes different molecules. However, the predictive capacity of SwissADME classifiers is grossly equivalent to the related SVM methods, both in terms of external accuracy (ACC ext ) and external area under ROC curve (AUC ext ). The models for which external validation was not found (P-gp of refs 15 and 53 ) have to be taken with extreme caution since they possibly suffer from overfitting biases. Noteworthy, some of the published models (e.g. CYP2C9 and CYP3A4 of ref. 54 or CYP2C9 of ref. 55 ) were built on severely unbalanced training sets and tested on clearly unbalanced external sets. As demonstrated by Carbon-Mangels et al . 56 the relevance of machine-learning classification methods, and especially SVM, are negatively impacted by datasets with one significantly more populated class. In that case, accuracy measurements are overestimated and prone to mislead the construction and the evaluation of the model. Moreover, some SVM models were published with small training and test sets (P-gp of refs 15 and 57 ), which imply questionable capacity of generalization and broadness of applicability domains. We emphasize that for SwissADME classifiers, both training and test sets were carefully cleansed and checked for size, diversity and balance between classes. Furthermore, our SVM models rely merely on molecular and physicochemical descriptors generated by SwissADME. We believe that this improves robustness and sustainability of the underlying methodologies. In particular, not using molecular fingerprints, molecular graphs or other structural descriptions can be an handicap to generate high statistical values but should also limit overfitting biases and yield more generalist predictive models, not necessarily influenced by specific chemical scaffolds or moieties. In our practice, these well-performing models able to estimate important ADME behaviours are of great support for pharmacokinetics optimization and evaluation of small molecules”content_tags.variables[8]
variableexternal area under ROC curve (external predictive-power outcome) — “The quantification of the models performance is not straightforwardly comparable, because the training sets are different, most of the published models are less than 10-fold cross-validated and some statistical parameters are missing. Nevertheless, the SwissADME classifiers are competitive with previous models in term of robustness, with cross-validation accuracy (ACC CV ) grossly at the same level. Furthermore, cross-validated areas under receiver operating characteristic (ROC) curves (AUC CV ) are equal to the corresponding values found in the literature. Likewise, external prediction power is difficult to compare, as each test set includes different molecules. However, the predictive capacity of SwissADME classifiers is grossly equivalent to the related SVM methods, both in terms of external accuracy (ACC ext ) and external area under ROC curve (AUC ext ). The models for which external validation was not found (P-gp of refs 15 and 53 ) have to be taken with extreme caution since they possibly suffer from overfitting biases. Noteworthy, some of the published models (e.g. CYP2C9 and CYP3A4 of ref. 54 or CYP2C9 of ref. 55 ) were built on severely unbalanced training sets and tested on clearly unbalanced external sets. As demonstrated by Carbon-Mangels et al . 56 the relevance of machine-learning classification methods, and especially SVM, are negatively impacted by datasets with one significantly more populated class. In that case, accuracy measurements are overestimated and prone to mislead the construction and the evaluation of the model. Moreover, some SVM models were published with small training and test sets (P-gp of refs 15 and 57 ), which imply questionable capacity of generalization and broadness of applicability domains. We emphasize that for SwissADME classifiers, both training and test sets were carefully cleansed and checked for size, diversity and balance between classes. Furthermore, our SVM models rely merely on molecular and physicochemical descriptors generated by SwissADME. We believe that this improves robustness and sustainability of the underlying methodologies. In particular, not using molecular fingerprints, molecular graphs or other structural descriptions can be an handicap to generate high statistical values but should also limit overfitting biases and yield more generalist predictive models, not necessarily influenced by specific chemical scaffolds or moieties. In our practice, these well-performing models able to estimate important ADME behaviours are of great support for pharmacokinetics optimization and evaluation of small molecules”content_tags.variables[9]
variablefrequency of molecular fragments (principal input to synthetic-accessibility contribution) — “SwissADME Synthetic Accessibility (SA) Score is based primarily on the assumption that the frequency of molecular fragments in ‘really’ obtainable molecules correlates with the ease of synthesis. The fragmental contribution to SA should be favourable for frequent chemical moieties and unfavourable for rare moieties. We examined the ‘All Now’ subset of ZINC database 76 (version 12, 2014, http://zinc.docking.org/subsets/all-now accessed April 2015) including 12′782′590 compounds immediately deliverable by vendors. This collection was not submitted to any other filter. FP2 fingerprints of all molecules were computed by OpenBabel 9 thus generating 12′782′590 bit strings (i.e. the fingerprints). The frequency of occupancy of each of the 1024 bits for the entire library was calculated and its contribution to SA obtained by applying natural logarithm to the normalized bit count. As a result, this fragmental system of bits allows extremely fast evaluation of any input molecule by reading its FP2 string. Fragmental contribution of bit occupancy is summed and linearly modulated by corrective factors, which are penalties for size (MW) and complexity. This latter is based on SMARTS recognition of chiral centres, spiro functions, bridged rings and macrocycles (more than 8-membered rings). The coefficients of the corrective terms are those defined by Ertl & Schuffenhauer 11 . Finally the score is normalized to range from 1 (very easy) to 10 (very difficult to synthetize). As crude as it may seem, SwissADME SA Score is extremely fast and performing slightly better than two similar methods previously published”content_tags.variables[10]
definitionpharmacokinetics — “During the time- and resource-consuming processes of drug discovery and development, a large number of molecular structures are evaluated according to very diverse parameters in order to steer the selection of which chemicals to synthetize, test and promote, with the final goal to identify those with the best chance to become an effective medicine for the patients. The molecules must show high biological activity together with low toxicity. Equally important is the access to and concentration at the therapeutic target in the organism. The traditional way to consider pharmacokinetics (i.e. the fate of a therapeutic compound in the organism) is to break down the various effects that impact the access to the target into individual parameters. In turn, these ADME parameters (for Absorption, Distribution, Metabolism and Excretion) can be evaluated separately by dedicated methods. It has been demonstrated that early estimation of ADME in the discovery phase reduces drastically the fraction of pharmacokinetics-related failure in the clinical phases 1 . Computer models have been fostered as a valid alternative to experimental procedures for prediction of ADME, especially at initial steps, when investigated chemical structures are numerous but the availability of compounds is scarce”content_tags.definitions[0]
definitionADME — “During the time- and resource-consuming processes of drug discovery and development, a large number of molecular structures are evaluated according to very diverse parameters in order to steer the selection of which chemicals to synthetize, test and promote, with the final goal to identify those with the best chance to become an effective medicine for the patients. The molecules must show high biological activity together with low toxicity. Equally important is the access to and concentration at the therapeutic target in the organism. The traditional way to consider pharmacokinetics (i.e. the fate of a therapeutic compound in the organism) is to break down the various effects that impact the access to the target into individual parameters. In turn, these ADME parameters (for Absorption, Distribution, Metabolism and Excretion) can be evaluated separately by dedicated methods. It has been demonstrated that early estimation of ADME in the discovery phase reduces drastically the fraction of pharmacokinetics-related failure in the clinical phases 1 . Computer models have been fostered as a valid alternative to experimental procedures for prediction of ADME, especially at initial steps, when investigated chemical structures are numerous but the availability of compounds is scarce”content_tags.definitions[1]
definitionmolecular fingerprint — “Cheminformaticians developed different molecular descriptors mined from chemical structures. One of the most popular examples is the molecular fingerprint (FP), which consists in a sequence of bits defining the presence or absence of chemical features in a molecule. The FP2 method 9 is one archetype of topological (or path-based) FP, which considers all fragments of the molecular structure following a linear path up to a given number of bonds. Every possible path is hashed to generate the bit string (i.e. the FP). A major advantage of FP is the efficiency by which computers handle such bit strings 10 , allowing for instance large-scale virtual screening or the rapid estimation of synthetic accessibility of molecules 11 . FP are also employed in classification models for ADME behaviours built by support vector machine (SVM) or Bayesian techniques 12 . Remarkably, computer-aided drug design (CADD) has been a pioneer field for the application of such machine learning technologies”content_tags.definitions[2]
definitionFP2 — “Cheminformaticians developed different molecular descriptors mined from chemical structures. One of the most popular examples is the molecular fingerprint (FP), which consists in a sequence of bits defining the presence or absence of chemical features in a molecule. The FP2 method 9 is one archetype of topological (or path-based) FP, which considers all fragments of the molecular structure following a linear path up to a given number of bonds. Every possible path is hashed to generate the bit string (i.e. the FP). A major advantage of FP is the efficiency by which computers handle such bit strings 10 , allowing for instance large-scale virtual screening or the rapid estimation of synthetic accessibility of molecules 11 . FP are also employed in classification models for ADME behaviours built by support vector machine (SVM) or Bayesian techniques 12 . Remarkably, computer-aided drug design (CADD) has been a pioneer field for the application of such machine learning technologies”content_tags.definitions[3]
definitiondrug-likeness — “As defined earlier, “drug-likeness” assesses qualitatively the chance for a molecule to become an oral drug with respect to bioavailability. Drug-likeness was established from structural or physicochemical inspections of development compounds advanced enough to be considered oral drug-candidates. This notion is routinely employed to perform filtering of chemical libraries to exclude molecules with properties most probably incompatible with an acceptable pharmacokinetics profile. This SwissADME section gives access to five different rule-based filters, with diverse ranges of properties inside of which the molecule is defined as drug-like. These filters often originate from analyses by major pharmaceutical companies aiming to improve the quality of their proprietary chemical collections. The Lipinski (Pfizer) filter is the pioneer rule-of-five implemented from ref. 4 . The Ghose (Amgen), Veber (GSK), Egan (Pharmacia) and Muegge (Bayer) methods were adapted from refs 58 , 59 , 60 , 61 , respectively. Multiple estimations allow consensus views or selection of methods best fitting the end-user’s specific needs in terms of chemical space or project-related demands. Any violation of any rule described here appears explicitly in the output panel. The Abbot Bioavailability Score 62 is similar but seeks to predict the probability of a compound to have at least 10% oral bioavailability in rat or measurable Caco-2 permeability. This semi-quantitative rule-based score relying on total charge, TPSA, and violation to the Lipinski filter defines four classes of compounds with probabilities of 11%, 17%, 56% or 85%. Like the other methods in this section, it primary focuses on the fast screening of chemical libraries, to select the best molecules to be purchased, synthetized or promoted at a further stage of a medicinal chemistry project”content_tags.definitions[4]
definitionleadlikeness — “The purpose of this section is to support medicinal chemists in their daily drug discovery endeavours. Two complementary pattern recognition methods allow for identification of potentially problematic fragments. PAINS (for pan assay interference compounds, a.k.a. frequent hitters or promiscuous compounds) are molecules containing substructures showing potent response in assays irrespective of the protein target. Such fragments, yielding false positive biological output, have been identified by Baell et al . 6 in analysing six orthogonal assays and breaking down the molecules active on 2 or more assays into 481 recurrent fragments, considered as potentially leading to promiscuous compounds. SwissADME returns warnings if such moieties are found in the molecule under evaluation. Besides, we implemented Structural Alert, which consists in a list of 105 fragments identified by Brenk et al . 5 to be putatively toxic, chemically reactive, metabolically unstable or to bear properties responsible for poor pharmacokinetics. In SwissADME, it is possible to have a chemical description of the problematic fragments found in a given molecule by flying over the “question mark” icon appearing after the fragment list. This is implemented for both PAINS and Brenk filters. By applying these and other physicochemical filters to design screening libraries, Brenk et al . 5 observed that most of the remaining compounds satisfy criteria for “leadlikeness”. This concept is similar to drug-likeness, yet focusing on physicochemical boundaries defining a good lead, i.e. a molecular entity suitable for optimization. By definition, leads are subjected to chemical modifications that will most likely increase size and lipophilicity 63 . As a consequence, leads are required to be smaller and less hydrophobic than drug-like molecules. Since it is crucial for a chemist to judge whether a given molecule is suitable to initiate lead optimization, in addition to structural filters, we implemented a rule-based method for leadlikeness”content_tags.definitions[5]
definitionPAINS — “The purpose of this section is to support medicinal chemists in their daily drug discovery endeavours. Two complementary pattern recognition methods allow for identification of potentially problematic fragments. PAINS (for pan assay interference compounds, a.k.a. frequent hitters or promiscuous compounds) are molecules containing substructures showing potent response in assays irrespective of the protein target. Such fragments, yielding false positive biological output, have been identified by Baell et al . 6 in analysing six orthogonal assays and breaking down the molecules active on 2 or more assays into 481 recurrent fragments, considered as potentially leading to promiscuous compounds. SwissADME returns warnings if such moieties are found in the molecule under evaluation. Besides, we implemented Structural Alert, which consists in a list of 105 fragments identified by Brenk et al . 5 to be putatively toxic, chemically reactive, metabolically unstable or to bear properties responsible for poor pharmacokinetics. In SwissADME, it is possible to have a chemical description of the problematic fragments found in a given molecule by flying over the “question mark” icon appearing after the fragment list. This is implemented for both PAINS and Brenk filters. By applying these and other physicochemical filters to design screening libraries, Brenk et al . 5 observed that most of the remaining compounds satisfy criteria for “leadlikeness”. This concept is similar to drug-likeness, yet focusing on physicochemical boundaries defining a good lead, i.e. a molecular entity suitable for optimization. By definition, leads are subjected to chemical modifications that will most likely increase size and lipophilicity 63 . As a consequence, leads are required to be smaller and less hydrophobic than drug-like molecules. Since it is crucial for a chemist to judge whether a given molecule is suitable to initiate lead optimization, in addition to structural filters, we implemented a rule-based method for leadlikeness”content_tags.definitions[6]
definitionconsensus log P o/w — “The partition coefficient between n -octanol and water (log P o/w ) is the classical descriptor for Lipophilicity . It has a dedicated section in SwissADME due to the critical importance of this physicochemical property for pharmacokinetics drug discovery 26 27 . Many computational methods for log P o/w estimation were developed with diverse performance on various chemical sets. Common practice is to use multiple predictors either to select the most accurate methods for a given chemical series or to generate consensus estimation. The models behind the predictors should be as diverse as possible to increase the prediction accuracy through consensus log P o/w 28 . In that regard, SwissADME gives access to five freely available predictive models; i.e. XLOGP3, an atomistic method including corrective factors and knowledge-based library 29 ; WLOGP, our own implementation of a purely atomistic method based on the fragmental system of Wildman and Crippen 30 ; MLOGP, an archetype of topological method relying on a linear relationship with 13 molecular descriptors implemented from refs 31 and 32 ; SILICOS-IT, an hybrid method relying on 27 fragments and 7 topological descriptors ( http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html , accessed June 2016); and finally iLOGP, our in-house physics-based method relying on free energies of solvation in n -octanol and water calculated by the Generalized-Born and solvent accessible surface area (GB/SA) model. iLOGP was benchmarked on two drug or drug-like external sets and performed equally as or better than six well-established predictors 16 . The consensus log P o/w is the arithmetic mean of the values predicted by the five proposed methods”content_tags.definitions[7]
definitionlog S — “Having a soluble molecule greatly facilitates many drug development activities, primarily the ease of handling and formulation 33 . Moreover, for discovery projects targeting oral administration, solubility is one major property influencing absorption 34 . As well, a drug meant for parenteral usage has to be highly soluble in water to deliver a sufficient quantity of active ingredient in the small volume of such pharmaceutical dosage 35 . Two topological methods to predict Water Solubility are included in SwissADME. The first one is an implementation of the ESOL model 36 and the second one is adapted from Ali et al . 37 . Both differ from the seminal general solubility equation 38 since they avoid the melting point parameter; the latter being challenging to predict. Moreover they demonstrate strong linear correlation between predicted and experimental values (R 2 = 0.69 and 0.81, respectively). SwissADME third predictor for solubility was developed by SILICOS-IT. The linear correlation coefficient of this fragmental method corrected by molecular weight is R 2 = 0.75 ( http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html , accessed June 2016). All predicted values are the decimal logarithm of the molar solubility in water (log S ). SwissADME also provides solubility in mol/l and mg/ml along with qualitative solubility classes”content_tags.definitions[8]
definitionBOILED-Egg — “After all calculations completed, the “Show BOILED-Egg” red button appears below the sketcher to display the graphical output on the same page (as exemplify in Fig. 4 ). This consists primarily in the BOILED-Egg, an intuitive method to predict simultaneously two key ADME parameters, i.e. the passive gastrointestinal absorption (HIA) and brain access (BBB). Although conceptually very simple as it relies on two physicochemical descriptors only (WLOGP and TPSA, for lipophilicity and apparent polarity), this classification model was built with extreme care regarding statistical significance and robustness 17 . As shown in Fig. 4 , the egg-shaped classification plot includes the yolk (i.e. the physicochemical space for highly probable BBB permeation) and the white (i.e. the physicochemical space for highly probable HIA absorption). Both compartments are not mutually exclusive and the outside grey region stands for molecules with properties implying predicted low absorption and limited brain penetration. In practice, the BOILED-Egg has proven straightforward interpretation and efficient translation to molecular design in a variety of drug discovery settings. Whereas the predictive power of the BOILED-Egg is broad in term of chemical space, it is restricted to passive penetration through gastro-intestinal wall and BBB. We took benefit of its implementation within SwissADME to enrich the graphical output with the prediction of P-gp substrate, which is the most important active efflux mechanism involved in those biological barriers 40 (refer to the SVM model described in Pharmacokinetics ). As a result, the user conveniently obtains on the same graph a global evaluation about passive absorption (inside/outside the white), passive brain access (inside/outside the yolk) and active efflux from the CNS or to the gastrointestinal lumen by colour-coding”content_tags.definitions[9]
definitionSA Score — “SwissADME Synthetic Accessibility (SA) Score is based primarily on the assumption that the frequency of molecular fragments in ‘really’ obtainable molecules correlates with the ease of synthesis. The fragmental contribution to SA should be favourable for frequent chemical moieties and unfavourable for rare moieties. We examined the ‘All Now’ subset of ZINC database 76 (version 12, 2014, http://zinc.docking.org/subsets/all-now accessed April 2015) including 12′782′590 compounds immediately deliverable by vendors. This collection was not submitted to any other filter. FP2 fingerprints of all molecules were computed by OpenBabel 9 thus generating 12′782′590 bit strings (i.e. the fingerprints). The frequency of occupancy of each of the 1024 bits for the entire library was calculated and its contribution to SA obtained by applying natural logarithm to the normalized bit count. As a result, this fragmental system of bits allows extremely fast evaluation of any input molecule by reading its FP2 string. Fragmental contribution of bit occupancy is summed and linearly modulated by corrective factors, which are penalties for size (MW) and complexity. This latter is based on SMARTS recognition of chiral centres, spiro functions, bridged rings and macrocycles (more than 8-membered rings). The coefficients of the corrective terms are those defined by Ertl & Schuffenhauer 11 . Finally the score is normalized to range from 1 (very easy) to 10 (very difficult to synthetize). As crude as it may seem, SwissADME SA Score is extremely fast and performing slightly better than two similar methods previously published”content_tags.definitions[10]
Concepts
terms this paper carries, each with the sentence it was cut from — the layer that joins one paper to another. Terms with no quote yet are on CONCEPTS.html.
conceptSwissADME web tool — not defined in this paper's own words; free web system for small-molecule property prediction — “To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur. Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. In that context, computer models constitute valid alternatives to experiments. Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar. Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch . Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours”concepts[0]
conceptSwissADME — not defined in this paper's own words; member tool in the SwissDrugDesign program — “Moreover, SwissADME is an integral part of the SwissDrugDesign program, an ambitious initiative driven by the Molecular Modeling Group of the SIB Swiss Institute of Bioinformatics that aims at providing a collection of free Web-based tools covering many aspects of CADD. As such, SwissADME users can access the different Web sites, through the black toolbar at the top of the page. By clicking on the name of the tool, a new tab opens with the corresponding submission page. We have undertaken the implementation of more advanced interoperability capabilities. At the time of writing this manuscript, three icons were placed top left of the output panel (below the name of the molecule, see Fig. 2 ). They allow one-click submission of the molecule to SwissTargetPrediction (for reverse screening to predict protein target, by clicking on the red target), SwissSimilarity (for ligand-based virtual screening, by clicking on the red twins) and to re-submit the molecule to SwissADME (for instance to get a single compound graphical output, by clicking the red pill). Reversely, other SwissDrugDesign websites include the SwissADME pill icon”concepts[1]
conceptabsorption, distribution, metabolism and excretion — not defined in this paper's own words; the component processes abbreviated ADME — “To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur. Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. In that context, computer models constitute valid alternatives to experiments. Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar. Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch . Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours”concepts[2]
conceptADME — not defined in this paper's own words; absorption, distribution, metabolism and excretion properties — “To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur. Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. In that context, computer models constitute valid alternatives to experiments. Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar. Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch . Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours”concepts[3]
conceptcomputer models — not defined in this paper's own words; in-silico alternatives to scarce early experiments — “To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur. Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. In that context, computer models constitute valid alternatives to experiments. Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar. Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch . Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours”concepts[4]
conceptexperiments — not defined in this paper's own words; physical procedures contrasted with early computational prediction — “To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur. Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. In that context, computer models constitute valid alternatives to experiments. Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar. Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch . Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours”concepts[5]
conceptpredictive models — not defined in this paper's own words; fast models pooled by SwissADME — “To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur. Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. In that context, computer models constitute valid alternatives to experiments. Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar. Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch . Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours”concepts[6]
conceptphysicochemical properties — not defined in this paper's own words; molecular properties predicted or filtered by SwissADME — “To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur. Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. In that context, computer models constitute valid alternatives to experiments. Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar. Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch . Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours”concepts[7]
conceptphysicochemical parameters — not defined in this paper's own words; global molecular-structure descriptors contrasted with substructure search — “Whereas physicochemical parameters give a global description of the structure, molecules can be directly described by substructure searches. These techniques are at the root of Structural Alert 5 , the PAINS 6 or the Lilly MedChem 7 filters applied to cleanse chemical libraries from compounds most likely unstable, reactive, toxic, or prone to interfere with biological assays because unspecific frequent hitters, dyes or aggregators”concepts[8]
conceptpharmacokinetics — not defined in this paper's own words; the fate of a therapeutic compound in an organism — “During the time- and resource-consuming processes of drug discovery and development, a large number of molecular structures are evaluated according to very diverse parameters in order to steer the selection of which chemicals to synthetize, test and promote, with the final goal to identify those with the best chance to become an effective medicine for the patients. The molecules must show high biological activity together with low toxicity. Equally important is the access to and concentration at the therapeutic target in the organism. The traditional way to consider pharmacokinetics (i.e. the fate of a therapeutic compound in the organism) is to break down the various effects that impact the access to the target into individual parameters. In turn, these ADME parameters (for Absorption, Distribution, Metabolism and Excretion) can be evaluated separately by dedicated methods. It has been demonstrated that early estimation of ADME in the discovery phase reduces drastically the fraction of pharmacokinetics-related failure in the clinical phases 1 . Computer models have been fostered as a valid alternative to experimental procedures for prediction of ADME, especially at initial steps, when investigated chemical structures are numerous but the availability of compounds is scarce”concepts[9]
conceptdrug-likeness — not defined in this paper's own words; qualitative chance of oral-drug suitability with respect to bioavailability — “As defined earlier, “drug-likeness” assesses qualitatively the chance for a molecule to become an oral drug with respect to bioavailability. Drug-likeness was established from structural or physicochemical inspections of development compounds advanced enough to be considered oral drug-candidates. This notion is routinely employed to perform filtering of chemical libraries to exclude molecules with properties most probably incompatible with an acceptable pharmacokinetics profile. This SwissADME section gives access to five different rule-based filters, with diverse ranges of properties inside of which the molecule is defined as drug-like. These filters often originate from analyses by major pharmaceutical companies aiming to improve the quality of their proprietary chemical collections. The Lipinski (Pfizer) filter is the pioneer rule-of-five implemented from ref. 4 . The Ghose (Amgen), Veber (GSK), Egan (Pharmacia) and Muegge (Bayer) methods were adapted from refs 58 , 59 , 60 , 61 , respectively. Multiple estimations allow consensus views or selection of methods best fitting the end-user’s specific needs in terms of chemical space or project-related demands. Any violation of any rule described here appears explicitly in the output panel. The Abbot Bioavailability Score 62 is similar but seeks to predict the probability of a compound to have at least 10% oral bioavailability in rat or measurable Caco-2 permeability. This semi-quantitative rule-based score relying on total charge, TPSA, and violation to the Lipinski filter defines four classes of compounds with probabilities of 11%, 17%, 56% or 85%. Like the other methods in this section, it primary focuses on the fast screening of chemical libraries, to select the best molecules to be purchased, synthetized or promoted at a further stage of a medicinal chemistry project”concepts[10]
conceptmedicinal chemistry friendliness — not defined in this paper's own words; computational support for medicinal-chemistry selection — “To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur. Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. In that context, computer models constitute valid alternatives to experiments. Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar. Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch . Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours”concepts[11]
conceptBOILED-Egg — not defined in this paper's own words; graphical classification model for HIA, BBB, and P-gp behaviour — “To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur. Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. In that context, computer models constitute valid alternatives to experiments. Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar. Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch . Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours”concepts[12]
conceptiLOGP — not defined in this paper's own words; in-house physics-based log-partition predictor — “Multiple freely available computational methods to predict n -octanol/water partition coefficient (log P o/w ) values are made available in the Lipophilicity section. iLOGP (for implicit log P ) is an in-house physics-based methods relying on Gibbs free energy of solvation calculated by GB/SA in water and n -octanol. Generalized-born (GB) parameters are computed through the GBMV2 method 68 and solvent-accessible surface area (SA) is the analytical approximation generated by CHARMM (version c36b1, 2011, https://www.charmm.org ) 69 . The iLOGP implemented in SwissADME corresponds to Model9 of the seminal publication 16 , which was trained on 11,993 molecules (r = 0.72, MAE = 0.89, and RMSE = 1.14 against experimental log P ). 5-fold crossvalidation ensured robustness (q 2 CV = 0.52, MAE CV = 0.89, and RMSE CV = 1.14) and external test benchmarks showed the excellent predictive power and extended applicability domain compared to well-established methods. XLOGP3 values are obtained through the command-line Linux program (version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry) including the knowledge-based corrections 29 . WLOGP is our own implementation of the atomistic method developed by Wildman and Crippen 30 . MLOGP values are computed through an in-house implementation of Moriguchi’s topological method 31 32 . SILICOS-IT is the log P o/w estimation returned by executing the FILTER-IT program (version 1.0.2, 2013, http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html ). Finally, SwissADME gives a consensus log P o/w value, which is the arithmetic mean of the five predictive values mentioned above”concepts[13]
conceptBioavailability Radar — not defined in this paper's own words; six-axis oral drug-likeness visualization — “The first section, including two-dimensional chemical structure and canonical SMILES, is located below the title ( Fig. 2 ). It shows on which chemical form the predictions were calculated (refer to Computational Methods ). Moreover, our Bioavailability Radar is displayed for a rapid appraisal of drug-likeness (refer to Fig. 3 ). Six physicochemical properties are taken into account: lipophilicity, size, polarity, solubility, flexibility and saturation. A physicochemical range on each axis was defined by descriptors adapted from refs 23 and 24 and depicted as a pink area in which the radar plot of the molecule has to fall entirely to be considered drug-like. Leaving the mouse over the radar gives further information about the descriptors”concepts[14]
conceptsubstructure searches — not defined in this paper's own words; direct structural-description technique underlying alert filters — “Whereas physicochemical parameters give a global description of the structure, molecules can be directly described by substructure searches. These techniques are at the root of Structural Alert 5 , the PAINS 6 or the Lilly MedChem 7 filters applied to cleanse chemical libraries from compounds most likely unstable, reactive, toxic, or prone to interfere with biological assays because unspecific frequent hitters, dyes or aggregators”concepts[15]
conceptStructural Alert — not defined in this paper's own words; fragment filter for unstable, reactive, toxic, or poor-PK structures — “Whereas physicochemical parameters give a global description of the structure, molecules can be directly described by substructure searches. These techniques are at the root of Structural Alert 5 , the PAINS 6 or the Lilly MedChem 7 filters applied to cleanse chemical libraries from compounds most likely unstable, reactive, toxic, or prone to interfere with biological assays because unspecific frequent hitters, dyes or aggregators”concepts[16]
conceptPAINS — not defined in this paper's own words; pan-assay interference fragment filter — “The purpose of this section is to support medicinal chemists in their daily drug discovery endeavours. Two complementary pattern recognition methods allow for identification of potentially problematic fragments. PAINS (for pan assay interference compounds, a.k.a. frequent hitters or promiscuous compounds) are molecules containing substructures showing potent response in assays irrespective of the protein target. Such fragments, yielding false positive biological output, have been identified by Baell et al . 6 in analysing six orthogonal assays and breaking down the molecules active on 2 or more assays into 481 recurrent fragments, considered as potentially leading to promiscuous compounds. SwissADME returns warnings if such moieties are found in the molecule under evaluation. Besides, we implemented Structural Alert, which consists in a list of 105 fragments identified by Brenk et al . 5 to be putatively toxic, chemically reactive, metabolically unstable or to bear properties responsible for poor pharmacokinetics. In SwissADME, it is possible to have a chemical description of the problematic fragments found in a given molecule by flying over the “question mark” icon appearing after the fragment list. This is implemented for both PAINS and Brenk filters. By applying these and other physicochemical filters to design screening libraries, Brenk et al . 5 observed that most of the remaining compounds satisfy criteria for “leadlikeness”. This concept is similar to drug-likeness, yet focusing on physicochemical boundaries defining a good lead, i.e. a molecular entity suitable for optimization. By definition, leads are subjected to chemical modifications that will most likely increase size and lipophilicity 63 . As a consequence, leads are required to be smaller and less hydrophobic than drug-like molecules. Since it is crucial for a chemist to judge whether a given molecule is suitable to initiate lead optimization, in addition to structural filters, we implemented a rule-based method for leadlikeness”concepts[17]
conceptmolecular descriptors — not defined in this paper's own words; features mined from chemical structures — “Cheminformaticians developed different molecular descriptors mined from chemical structures. One of the most popular examples is the molecular fingerprint (FP), which consists in a sequence of bits defining the presence or absence of chemical features in a molecule. The FP2 method 9 is one archetype of topological (or path-based) FP, which considers all fragments of the molecular structure following a linear path up to a given number of bonds. Every possible path is hashed to generate the bit string (i.e. the FP). A major advantage of FP is the efficiency by which computers handle such bit strings 10 , allowing for instance large-scale virtual screening or the rapid estimation of synthetic accessibility of molecules 11 . FP are also employed in classification models for ADME behaviours built by support vector machine (SVM) or Bayesian techniques 12 . Remarkably, computer-aided drug design (CADD) has been a pioneer field for the application of such machine learning technologies”concepts[18]
conceptphysicochemical descriptors — not defined in this paper's own words; computed molecular-property features — “Simple molecular and physicochemical descriptors like molecular weight (MW), molecular refractivity (MR), count of specific atom types and polar surface area (PSA) are compiled in this section. The values are computed with OpenBabel 9 , version 2.3.0. The PSA is calculated using the fragmental technique called topological polar surface area (TPSA), considering sulfur and phosphorus as polar atoms 25 . This has proven a useful descriptor in many models and rules to quickly estimate some ADME properties, especially with regards to biological barrier crossing such as absorption and brain access”concepts[19]
conceptmolecular fingerprint — not defined in this paper's own words; bit sequence indicating feature presence or absence — “Cheminformaticians developed different molecular descriptors mined from chemical structures. One of the most popular examples is the molecular fingerprint (FP), which consists in a sequence of bits defining the presence or absence of chemical features in a molecule. The FP2 method 9 is one archetype of topological (or path-based) FP, which considers all fragments of the molecular structure following a linear path up to a given number of bonds. Every possible path is hashed to generate the bit string (i.e. the FP). A major advantage of FP is the efficiency by which computers handle such bit strings 10 , allowing for instance large-scale virtual screening or the rapid estimation of synthetic accessibility of molecules 11 . FP are also employed in classification models for ADME behaviours built by support vector machine (SVM) or Bayesian techniques 12 . Remarkably, computer-aided drug design (CADD) has been a pioneer field for the application of such machine learning technologies”concepts[20]
conceptFP — not defined in this paper's own words; abbreviation for molecular fingerprint — “Cheminformaticians developed different molecular descriptors mined from chemical structures. One of the most popular examples is the molecular fingerprint (FP), which consists in a sequence of bits defining the presence or absence of chemical features in a molecule. The FP2 method 9 is one archetype of topological (or path-based) FP, which considers all fragments of the molecular structure following a linear path up to a given number of bonds. Every possible path is hashed to generate the bit string (i.e. the FP). A major advantage of FP is the efficiency by which computers handle such bit strings 10 , allowing for instance large-scale virtual screening or the rapid estimation of synthetic accessibility of molecules 11 . FP are also employed in classification models for ADME behaviours built by support vector machine (SVM) or Bayesian techniques 12 . Remarkably, computer-aided drug design (CADD) has been a pioneer field for the application of such machine learning technologies”concepts[21]
conceptFP2 method — not defined in this paper's own words; topological path-based molecular fingerprint — “Cheminformaticians developed different molecular descriptors mined from chemical structures. One of the most popular examples is the molecular fingerprint (FP), which consists in a sequence of bits defining the presence or absence of chemical features in a molecule. The FP2 method 9 is one archetype of topological (or path-based) FP, which considers all fragments of the molecular structure following a linear path up to a given number of bonds. Every possible path is hashed to generate the bit string (i.e. the FP). A major advantage of FP is the efficiency by which computers handle such bit strings 10 , allowing for instance large-scale virtual screening or the rapid estimation of synthetic accessibility of molecules 11 . FP are also employed in classification models for ADME behaviours built by support vector machine (SVM) or Bayesian techniques 12 . Remarkably, computer-aided drug design (CADD) has been a pioneer field for the application of such machine learning technologies”concepts[22]
conceptsequence of bits — not defined in this paper's own words; bit-string representation of chemical features — “Cheminformaticians developed different molecular descriptors mined from chemical structures. One of the most popular examples is the molecular fingerprint (FP), which consists in a sequence of bits defining the presence or absence of chemical features in a molecule. The FP2 method 9 is one archetype of topological (or path-based) FP, which considers all fragments of the molecular structure following a linear path up to a given number of bonds. Every possible path is hashed to generate the bit string (i.e. the FP). A major advantage of FP is the efficiency by which computers handle such bit strings 10 , allowing for instance large-scale virtual screening or the rapid estimation of synthetic accessibility of molecules 11 . FP are also employed in classification models for ADME behaviours built by support vector machine (SVM) or Bayesian techniques 12 . Remarkably, computer-aided drug design (CADD) has been a pioneer field for the application of such machine learning technologies”concepts[23]
conceptvirtual screening — not defined in this paper's own words; large-scale computational screening enabled by fingerprints — “Cheminformaticians developed different molecular descriptors mined from chemical structures. One of the most popular examples is the molecular fingerprint (FP), which consists in a sequence of bits defining the presence or absence of chemical features in a molecule. The FP2 method 9 is one archetype of topological (or path-based) FP, which considers all fragments of the molecular structure following a linear path up to a given number of bonds. Every possible path is hashed to generate the bit string (i.e. the FP). A major advantage of FP is the efficiency by which computers handle such bit strings 10 , allowing for instance large-scale virtual screening or the rapid estimation of synthetic accessibility of molecules 11 . FP are also employed in classification models for ADME behaviours built by support vector machine (SVM) or Bayesian techniques 12 . Remarkably, computer-aided drug design (CADD) has been a pioneer field for the application of such machine learning technologies”concepts[24]
conceptsupport vector machine — not defined in this paper's own words; machine-learning classifier used for ADME behaviour — “Cheminformaticians developed different molecular descriptors mined from chemical structures. One of the most popular examples is the molecular fingerprint (FP), which consists in a sequence of bits defining the presence or absence of chemical features in a molecule. The FP2 method 9 is one archetype of topological (or path-based) FP, which considers all fragments of the molecular structure following a linear path up to a given number of bonds. Every possible path is hashed to generate the bit string (i.e. the FP). A major advantage of FP is the efficiency by which computers handle such bit strings 10 , allowing for instance large-scale virtual screening or the rapid estimation of synthetic accessibility of molecules 11 . FP are also employed in classification models for ADME behaviours built by support vector machine (SVM) or Bayesian techniques 12 . Remarkably, computer-aided drug design (CADD) has been a pioneer field for the application of such machine learning technologies”concepts[25]
conceptSVM — not defined in this paper's own words; abbreviation for support vector machine — “SwissADME enables the estimation for a chemical to be substrate of P-gp or inhibitor of the most important CYP isoenzymes. We applied the support vector machine algorithm (SVM) 51 on meticulously cleansed large datasets of known substrates/non-substrates or inhibitors/non-inhibitors (for details, see Computational Methods ). In similar contexts, SVM was found to perform better than other machine-learning algorithms for binary classification 40 52 . The models return “Yes” or “No” if the molecule under investigation has higher probability to be substrate or non-substrate of P-gp (respectively inhibitor or non-inhibitor of a given CYP). The statistical performance of the classification models is given in Table 1 , in comparison with previous SVM models on the same targets. We restricted the benchmark to state-of-the-art methods, published after 2010”concepts[26]
conceptcomputer-aided drug design — not defined in this paper's own words; computational molecular-design field — “Cheminformaticians developed different molecular descriptors mined from chemical structures. One of the most popular examples is the molecular fingerprint (FP), which consists in a sequence of bits defining the presence or absence of chemical features in a molecule. The FP2 method 9 is one archetype of topological (or path-based) FP, which considers all fragments of the molecular structure following a linear path up to a given number of bonds. Every possible path is hashed to generate the bit string (i.e. the FP). A major advantage of FP is the efficiency by which computers handle such bit strings 10 , allowing for instance large-scale virtual screening or the rapid estimation of synthetic accessibility of molecules 11 . FP are also employed in classification models for ADME behaviours built by support vector machine (SVM) or Bayesian techniques 12 . Remarkably, computer-aided drug design (CADD) has been a pioneer field for the application of such machine learning technologies”concepts[27]
conceptCADD — not defined in this paper's own words; abbreviation for computer-aided drug design — “Cheminformaticians developed different molecular descriptors mined from chemical structures. One of the most popular examples is the molecular fingerprint (FP), which consists in a sequence of bits defining the presence or absence of chemical features in a molecule. The FP2 method 9 is one archetype of topological (or path-based) FP, which considers all fragments of the molecular structure following a linear path up to a given number of bonds. Every possible path is hashed to generate the bit string (i.e. the FP). A major advantage of FP is the efficiency by which computers handle such bit strings 10 , allowing for instance large-scale virtual screening or the rapid estimation of synthetic accessibility of molecules 11 . FP are also employed in classification models for ADME behaviours built by support vector machine (SVM) or Bayesian techniques 12 . Remarkably, computer-aided drug design (CADD) has been a pioneer field for the application of such machine learning technologies”concepts[28]
conceptfreely available in silico ADME tools — not defined in this paper's own words; single-property or single-model free tools — “Because most freely available in silico ADME tools focus on one specific property or model only, while generalist ADME packages are commercial software, we felt the need of gathering what we consider the most relevant computational methods to provide a global appraisal of the pharmacokinetics profile of small molecules. The methods were selected for robustness, speed, but also and importantly for ease of interpretation to enable efficient translation to medicinal chemistry through molecular design. Some of them were adapted with open-source algorithms to ensure freedom to operate for the global scientific community. Others are our own models developed and tested on purpose. When applicable, multiple predictions of the same parameter are provided to allow for a consensus view of a given property”concepts[29]
conceptgeneralist ADME packages — not defined in this paper's own words; commercial multi-property alternatives — “Because most freely available in silico ADME tools focus on one specific property or model only, while generalist ADME packages are commercial software, we felt the need of gathering what we consider the most relevant computational methods to provide a global appraisal of the pharmacokinetics profile of small molecules. The methods were selected for robustness, speed, but also and importantly for ease of interpretation to enable efficient translation to medicinal chemistry through molecular design. Some of them were adapted with open-source algorithms to ensure freedom to operate for the global scientific community. Others are our own models developed and tested on purpose. When applicable, multiple predictions of the same parameter are provided to allow for a consensus view of a given property”concepts[30]
conceptconsensus view — not defined in this paper's own words; multi-predictor appraisal of one property — “Because most freely available in silico ADME tools focus on one specific property or model only, while generalist ADME packages are commercial software, we felt the need of gathering what we consider the most relevant computational methods to provide a global appraisal of the pharmacokinetics profile of small molecules. The methods were selected for robustness, speed, but also and importantly for ease of interpretation to enable efficient translation to medicinal chemistry through molecular design. Some of them were adapted with open-source algorithms to ensure freedom to operate for the global scientific community. Others are our own models developed and tested on purpose. When applicable, multiple predictions of the same parameter are provided to allow for a consensus view of a given property”concepts[31]
conceptmultiple predictions — not defined in this paper's own words; several estimates of the same molecular property — “Because most freely available in silico ADME tools focus on one specific property or model only, while generalist ADME packages are commercial software, we felt the need of gathering what we consider the most relevant computational methods to provide a global appraisal of the pharmacokinetics profile of small molecules. The methods were selected for robustness, speed, but also and importantly for ease of interpretation to enable efficient translation to medicinal chemistry through molecular design. Some of them were adapted with open-source algorithms to ensure freedom to operate for the global scientific community. Others are our own models developed and tested on purpose. When applicable, multiple predictions of the same parameter are provided to allow for a consensus view of a given property”concepts[32]
conceptmolecular sketcher — not defined in this paper's own words; Marvin JS interface for structure entry and editing — “The input zone itself comprises a molecular sketcher based on ChemAxon’s Marvin JS ( http://www.chemaxon.com ) that enables the user to import (from a file or an external database), draw, and edit a 2D chemical structure, and to transfer it to a list of molecules. This list, on the right-hand side of the submission page, is the actual input for computation. It can be edited as a standard text, allowing for typing or pasting SMILES. The list is made to contain one input molecule per line, defined by a SMILES and optionally a name separated by a space. If name is omitted, SwissADME will automatically provide an identifier. Noteworthy, both buttons for transferring the sketch to SMILES list and for running the computation are dynamic, in the sense that they are active only if the action is possible. At the time of writing, one can expect a result in 1 to 5 seconds for a drug-like molecule”concepts[33]
conceptSMILES — not defined in this paper's own words; line-oriented molecule input representation — “The input zone itself comprises a molecular sketcher based on ChemAxon’s Marvin JS ( http://www.chemaxon.com ) that enables the user to import (from a file or an external database), draw, and edit a 2D chemical structure, and to transfer it to a list of molecules. This list, on the right-hand side of the submission page, is the actual input for computation. It can be edited as a standard text, allowing for typing or pasting SMILES. The list is made to contain one input molecule per line, defined by a SMILES and optionally a name separated by a space. If name is omitted, SwissADME will automatically provide an identifier. Noteworthy, both buttons for transferring the sketch to SMILES list and for running the computation are dynamic, in the sense that they are active only if the action is possible. At the time of writing, one can expect a result in 1 to 5 seconds for a drug-like molecule”concepts[34]
conceptone-panel-per-molecule — not defined in this paper's own words; output organization compiling values per molecule — “The output panels are loaded in the same Web page. There is one panel compiling all values for each molecule. It is filled immediately after calculation completion, one molecule after the other. This way it is possible to inspect the results for the first compounds without waiting for the whole list to be treated. This one-panel-per-molecule ( Fig. 2 ) is headed by the molecule name and divided into different sections”concepts[35]
conceptmolecular weight — not defined in this paper's own words; size descriptor abbreviated MW — “Simple molecular and physicochemical descriptors like molecular weight (MW), molecular refractivity (MR), count of specific atom types and polar surface area (PSA) are compiled in this section. The values are computed with OpenBabel 9 , version 2.3.0. The PSA is calculated using the fragmental technique called topological polar surface area (TPSA), considering sulfur and phosphorus as polar atoms 25 . This has proven a useful descriptor in many models and rules to quickly estimate some ADME properties, especially with regards to biological barrier crossing such as absorption and brain access”concepts[36]
conceptmolecular refractivity — not defined in this paper's own words; physicochemical descriptor abbreviated MR — “Simple molecular and physicochemical descriptors like molecular weight (MW), molecular refractivity (MR), count of specific atom types and polar surface area (PSA) are compiled in this section. The values are computed with OpenBabel 9 , version 2.3.0. The PSA is calculated using the fragmental technique called topological polar surface area (TPSA), considering sulfur and phosphorus as polar atoms 25 . This has proven a useful descriptor in many models and rules to quickly estimate some ADME properties, especially with regards to biological barrier crossing such as absorption and brain access”concepts[37]
conceptpolar surface area — not defined in this paper's own words; barrier-crossing descriptor abbreviated PSA — “Simple molecular and physicochemical descriptors like molecular weight (MW), molecular refractivity (MR), count of specific atom types and polar surface area (PSA) are compiled in this section. The values are computed with OpenBabel 9 , version 2.3.0. The PSA is calculated using the fragmental technique called topological polar surface area (TPSA), considering sulfur and phosphorus as polar atoms 25 . This has proven a useful descriptor in many models and rules to quickly estimate some ADME properties, especially with regards to biological barrier crossing such as absorption and brain access”concepts[38]
conceptPSA — not defined in this paper's own words; abbreviation for polar surface area — “Simple molecular and physicochemical descriptors like molecular weight (MW), molecular refractivity (MR), count of specific atom types and polar surface area (PSA) are compiled in this section. The values are computed with OpenBabel 9 , version 2.3.0. The PSA is calculated using the fragmental technique called topological polar surface area (TPSA), considering sulfur and phosphorus as polar atoms 25 . This has proven a useful descriptor in many models and rules to quickly estimate some ADME properties, especially with regards to biological barrier crossing such as absorption and brain access”concepts[39]
concepttopological polar surface area — not defined in this paper's own words; fragmentally calculated polar surface-area descriptor — “Simple molecular and physicochemical descriptors like molecular weight (MW), molecular refractivity (MR), count of specific atom types and polar surface area (PSA) are compiled in this section. The values are computed with OpenBabel 9 , version 2.3.0. The PSA is calculated using the fragmental technique called topological polar surface area (TPSA), considering sulfur and phosphorus as polar atoms 25 . This has proven a useful descriptor in many models and rules to quickly estimate some ADME properties, especially with regards to biological barrier crossing such as absorption and brain access”concepts[40]
conceptTPSA — not defined in this paper's own words; abbreviation for topological polar surface area — “Simple molecular and physicochemical descriptors like molecular weight (MW), molecular refractivity (MR), count of specific atom types and polar surface area (PSA) are compiled in this section. The values are computed with OpenBabel 9 , version 2.3.0. The PSA is calculated using the fragmental technique called topological polar surface area (TPSA), considering sulfur and phosphorus as polar atoms 25 . This has proven a useful descriptor in many models and rules to quickly estimate some ADME properties, especially with regards to biological barrier crossing such as absorption and brain access”concepts[41]
conceptpartition coefficient between n -octanol and water — not defined in this paper's own words; classical lipophilicity descriptor — “The partition coefficient between n -octanol and water (log P o/w ) is the classical descriptor for Lipophilicity . It has a dedicated section in SwissADME due to the critical importance of this physicochemical property for pharmacokinetics drug discovery 26 27 . Many computational methods for log P o/w estimation were developed with diverse performance on various chemical sets. Common practice is to use multiple predictors either to select the most accurate methods for a given chemical series or to generate consensus estimation. The models behind the predictors should be as diverse as possible to increase the prediction accuracy through consensus log P o/w 28 . In that regard, SwissADME gives access to five freely available predictive models; i.e. XLOGP3, an atomistic method including corrective factors and knowledge-based library 29 ; WLOGP, our own implementation of a purely atomistic method based on the fragmental system of Wildman and Crippen 30 ; MLOGP, an archetype of topological method relying on a linear relationship with 13 molecular descriptors implemented from refs 31 and 32 ; SILICOS-IT, an hybrid method relying on 27 fragments and 7 topological descriptors ( http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html , accessed June 2016); and finally iLOGP, our in-house physics-based method relying on free energies of solvation in n -octanol and water calculated by the Generalized-Born and solvent accessible surface area (GB/SA) model. iLOGP was benchmarked on two drug or drug-like external sets and performed equally as or better than six well-established predictors 16 . The consensus log P o/w is the arithmetic mean of the values predicted by the five proposed methods”concepts[42]
conceptlog P o/w — not defined in this paper's own words; logarithmic octanol-water partition coefficient — “The partition coefficient between n -octanol and water (log P o/w ) is the classical descriptor for Lipophilicity . It has a dedicated section in SwissADME due to the critical importance of this physicochemical property for pharmacokinetics drug discovery 26 27 . Many computational methods for log P o/w estimation were developed with diverse performance on various chemical sets. Common practice is to use multiple predictors either to select the most accurate methods for a given chemical series or to generate consensus estimation. The models behind the predictors should be as diverse as possible to increase the prediction accuracy through consensus log P o/w 28 . In that regard, SwissADME gives access to five freely available predictive models; i.e. XLOGP3, an atomistic method including corrective factors and knowledge-based library 29 ; WLOGP, our own implementation of a purely atomistic method based on the fragmental system of Wildman and Crippen 30 ; MLOGP, an archetype of topological method relying on a linear relationship with 13 molecular descriptors implemented from refs 31 and 32 ; SILICOS-IT, an hybrid method relying on 27 fragments and 7 topological descriptors ( http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html , accessed June 2016); and finally iLOGP, our in-house physics-based method relying on free energies of solvation in n -octanol and water calculated by the Generalized-Born and solvent accessible surface area (GB/SA) model. iLOGP was benchmarked on two drug or drug-like external sets and performed equally as or better than six well-established predictors 16 . The consensus log P o/w is the arithmetic mean of the values predicted by the five proposed methods”concepts[43]
conceptconsensus log P o/w — not defined in this paper's own words; arithmetic mean across five lipophilicity predictions — “The partition coefficient between n -octanol and water (log P o/w ) is the classical descriptor for Lipophilicity . It has a dedicated section in SwissADME due to the critical importance of this physicochemical property for pharmacokinetics drug discovery 26 27 . Many computational methods for log P o/w estimation were developed with diverse performance on various chemical sets. Common practice is to use multiple predictors either to select the most accurate methods for a given chemical series or to generate consensus estimation. The models behind the predictors should be as diverse as possible to increase the prediction accuracy through consensus log P o/w 28 . In that regard, SwissADME gives access to five freely available predictive models; i.e. XLOGP3, an atomistic method including corrective factors and knowledge-based library 29 ; WLOGP, our own implementation of a purely atomistic method based on the fragmental system of Wildman and Crippen 30 ; MLOGP, an archetype of topological method relying on a linear relationship with 13 molecular descriptors implemented from refs 31 and 32 ; SILICOS-IT, an hybrid method relying on 27 fragments and 7 topological descriptors ( http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html , accessed June 2016); and finally iLOGP, our in-house physics-based method relying on free energies of solvation in n -octanol and water calculated by the Generalized-Born and solvent accessible surface area (GB/SA) model. iLOGP was benchmarked on two drug or drug-like external sets and performed equally as or better than six well-established predictors 16 . The consensus log P o/w is the arithmetic mean of the values predicted by the five proposed methods”concepts[44]
conceptWater Solubility — not defined in this paper's own words; aqueous-solubility outcome predicted by three methods — “Having a soluble molecule greatly facilitates many drug development activities, primarily the ease of handling and formulation 33 . Moreover, for discovery projects targeting oral administration, solubility is one major property influencing absorption 34 . As well, a drug meant for parenteral usage has to be highly soluble in water to deliver a sufficient quantity of active ingredient in the small volume of such pharmaceutical dosage 35 . Two topological methods to predict Water Solubility are included in SwissADME. The first one is an implementation of the ESOL model 36 and the second one is adapted from Ali et al . 37 . Both differ from the seminal general solubility equation 38 since they avoid the melting point parameter; the latter being challenging to predict. Moreover they demonstrate strong linear correlation between predicted and experimental values (R 2 = 0.69 and 0.81, respectively). SwissADME third predictor for solubility was developed by SILICOS-IT. The linear correlation coefficient of this fragmental method corrected by molecular weight is R 2 = 0.75 ( http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html , accessed June 2016). All predicted values are the decimal logarithm of the molar solubility in water (log S ). SwissADME also provides solubility in mol/l and mg/ml along with qualitative solubility classes”concepts[45]
conceptlog S — not defined in this paper's own words; decimal logarithm of molar water solubility — “Having a soluble molecule greatly facilitates many drug development activities, primarily the ease of handling and formulation 33 . Moreover, for discovery projects targeting oral administration, solubility is one major property influencing absorption 34 . As well, a drug meant for parenteral usage has to be highly soluble in water to deliver a sufficient quantity of active ingredient in the small volume of such pharmaceutical dosage 35 . Two topological methods to predict Water Solubility are included in SwissADME. The first one is an implementation of the ESOL model 36 and the second one is adapted from Ali et al . 37 . Both differ from the seminal general solubility equation 38 since they avoid the melting point parameter; the latter being challenging to predict. Moreover they demonstrate strong linear correlation between predicted and experimental values (R 2 = 0.69 and 0.81, respectively). SwissADME third predictor for solubility was developed by SILICOS-IT. The linear correlation coefficient of this fragmental method corrected by molecular weight is R 2 = 0.75 ( http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html , accessed June 2016). All predicted values are the decimal logarithm of the molar solubility in water (log S ). SwissADME also provides solubility in mol/l and mg/ml along with qualitative solubility classes”concepts[46]
conceptskin permeability coefficient — not defined in this paper's own words; permeation outcome abbreviated Kp — “One model is a multiple linear regression, which aims at predicting the skin permeability coefficient ( K p ). It is adapted from Potts and Guy 39 , who found K p linearly correlated with molecular size and lipophilicity (R 2 = 0.67). The more negative the log K p (with K p in cm/s), the less skin permeant is the molecule”concepts[47]
conceptlog K p — not defined in this paper's own words; decimal logarithm of skin permeability coefficient — “One model is a multiple linear regression, which aims at predicting the skin permeability coefficient ( K p ). It is adapted from Potts and Guy 39 , who found K p linearly correlated with molecular size and lipophilicity (R 2 = 0.67). The more negative the log K p (with K p in cm/s), the less skin permeant is the molecule”concepts[48]
concepthuman gastrointestinal absorption — not defined in this paper's own words; passive gut-absorption behaviour — “The predictions for passive human gastrointestinal absorption (HIA) and blood-brain barrier (BBB) permeation both consist in the readout of the BOILED-Egg model 17 , an intuitive graphical classification model, which can be displayed in the SwissADME result page by clicking the red button appearing below the sketcher when all input molecules have been processed (refer to Graphical Output ). Other binary classification models are included, which focus on the propensity for a given small molecule to be substrate or inhibitor of proteins governing important pharmacokinetic behaviours”concepts[49]
conceptHIA — not defined in this paper's own words; abbreviation for human gastrointestinal absorption — “The predictions for passive human gastrointestinal absorption (HIA) and blood-brain barrier (BBB) permeation both consist in the readout of the BOILED-Egg model 17 , an intuitive graphical classification model, which can be displayed in the SwissADME result page by clicking the red button appearing below the sketcher when all input molecules have been processed (refer to Graphical Output ). Other binary classification models are included, which focus on the propensity for a given small molecule to be substrate or inhibitor of proteins governing important pharmacokinetic behaviours”concepts[50]
conceptblood-brain barrier — not defined in this paper's own words; barrier whose passive permeation is predicted — “The predictions for passive human gastrointestinal absorption (HIA) and blood-brain barrier (BBB) permeation both consist in the readout of the BOILED-Egg model 17 , an intuitive graphical classification model, which can be displayed in the SwissADME result page by clicking the red button appearing below the sketcher when all input molecules have been processed (refer to Graphical Output ). Other binary classification models are included, which focus on the propensity for a given small molecule to be substrate or inhibitor of proteins governing important pharmacokinetic behaviours”concepts[51]
conceptBBB — not defined in this paper's own words; abbreviation for blood-brain barrier — “The predictions for passive human gastrointestinal absorption (HIA) and blood-brain barrier (BBB) permeation both consist in the readout of the BOILED-Egg model 17 , an intuitive graphical classification model, which can be displayed in the SwissADME result page by clicking the red button appearing below the sketcher when all input molecules have been processed (refer to Graphical Output ). Other binary classification models are included, which focus on the propensity for a given small molecule to be substrate or inhibitor of proteins governing important pharmacokinetic behaviours”concepts[52]
conceptpermeability glycoprotein — not defined in this paper's own words; active-efflux protein abbreviated P-gp — “The knowledge about compounds being substrate or non-substrate of the permeability glycoprotein (P-gp, suggested the most important member among ATP-binding cassette transporters or ABC-transporters) is key to appraise active efflux through biological membranes, for instance from the gastrointestinal wall to the lumen or from the brain 40 . One major role of P-gp is to protect the central nervous system (CNS) from xenobiotics 41 . Importantly as well, P-gp is overexpressed in some tumour cells and leads to multidrug-resistant cancers”concepts[53]
conceptP-gp — not defined in this paper's own words; permeability-glycoprotein efflux mechanism — “The knowledge about compounds being substrate or non-substrate of the permeability glycoprotein (P-gp, suggested the most important member among ATP-binding cassette transporters or ABC-transporters) is key to appraise active efflux through biological membranes, for instance from the gastrointestinal wall to the lumen or from the brain 40 . One major role of P-gp is to protect the central nervous system (CNS) from xenobiotics 41 . Importantly as well, P-gp is overexpressed in some tumour cells and leads to multidrug-resistant cancers”concepts[54]
conceptcentral nervous system — not defined in this paper's own words; tissue system protected from xenobiotics by P-gp — “The knowledge about compounds being substrate or non-substrate of the permeability glycoprotein (P-gp, suggested the most important member among ATP-binding cassette transporters or ABC-transporters) is key to appraise active efflux through biological membranes, for instance from the gastrointestinal wall to the lumen or from the brain 40 . One major role of P-gp is to protect the central nervous system (CNS) from xenobiotics 41 . Importantly as well, P-gp is overexpressed in some tumour cells and leads to multidrug-resistant cancers”concepts[55]
conceptcytochromes P450 — not defined in this paper's own words; drug-metabolizing isoenzyme superfamily — “Also essential is the knowledge about interaction of molecules with cytochromes P450 (CYP). This superfamily of isoenzymes is a key player in drug elimination through metabolic biotransformation 43 . It has been suggested that CYP and P-gp can process small molecules synergistically to improve protection of tissues and organisms 44 . One can estimate that 50 to 90% (depending on the authors) of therapeutic molecules are substrate of five major isoforms (CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4) 45 46 . Inhibition of these isoenzymes is certainly one major cause of pharmacokinetics-related drug-drug interactions 47 48 leading to toxic or other unwanted adverse effects due to the lower clearance and accumulation of the drug or its metabolites 49 . Numerous inhibitors of the CYP isoforms have been identified. Some are affecting different CYP isoforms, while other compounds show selectivity for specific isoenzymes 50 . It is therefore of great importance for drug discovery to predict the propensity with which the molecule will cause significant drug interactions through inhibition of CYPs, and to determine which isoforms are affected”concepts[56]
conceptCYP — not defined in this paper's own words; abbreviation for cytochromes P450 — “Also essential is the knowledge about interaction of molecules with cytochromes P450 (CYP). This superfamily of isoenzymes is a key player in drug elimination through metabolic biotransformation 43 . It has been suggested that CYP and P-gp can process small molecules synergistically to improve protection of tissues and organisms 44 . One can estimate that 50 to 90% (depending on the authors) of therapeutic molecules are substrate of five major isoforms (CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4) 45 46 . Inhibition of these isoenzymes is certainly one major cause of pharmacokinetics-related drug-drug interactions 47 48 leading to toxic or other unwanted adverse effects due to the lower clearance and accumulation of the drug or its metabolites 49 . Numerous inhibitors of the CYP isoforms have been identified. Some are affecting different CYP isoforms, while other compounds show selectivity for specific isoenzymes 50 . It is therefore of great importance for drug discovery to predict the propensity with which the molecule will cause significant drug interactions through inhibition of CYPs, and to determine which isoforms are affected”concepts[57]
conceptInhibition of these isoenzymes — not defined in this paper's own words; CYP inhibition implicated in drug interactions — “Also essential is the knowledge about interaction of molecules with cytochromes P450 (CYP). This superfamily of isoenzymes is a key player in drug elimination through metabolic biotransformation 43 . It has been suggested that CYP and P-gp can process small molecules synergistically to improve protection of tissues and organisms 44 . One can estimate that 50 to 90% (depending on the authors) of therapeutic molecules are substrate of five major isoforms (CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4) 45 46 . Inhibition of these isoenzymes is certainly one major cause of pharmacokinetics-related drug-drug interactions 47 48 leading to toxic or other unwanted adverse effects due to the lower clearance and accumulation of the drug or its metabolites 49 . Numerous inhibitors of the CYP isoforms have been identified. Some are affecting different CYP isoforms, while other compounds show selectivity for specific isoenzymes 50 . It is therefore of great importance for drug discovery to predict the propensity with which the molecule will cause significant drug interactions through inhibition of CYPs, and to determine which isoforms are affected”concepts[58]
conceptpharmacokinetics-related drug-drug interactions — not defined in this paper's own words; adverse interaction outcome of CYP inhibition — “Also essential is the knowledge about interaction of molecules with cytochromes P450 (CYP). This superfamily of isoenzymes is a key player in drug elimination through metabolic biotransformation 43 . It has been suggested that CYP and P-gp can process small molecules synergistically to improve protection of tissues and organisms 44 . One can estimate that 50 to 90% (depending on the authors) of therapeutic molecules are substrate of five major isoforms (CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4) 45 46 . Inhibition of these isoenzymes is certainly one major cause of pharmacokinetics-related drug-drug interactions 47 48 leading to toxic or other unwanted adverse effects due to the lower clearance and accumulation of the drug or its metabolites 49 . Numerous inhibitors of the CYP isoforms have been identified. Some are affecting different CYP isoforms, while other compounds show selectivity for specific isoenzymes 50 . It is therefore of great importance for drug discovery to predict the propensity with which the molecule will cause significant drug interactions through inhibition of CYPs, and to determine which isoforms are affected”concepts[59]
concepttoxic or other unwanted adverse effects — not defined in this paper's own words; downstream harms of drug interactions — “Also essential is the knowledge about interaction of molecules with cytochromes P450 (CYP). This superfamily of isoenzymes is a key player in drug elimination through metabolic biotransformation 43 . It has been suggested that CYP and P-gp can process small molecules synergistically to improve protection of tissues and organisms 44 . One can estimate that 50 to 90% (depending on the authors) of therapeutic molecules are substrate of five major isoforms (CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4) 45 46 . Inhibition of these isoenzymes is certainly one major cause of pharmacokinetics-related drug-drug interactions 47 48 leading to toxic or other unwanted adverse effects due to the lower clearance and accumulation of the drug or its metabolites 49 . Numerous inhibitors of the CYP isoforms have been identified. Some are affecting different CYP isoforms, while other compounds show selectivity for specific isoenzymes 50 . It is therefore of great importance for drug discovery to predict the propensity with which the molecule will cause significant drug interactions through inhibition of CYPs, and to determine which isoforms are affected”concepts[60]
concepttraining and test sets — not defined in this paper's own words; datasets used to build and evaluate classifiers — “The quantification of the models performance is not straightforwardly comparable, because the training sets are different, most of the published models are less than 10-fold cross-validated and some statistical parameters are missing. Nevertheless, the SwissADME classifiers are competitive with previous models in term of robustness, with cross-validation accuracy (ACC CV ) grossly at the same level. Furthermore, cross-validated areas under receiver operating characteristic (ROC) curves (AUC CV ) are equal to the corresponding values found in the literature. Likewise, external prediction power is difficult to compare, as each test set includes different molecules. However, the predictive capacity of SwissADME classifiers is grossly equivalent to the related SVM methods, both in terms of external accuracy (ACC ext ) and external area under ROC curve (AUC ext ). The models for which external validation was not found (P-gp of refs 15 and 53 ) have to be taken with extreme caution since they possibly suffer from overfitting biases. Noteworthy, some of the published models (e.g. CYP2C9 and CYP3A4 of ref. 54 or CYP2C9 of ref. 55 ) were built on severely unbalanced training sets and tested on clearly unbalanced external sets. As demonstrated by Carbon-Mangels et al . 56 the relevance of machine-learning classification methods, and especially SVM, are negatively impacted by datasets with one significantly more populated class. In that case, accuracy measurements are overestimated and prone to mislead the construction and the evaluation of the model. Moreover, some SVM models were published with small training and test sets (P-gp of refs 15 and 57 ), which imply questionable capacity of generalization and broadness of applicability domains. We emphasize that for SwissADME classifiers, both training and test sets were carefully cleansed and checked for size, diversity and balance between classes. Furthermore, our SVM models rely merely on molecular and physicochemical descriptors generated by SwissADME. We believe that this improves robustness and sustainability of the underlying methodologies. In particular, not using molecular fingerprints, molecular graphs or other structural descriptions can be an handicap to generate high statistical values but should also limit overfitting biases and yield more generalist predictive models, not necessarily influenced by specific chemical scaffolds or moieties. In our practice, these well-performing models able to estimate important ADME behaviours are of great support for pharmacokinetics optimization and evaluation of small molecules”concepts[61]
conceptcross-validation accuracy — not defined in this paper's own words; internal classifier-robustness statistic — “The quantification of the models performance is not straightforwardly comparable, because the training sets are different, most of the published models are less than 10-fold cross-validated and some statistical parameters are missing. Nevertheless, the SwissADME classifiers are competitive with previous models in term of robustness, with cross-validation accuracy (ACC CV ) grossly at the same level. Furthermore, cross-validated areas under receiver operating characteristic (ROC) curves (AUC CV ) are equal to the corresponding values found in the literature. Likewise, external prediction power is difficult to compare, as each test set includes different molecules. However, the predictive capacity of SwissADME classifiers is grossly equivalent to the related SVM methods, both in terms of external accuracy (ACC ext ) and external area under ROC curve (AUC ext ). The models for which external validation was not found (P-gp of refs 15 and 53 ) have to be taken with extreme caution since they possibly suffer from overfitting biases. Noteworthy, some of the published models (e.g. CYP2C9 and CYP3A4 of ref. 54 or CYP2C9 of ref. 55 ) were built on severely unbalanced training sets and tested on clearly unbalanced external sets. As demonstrated by Carbon-Mangels et al . 56 the relevance of machine-learning classification methods, and especially SVM, are negatively impacted by datasets with one significantly more populated class. In that case, accuracy measurements are overestimated and prone to mislead the construction and the evaluation of the model. Moreover, some SVM models were published with small training and test sets (P-gp of refs 15 and 57 ), which imply questionable capacity of generalization and broadness of applicability domains. We emphasize that for SwissADME classifiers, both training and test sets were carefully cleansed and checked for size, diversity and balance between classes. Furthermore, our SVM models rely merely on molecular and physicochemical descriptors generated by SwissADME. We believe that this improves robustness and sustainability of the underlying methodologies. In particular, not using molecular fingerprints, molecular graphs or other structural descriptions can be an handicap to generate high statistical values but should also limit overfitting biases and yield more generalist predictive models, not necessarily influenced by specific chemical scaffolds or moieties. In our practice, these well-performing models able to estimate important ADME behaviours are of great support for pharmacokinetics optimization and evaluation of small molecules”concepts[62]
conceptexternal area under ROC curve — not defined in this paper's own words; external predictive-power statistic — “The quantification of the models performance is not straightforwardly comparable, because the training sets are different, most of the published models are less than 10-fold cross-validated and some statistical parameters are missing. Nevertheless, the SwissADME classifiers are competitive with previous models in term of robustness, with cross-validation accuracy (ACC CV ) grossly at the same level. Furthermore, cross-validated areas under receiver operating characteristic (ROC) curves (AUC CV ) are equal to the corresponding values found in the literature. Likewise, external prediction power is difficult to compare, as each test set includes different molecules. However, the predictive capacity of SwissADME classifiers is grossly equivalent to the related SVM methods, both in terms of external accuracy (ACC ext ) and external area under ROC curve (AUC ext ). The models for which external validation was not found (P-gp of refs 15 and 53 ) have to be taken with extreme caution since they possibly suffer from overfitting biases. Noteworthy, some of the published models (e.g. CYP2C9 and CYP3A4 of ref. 54 or CYP2C9 of ref. 55 ) were built on severely unbalanced training sets and tested on clearly unbalanced external sets. As demonstrated by Carbon-Mangels et al . 56 the relevance of machine-learning classification methods, and especially SVM, are negatively impacted by datasets with one significantly more populated class. In that case, accuracy measurements are overestimated and prone to mislead the construction and the evaluation of the model. Moreover, some SVM models were published with small training and test sets (P-gp of refs 15 and 57 ), which imply questionable capacity of generalization and broadness of applicability domains. We emphasize that for SwissADME classifiers, both training and test sets were carefully cleansed and checked for size, diversity and balance between classes. Furthermore, our SVM models rely merely on molecular and physicochemical descriptors generated by SwissADME. We believe that this improves robustness and sustainability of the underlying methodologies. In particular, not using molecular fingerprints, molecular graphs or other structural descriptions can be an handicap to generate high statistical values but should also limit overfitting biases and yield more generalist predictive models, not necessarily influenced by specific chemical scaffolds or moieties. In our practice, these well-performing models able to estimate important ADME behaviours are of great support for pharmacokinetics optimization and evaluation of small molecules”concepts[63]
conceptoverfitting biases — not defined in this paper's own words; generalization risk from weak validation or skewed data — “The quantification of the models performance is not straightforwardly comparable, because the training sets are different, most of the published models are less than 10-fold cross-validated and some statistical parameters are missing. Nevertheless, the SwissADME classifiers are competitive with previous models in term of robustness, with cross-validation accuracy (ACC CV ) grossly at the same level. Furthermore, cross-validated areas under receiver operating characteristic (ROC) curves (AUC CV ) are equal to the corresponding values found in the literature. Likewise, external prediction power is difficult to compare, as each test set includes different molecules. However, the predictive capacity of SwissADME classifiers is grossly equivalent to the related SVM methods, both in terms of external accuracy (ACC ext ) and external area under ROC curve (AUC ext ). The models for which external validation was not found (P-gp of refs 15 and 53 ) have to be taken with extreme caution since they possibly suffer from overfitting biases. Noteworthy, some of the published models (e.g. CYP2C9 and CYP3A4 of ref. 54 or CYP2C9 of ref. 55 ) were built on severely unbalanced training sets and tested on clearly unbalanced external sets. As demonstrated by Carbon-Mangels et al . 56 the relevance of machine-learning classification methods, and especially SVM, are negatively impacted by datasets with one significantly more populated class. In that case, accuracy measurements are overestimated and prone to mislead the construction and the evaluation of the model. Moreover, some SVM models were published with small training and test sets (P-gp of refs 15 and 57 ), which imply questionable capacity of generalization and broadness of applicability domains. We emphasize that for SwissADME classifiers, both training and test sets were carefully cleansed and checked for size, diversity and balance between classes. Furthermore, our SVM models rely merely on molecular and physicochemical descriptors generated by SwissADME. We believe that this improves robustness and sustainability of the underlying methodologies. In particular, not using molecular fingerprints, molecular graphs or other structural descriptions can be an handicap to generate high statistical values but should also limit overfitting biases and yield more generalist predictive models, not necessarily influenced by specific chemical scaffolds or moieties. In our practice, these well-performing models able to estimate important ADME behaviours are of great support for pharmacokinetics optimization and evaluation of small molecules”concepts[64]
conceptapplicability domains — not defined in this paper's own words; chemical spaces over which classifiers generalize — “The quantification of the models performance is not straightforwardly comparable, because the training sets are different, most of the published models are less than 10-fold cross-validated and some statistical parameters are missing. Nevertheless, the SwissADME classifiers are competitive with previous models in term of robustness, with cross-validation accuracy (ACC CV ) grossly at the same level. Furthermore, cross-validated areas under receiver operating characteristic (ROC) curves (AUC CV ) are equal to the corresponding values found in the literature. Likewise, external prediction power is difficult to compare, as each test set includes different molecules. However, the predictive capacity of SwissADME classifiers is grossly equivalent to the related SVM methods, both in terms of external accuracy (ACC ext ) and external area under ROC curve (AUC ext ). The models for which external validation was not found (P-gp of refs 15 and 53 ) have to be taken with extreme caution since they possibly suffer from overfitting biases. Noteworthy, some of the published models (e.g. CYP2C9 and CYP3A4 of ref. 54 or CYP2C9 of ref. 55 ) were built on severely unbalanced training sets and tested on clearly unbalanced external sets. As demonstrated by Carbon-Mangels et al . 56 the relevance of machine-learning classification methods, and especially SVM, are negatively impacted by datasets with one significantly more populated class. In that case, accuracy measurements are overestimated and prone to mislead the construction and the evaluation of the model. Moreover, some SVM models were published with small training and test sets (P-gp of refs 15 and 57 ), which imply questionable capacity of generalization and broadness of applicability domains. We emphasize that for SwissADME classifiers, both training and test sets were carefully cleansed and checked for size, diversity and balance between classes. Furthermore, our SVM models rely merely on molecular and physicochemical descriptors generated by SwissADME. We believe that this improves robustness and sustainability of the underlying methodologies. In particular, not using molecular fingerprints, molecular graphs or other structural descriptions can be an handicap to generate high statistical values but should also limit overfitting biases and yield more generalist predictive models, not necessarily influenced by specific chemical scaffolds or moieties. In our practice, these well-performing models able to estimate important ADME behaviours are of great support for pharmacokinetics optimization and evaluation of small molecules”concepts[65]
conceptrule-based filters — not defined in this paper's own words; property-range screens for drug-likeness — “As defined earlier, “drug-likeness” assesses qualitatively the chance for a molecule to become an oral drug with respect to bioavailability. Drug-likeness was established from structural or physicochemical inspections of development compounds advanced enough to be considered oral drug-candidates. This notion is routinely employed to perform filtering of chemical libraries to exclude molecules with properties most probably incompatible with an acceptable pharmacokinetics profile. This SwissADME section gives access to five different rule-based filters, with diverse ranges of properties inside of which the molecule is defined as drug-like. These filters often originate from analyses by major pharmaceutical companies aiming to improve the quality of their proprietary chemical collections. The Lipinski (Pfizer) filter is the pioneer rule-of-five implemented from ref. 4 . The Ghose (Amgen), Veber (GSK), Egan (Pharmacia) and Muegge (Bayer) methods were adapted from refs 58 , 59 , 60 , 61 , respectively. Multiple estimations allow consensus views or selection of methods best fitting the end-user’s specific needs in terms of chemical space or project-related demands. Any violation of any rule described here appears explicitly in the output panel. The Abbot Bioavailability Score 62 is similar but seeks to predict the probability of a compound to have at least 10% oral bioavailability in rat or measurable Caco-2 permeability. This semi-quantitative rule-based score relying on total charge, TPSA, and violation to the Lipinski filter defines four classes of compounds with probabilities of 11%, 17%, 56% or 85%. Like the other methods in this section, it primary focuses on the fast screening of chemical libraries, to select the best molecules to be purchased, synthetized or promoted at a further stage of a medicinal chemistry project”concepts[66]
conceptrule-of-five — not defined in this paper's own words; pioneer Lipinski drug-likeness filter — “As defined earlier, “drug-likeness” assesses qualitatively the chance for a molecule to become an oral drug with respect to bioavailability. Drug-likeness was established from structural or physicochemical inspections of development compounds advanced enough to be considered oral drug-candidates. This notion is routinely employed to perform filtering of chemical libraries to exclude molecules with properties most probably incompatible with an acceptable pharmacokinetics profile. This SwissADME section gives access to five different rule-based filters, with diverse ranges of properties inside of which the molecule is defined as drug-like. These filters often originate from analyses by major pharmaceutical companies aiming to improve the quality of their proprietary chemical collections. The Lipinski (Pfizer) filter is the pioneer rule-of-five implemented from ref. 4 . The Ghose (Amgen), Veber (GSK), Egan (Pharmacia) and Muegge (Bayer) methods were adapted from refs 58 , 59 , 60 , 61 , respectively. Multiple estimations allow consensus views or selection of methods best fitting the end-user’s specific needs in terms of chemical space or project-related demands. Any violation of any rule described here appears explicitly in the output panel. The Abbot Bioavailability Score 62 is similar but seeks to predict the probability of a compound to have at least 10% oral bioavailability in rat or measurable Caco-2 permeability. This semi-quantitative rule-based score relying on total charge, TPSA, and violation to the Lipinski filter defines four classes of compounds with probabilities of 11%, 17%, 56% or 85%. Like the other methods in this section, it primary focuses on the fast screening of chemical libraries, to select the best molecules to be purchased, synthetized or promoted at a further stage of a medicinal chemistry project”concepts[67]
conceptBioavailability Score — not defined in this paper's own words; rule-based oral-bioavailability probability score — “As defined earlier, “drug-likeness” assesses qualitatively the chance for a molecule to become an oral drug with respect to bioavailability. Drug-likeness was established from structural or physicochemical inspections of development compounds advanced enough to be considered oral drug-candidates. This notion is routinely employed to perform filtering of chemical libraries to exclude molecules with properties most probably incompatible with an acceptable pharmacokinetics profile. This SwissADME section gives access to five different rule-based filters, with diverse ranges of properties inside of which the molecule is defined as drug-like. These filters often originate from analyses by major pharmaceutical companies aiming to improve the quality of their proprietary chemical collections. The Lipinski (Pfizer) filter is the pioneer rule-of-five implemented from ref. 4 . The Ghose (Amgen), Veber (GSK), Egan (Pharmacia) and Muegge (Bayer) methods were adapted from refs 58 , 59 , 60 , 61 , respectively. Multiple estimations allow consensus views or selection of methods best fitting the end-user’s specific needs in terms of chemical space or project-related demands. Any violation of any rule described here appears explicitly in the output panel. The Abbot Bioavailability Score 62 is similar but seeks to predict the probability of a compound to have at least 10% oral bioavailability in rat or measurable Caco-2 permeability. This semi-quantitative rule-based score relying on total charge, TPSA, and violation to the Lipinski filter defines four classes of compounds with probabilities of 11%, 17%, 56% or 85%. Like the other methods in this section, it primary focuses on the fast screening of chemical libraries, to select the best molecules to be purchased, synthetized or promoted at a further stage of a medicinal chemistry project”concepts[68]
conceptleadlikeness — not defined in this paper's own words; physicochemical suitability for lead optimization — “The purpose of this section is to support medicinal chemists in their daily drug discovery endeavours. Two complementary pattern recognition methods allow for identification of potentially problematic fragments. PAINS (for pan assay interference compounds, a.k.a. frequent hitters or promiscuous compounds) are molecules containing substructures showing potent response in assays irrespective of the protein target. Such fragments, yielding false positive biological output, have been identified by Baell et al . 6 in analysing six orthogonal assays and breaking down the molecules active on 2 or more assays into 481 recurrent fragments, considered as potentially leading to promiscuous compounds. SwissADME returns warnings if such moieties are found in the molecule under evaluation. Besides, we implemented Structural Alert, which consists in a list of 105 fragments identified by Brenk et al . 5 to be putatively toxic, chemically reactive, metabolically unstable or to bear properties responsible for poor pharmacokinetics. In SwissADME, it is possible to have a chemical description of the problematic fragments found in a given molecule by flying over the “question mark” icon appearing after the fragment list. This is implemented for both PAINS and Brenk filters. By applying these and other physicochemical filters to design screening libraries, Brenk et al . 5 observed that most of the remaining compounds satisfy criteria for “leadlikeness”. This concept is similar to drug-likeness, yet focusing on physicochemical boundaries defining a good lead, i.e. a molecular entity suitable for optimization. By definition, leads are subjected to chemical modifications that will most likely increase size and lipophilicity 63 . As a consequence, leads are required to be smaller and less hydrophobic than drug-like molecules. Since it is crucial for a chemist to judge whether a given molecule is suitable to initiate lead optimization, in addition to structural filters, we implemented a rule-based method for leadlikeness”concepts[69]
conceptleads — not defined in this paper's own words; molecular entities suitable for optimization — “The purpose of this section is to support medicinal chemists in their daily drug discovery endeavours. Two complementary pattern recognition methods allow for identification of potentially problematic fragments. PAINS (for pan assay interference compounds, a.k.a. frequent hitters or promiscuous compounds) are molecules containing substructures showing potent response in assays irrespective of the protein target. Such fragments, yielding false positive biological output, have been identified by Baell et al . 6 in analysing six orthogonal assays and breaking down the molecules active on 2 or more assays into 481 recurrent fragments, considered as potentially leading to promiscuous compounds. SwissADME returns warnings if such moieties are found in the molecule under evaluation. Besides, we implemented Structural Alert, which consists in a list of 105 fragments identified by Brenk et al . 5 to be putatively toxic, chemically reactive, metabolically unstable or to bear properties responsible for poor pharmacokinetics. In SwissADME, it is possible to have a chemical description of the problematic fragments found in a given molecule by flying over the “question mark” icon appearing after the fragment list. This is implemented for both PAINS and Brenk filters. By applying these and other physicochemical filters to design screening libraries, Brenk et al . 5 observed that most of the remaining compounds satisfy criteria for “leadlikeness”. This concept is similar to drug-likeness, yet focusing on physicochemical boundaries defining a good lead, i.e. a molecular entity suitable for optimization. By definition, leads are subjected to chemical modifications that will most likely increase size and lipophilicity 63 . As a consequence, leads are required to be smaller and less hydrophobic than drug-like molecules. Since it is crucial for a chemist to judge whether a given molecule is suitable to initiate lead optimization, in addition to structural filters, we implemented a rule-based method for leadlikeness”concepts[70]
conceptdrug-like molecules — not defined in this paper's own words; molecules meeting oral-drug property ranges — “The purpose of this section is to support medicinal chemists in their daily drug discovery endeavours. Two complementary pattern recognition methods allow for identification of potentially problematic fragments. PAINS (for pan assay interference compounds, a.k.a. frequent hitters or promiscuous compounds) are molecules containing substructures showing potent response in assays irrespective of the protein target. Such fragments, yielding false positive biological output, have been identified by Baell et al . 6 in analysing six orthogonal assays and breaking down the molecules active on 2 or more assays into 481 recurrent fragments, considered as potentially leading to promiscuous compounds. SwissADME returns warnings if such moieties are found in the molecule under evaluation. Besides, we implemented Structural Alert, which consists in a list of 105 fragments identified by Brenk et al . 5 to be putatively toxic, chemically reactive, metabolically unstable or to bear properties responsible for poor pharmacokinetics. In SwissADME, it is possible to have a chemical description of the problematic fragments found in a given molecule by flying over the “question mark” icon appearing after the fragment list. This is implemented for both PAINS and Brenk filters. By applying these and other physicochemical filters to design screening libraries, Brenk et al . 5 observed that most of the remaining compounds satisfy criteria for “leadlikeness”. This concept is similar to drug-likeness, yet focusing on physicochemical boundaries defining a good lead, i.e. a molecular entity suitable for optimization. By definition, leads are subjected to chemical modifications that will most likely increase size and lipophilicity 63 . As a consequence, leads are required to be smaller and less hydrophobic than drug-like molecules. Since it is crucial for a chemist to judge whether a given molecule is suitable to initiate lead optimization, in addition to structural filters, we implemented a rule-based method for leadlikeness”concepts[71]
conceptsynthetic accessibility — not defined in this paper's own words; estimated ease of molecular synthesis — “One of the key aspects of CADD activities is to help the selection of the most promising virtual molecules that will be synthetized and submitted to biological assays or other experiments. Synthetic accessibility (SA) is a major factor to consider in this selection process. Obviously, for a reasonable number of molecules, medicinal chemists are the best able to determine SA. However, when too many molecular structures prevent an expert evaluation, in silico estimation can be used for pre-filtering. Ertl & Schuffenhauer 11 proposed a fingerprint-based approach for SA estimation but including closed-source information about fingerprint definition that prevents a straightforward implementation in our tool open to the scientific community. As a consequence, we have built our own fragmental method by analysing more than 13 millions compounds immediately deliverable by vendors. We assumed that the most frequent molecular fragments (technically, FP2 bits, refer to Computational Methods ) in this large collection indicates a probably high SA, while rare fragments imply a difficult synthesis. For a given molecule, the fragmental contributions to SA are summed and corrected by the terms describing size and complexity, such as macrocycles, chiral centres, or spiro functions as defined by Ertl & Schuffenhauer 11 . After normalization, the SA Score ranges from 1 (very easy) to 10 (very difficult). To assess the performance of the method developed for SwissADME, we retrieved two test sets of SA previously published. Both sets involved external molecules, whose difficulty of synthesis was marked from 1 to 10 by nine 11 and four 65 medicinal chemists, respectively. The averaged expert score can then be compared to an in silico SA Score. As seen in Table 2 , the predictive capacity of all three methods appears very dependent of the test set. Indeed the SAs of set 1, smaller and evaluated by more chemists, turned out to be much more robustly predictable than set 2. Human evaluation of synthetic complexity is undeniably subjective and relies on individual chemist’s training and experience. However, significant linear correlation and small errors — especially with SwissADME SA Score that outperformed the reference methods on both sets with smaller errors, and equal or higher linear correlation coefficients — demonstrate how this simple and fast methodology can help prioritizing molecules to synthetize”concepts[72]
conceptSA Score — not defined in this paper's own words; normalized synthetic-accessibility score — “One of the key aspects of CADD activities is to help the selection of the most promising virtual molecules that will be synthetized and submitted to biological assays or other experiments. Synthetic accessibility (SA) is a major factor to consider in this selection process. Obviously, for a reasonable number of molecules, medicinal chemists are the best able to determine SA. However, when too many molecular structures prevent an expert evaluation, in silico estimation can be used for pre-filtering. Ertl & Schuffenhauer 11 proposed a fingerprint-based approach for SA estimation but including closed-source information about fingerprint definition that prevents a straightforward implementation in our tool open to the scientific community. As a consequence, we have built our own fragmental method by analysing more than 13 millions compounds immediately deliverable by vendors. We assumed that the most frequent molecular fragments (technically, FP2 bits, refer to Computational Methods ) in this large collection indicates a probably high SA, while rare fragments imply a difficult synthesis. For a given molecule, the fragmental contributions to SA are summed and corrected by the terms describing size and complexity, such as macrocycles, chiral centres, or spiro functions as defined by Ertl & Schuffenhauer 11 . After normalization, the SA Score ranges from 1 (very easy) to 10 (very difficult). To assess the performance of the method developed for SwissADME, we retrieved two test sets of SA previously published. Both sets involved external molecules, whose difficulty of synthesis was marked from 1 to 10 by nine 11 and four 65 medicinal chemists, respectively. The averaged expert score can then be compared to an in silico SA Score. As seen in Table 2 , the predictive capacity of all three methods appears very dependent of the test set. Indeed the SAs of set 1, smaller and evaluated by more chemists, turned out to be much more robustly predictable than set 2. Human evaluation of synthetic complexity is undeniably subjective and relies on individual chemist’s training and experience. However, significant linear correlation and small errors — especially with SwissADME SA Score that outperformed the reference methods on both sets with smaller errors, and equal or higher linear correlation coefficients — demonstrate how this simple and fast methodology can help prioritizing molecules to synthetize”concepts[73]
conceptmolecular fragments — not defined in this paper's own words; fingerprint fragments whose frequency informs synthesis ease — “One of the key aspects of CADD activities is to help the selection of the most promising virtual molecules that will be synthetized and submitted to biological assays or other experiments. Synthetic accessibility (SA) is a major factor to consider in this selection process. Obviously, for a reasonable number of molecules, medicinal chemists are the best able to determine SA. However, when too many molecular structures prevent an expert evaluation, in silico estimation can be used for pre-filtering. Ertl & Schuffenhauer 11 proposed a fingerprint-based approach for SA estimation but including closed-source information about fingerprint definition that prevents a straightforward implementation in our tool open to the scientific community. As a consequence, we have built our own fragmental method by analysing more than 13 millions compounds immediately deliverable by vendors. We assumed that the most frequent molecular fragments (technically, FP2 bits, refer to Computational Methods ) in this large collection indicates a probably high SA, while rare fragments imply a difficult synthesis. For a given molecule, the fragmental contributions to SA are summed and corrected by the terms describing size and complexity, such as macrocycles, chiral centres, or spiro functions as defined by Ertl & Schuffenhauer 11 . After normalization, the SA Score ranges from 1 (very easy) to 10 (very difficult). To assess the performance of the method developed for SwissADME, we retrieved two test sets of SA previously published. Both sets involved external molecules, whose difficulty of synthesis was marked from 1 to 10 by nine 11 and four 65 medicinal chemists, respectively. The averaged expert score can then be compared to an in silico SA Score. As seen in Table 2 , the predictive capacity of all three methods appears very dependent of the test set. Indeed the SAs of set 1, smaller and evaluated by more chemists, turned out to be much more robustly predictable than set 2. Human evaluation of synthetic complexity is undeniably subjective and relies on individual chemist’s training and experience. However, significant linear correlation and small errors — especially with SwissADME SA Score that outperformed the reference methods on both sets with smaller errors, and equal or higher linear correlation coefficients — demonstrate how this simple and fast methodology can help prioritizing molecules to synthetize”concepts[74]
conceptOpenBabel — not defined in this paper's own words; software used for canonicalization, descriptors, and SMARTS matching — “The molecule inputted through the sketcher Marvin JS (version 16.4.18, 2016, www.chemaxon.com ) are converted into SMILES by JChem Web Services (version 14.9.29, 2013, www.chemaxon.com ) installed on one of our servers. This on-the-fly conversion allows seamless paste of SMILES in the input list. The user has the possibility to edit this list as a standard text, e.g. to modify SMILES or add a name to the molecule. Upon calculation submission by clicking the “Run” button, the SMILES of each molecule is canonicalised by OpenBabel (version 2.3.0, 2012, http://openbabel.org ) 9 and processed individually. Several actions are performed through JChem Web Services APIs. First hydrogen atoms are added to the molecular structure, which is dearomatised (i.e. kekulised), neutralised and checked by the Standardizer API. Then a tridimensional conformation is generated though the StringMolExport function with the Clean3D option and stored in MOL2 format. Besides, a two-dimensional image created through the MolConverter API is displayed on demand when scrolling the output web page”concepts[75]
conceptESOL model — not defined in this paper's own words; QSPR model for water-solubility prediction — “Similarly to lipophilicity, the Water Solubility section includes multiple predictive methods for the user to choose between the most accurate model for a given chemical series and an averaged consensus value. The ESOL model 36 is a QSPR model establishing the linear relationship between log S and five molecular parameters, i.e. MW, the number of rotatable bonds, the fraction of aromatic heavy atoms and Daylight’s CLOGP. Because the lipophilicity descriptor is not freely available, the implementation of ESOL in SwissADME replaces CLOGP by XLOGP3 as parameter in the linear equation to predict log S . XLOGP3 is known to perform well on external datasets and to return similar predictions as CLOGP 28 . The other three parameters were computed with OpenBabel. Likewise, Ali et al . 37 linked log S with log P o/w and TPSA. The model implemented in SwissADME corresponds to the model 3 of the original publication, with XLOGP3 as lipophilicity descriptor. The third solubility method available in SwissADME is the log S estimated by the FILTER-IT program (version 1.0.2, 2013, http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html ). This prediction is based on a system of 16 fragmental contributions modulated by the squared root of MW. All three models are predicting log S values, which are also translated within SwissADME into solubility in mol/l and mg/ml. Finally a qualitative estimation of the solubility class is given according to the following log S scale: insoluble <−10 <poorly <−6 <moderately <−4 <soluble <−2 <very <0 <highly”concepts[76]
conceptQSPR model — not defined in this paper's own words; linear structure-property prediction model — “Similarly to lipophilicity, the Water Solubility section includes multiple predictive methods for the user to choose between the most accurate model for a given chemical series and an averaged consensus value. The ESOL model 36 is a QSPR model establishing the linear relationship between log S and five molecular parameters, i.e. MW, the number of rotatable bonds, the fraction of aromatic heavy atoms and Daylight’s CLOGP. Because the lipophilicity descriptor is not freely available, the implementation of ESOL in SwissADME replaces CLOGP by XLOGP3 as parameter in the linear equation to predict log S . XLOGP3 is known to perform well on external datasets and to return similar predictions as CLOGP 28 . The other three parameters were computed with OpenBabel. Likewise, Ali et al . 37 linked log S with log P o/w and TPSA. The model implemented in SwissADME corresponds to the model 3 of the original publication, with XLOGP3 as lipophilicity descriptor. The third solubility method available in SwissADME is the log S estimated by the FILTER-IT program (version 1.0.2, 2013, http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html ). This prediction is based on a system of 16 fragmental contributions modulated by the squared root of MW. All three models are predicting log S values, which are also translated within SwissADME into solubility in mol/l and mg/ml. Finally a qualitative estimation of the solubility class is given according to the following log S scale: insoluble <−10 <poorly <−6 <moderately <−4 <soluble <−2 <very <0 <highly”concepts[77]
conceptin-house physics-based methods — not defined in this paper's own words; method class assigned to iLOGP — “Multiple freely available computational methods to predict n -octanol/water partition coefficient (log P o/w ) values are made available in the Lipophilicity section. iLOGP (for implicit log P ) is an in-house physics-based methods relying on Gibbs free energy of solvation calculated by GB/SA in water and n -octanol. Generalized-born (GB) parameters are computed through the GBMV2 method 68 and solvent-accessible surface area (SA) is the analytical approximation generated by CHARMM (version c36b1, 2011, https://www.charmm.org ) 69 . The iLOGP implemented in SwissADME corresponds to Model9 of the seminal publication 16 , which was trained on 11,993 molecules (r = 0.72, MAE = 0.89, and RMSE = 1.14 against experimental log P ). 5-fold crossvalidation ensured robustness (q 2 CV = 0.52, MAE CV = 0.89, and RMSE CV = 1.14) and external test benchmarks showed the excellent predictive power and extended applicability domain compared to well-established methods. XLOGP3 values are obtained through the command-line Linux program (version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry) including the knowledge-based corrections 29 . WLOGP is our own implementation of the atomistic method developed by Wildman and Crippen 30 . MLOGP values are computed through an in-house implementation of Moriguchi’s topological method 31 32 . SILICOS-IT is the log P o/w estimation returned by executing the FILTER-IT program (version 1.0.2, 2013, http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html ). Finally, SwissADME gives a consensus log P o/w value, which is the arithmetic mean of the five predictive values mentioned above”concepts[78]
conceptRBF Gaussian kernel function — not defined in this paper's own words; kernel optimized for the SVM models — “SwissADME’s backend calculations were ran to generate 50 molecular and physicochemical descriptors per molecule (described in the Supplementary Table S1 ). For a given model, a descriptor was rejected if non-zero values for all molecules in the training set are less than 20% or if the coefficient of variation is less than 3%. In case of correlation higher than 0.9 between remaining descriptors, a selection is made based on F-score. The selected descriptors for each model are shown in Supplementary Tables S2–S7 . These tables also include the minimum and maximum values for each descriptor among all molecules used in the training. This enables beholding the broadness of physicochemical space involved and the applicability domain of the SVM models. The predictive capability of each model can be further appraised on Supplementary Table S8 , where external accuracy was split in sensitivity and specificity to ensure that positive and negative molecules are predicted with the same level of robustness. The final training and test sets with selected descriptors were normalized and the respective model ready to be built. First, the libSVM support vector machine python library (version 3.20, 2015, https://www.csie.ntu.edu.tw/~cjlin/libsvm/ ) 74 was used for multi-step grid-based optimization of the best coefficients for the above-selected descriptors as well as for the soft-margin permissivity (C) and the hyper-parameter (ϒ) of the RBF Gaussian kernel function. The 10-fold crossvalidated accuracy (ACC CV ) for each model was so maximized and AUC CV was calculated. In a second step, the so-built models were used on the external test sets (normalized according to the training set) in order to evaluate predictive power in terms of external accuracy (ACC ext ) and AUC ext . All final SVM models were stored in separate files, which are read through the libSVM API upon SwissADME job submission”concepts[79]
conceptSwissDrugDesign program — not defined in this paper's own words; workspace of interoperable CADD web tools — “Moreover, SwissADME is an integral part of the SwissDrugDesign program, an ambitious initiative driven by the Molecular Modeling Group of the SIB Swiss Institute of Bioinformatics that aims at providing a collection of free Web-based tools covering many aspects of CADD. As such, SwissADME users can access the different Web sites, through the black toolbar at the top of the page. By clicking on the name of the tool, a new tab opens with the corresponding submission page. We have undertaken the implementation of more advanced interoperability capabilities. At the time of writing this manuscript, three icons were placed top left of the output panel (below the name of the molecule, see Fig. 2 ). They allow one-click submission of the molecule to SwissTargetPrediction (for reverse screening to predict protein target, by clicking on the red target), SwissSimilarity (for ligand-based virtual screening, by clicking on the red twins) and to re-submit the molecule to SwissADME (for instance to get a single compound graphical output, by clicking the red pill). Reversely, other SwissDrugDesign websites include the SwissADME pill icon”concepts[80]
conceptSwissDrugDesign web tools — not defined in this paper's own words; linked tools reached through SwissADME interoperability — “The SwissADME Web tool enables the computation of key physicochemical, pharmacokinetic, drug-like and related parameters for one or multiple molecules. In one hand, efforts were put in the backend to embed free open-access and fast predictive models showing statistical significance, predictive power, intuitive interpretation, and straightforward translation to molecular design. These models are adapted from published renowned approaches or in-house original methods, specially developed and thoroughly benchmarked. On the other hand, we focused on an ergonomic and user-friendly graphical interface for the cost- and login-free Web site http://www.swissadme.ch . The latter enables easy input and efficient analysis of the output through interactive capabilities, and does not require any prior knowledge in CADD. Moreover, interoperability allows for direct access to other SwissDrugDesign web tools, including SwissSimilarity 66 (virtual screening), SwissBioisostere 21 (ligand-based design), SwissTargetPrediction 19 (prediction of biotargets), SwissDock 20 (molecular docking), SwissSideChain 67 (protein modeling) and SwissParam 22 (molecular mechanics). As a result, SwissADME has been designed to support the entire community (specialists and nonexperts) in their drug discovery endeavours”concepts[81]
conceptinteroperability — not defined in this paper's own words; direct transfer among SwissDrugDesign tools — “The SwissADME Web tool enables the computation of key physicochemical, pharmacokinetic, drug-like and related parameters for one or multiple molecules. In one hand, efforts were put in the backend to embed free open-access and fast predictive models showing statistical significance, predictive power, intuitive interpretation, and straightforward translation to molecular design. These models are adapted from published renowned approaches or in-house original methods, specially developed and thoroughly benchmarked. On the other hand, we focused on an ergonomic and user-friendly graphical interface for the cost- and login-free Web site http://www.swissadme.ch . The latter enables easy input and efficient analysis of the output through interactive capabilities, and does not require any prior knowledge in CADD. Moreover, interoperability allows for direct access to other SwissDrugDesign web tools, including SwissSimilarity 66 (virtual screening), SwissBioisostere 21 (ligand-based design), SwissTargetPrediction 19 (prediction of biotargets), SwissDock 20 (molecular docking), SwissSideChain 67 (protein modeling) and SwissParam 22 (molecular mechanics). As a result, SwissADME has been designed to support the entire community (specialists and nonexperts) in their drug discovery endeavours”concepts[82]

Full text — tagged

The reference list is not part of the text we hold for this paper. Our copy was extracted from the publisher's page and the bibliography did not survive that extraction, so the article below ends before its references. Nothing has been removed by us.

SwissADMEterm: a free web tool to evaluate pharmacokineticsterm, drug-likenessterm and medicinal chemistry friendlinessterm of small molecules Abstract To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur. Drug development involves assessment of absorption, distribution, metabolism and excretionterm (ADMEterm) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. In that context, computer modelsterm constitute valid alternatives to experimentsterm. Here, we present the new SwissADME web toolterm that gives free access to a pool of fast yet robust predictive modelsterm for physicochemical propertiesterm, pharmacokineticsterm, drug-likenessterm and medicinal chemistry friendlinessterm, among which in-house proficient methods such as the BOILED-Eggterm, iLOGPterm and Bioavailability Radarterm. Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadmeterm.ch . Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours.

During the time- and resource-consuming processes of drug discovery and development, a large number of molecular structures are evaluated according to very diverse parameters in order to steer the selection of which chemicals to synthetize, test and promote, with the final goal to identify those with the best chance to become an effective medicine for the patients. The molecules must show high biological activity together with low toxicity. Equally important is the access to and concentration at the therapeutic target in the organism. The traditional way to consider pharmacokineticsterm (i.e. the fate of a therapeutic compound in the organism) is to break down the various effects that impact the access to the target into individual parameters. In turn, these ADMEterm parameters (for Absorption, Distribution, Metabolism and Excretionterm) can be evaluated separately by dedicated methods. It has been demonstrated that early estimation of ADMEterm in the discovery phase reduces drastically the fraction of pharmacokinetics-related failure in the clinical phases 1 . Computer modelsterm have been fostered as a valid alternative to experimental procedures for prediction of ADMEterm, especially at initial steps, when investigated chemical structures are numerous but the availability of compounds is scarce 2 .

A large variety of in silico methods share the objective of predicting ADMEterm parameters from molecular structure 3 . Noteworthy, the pioneer work of Lipinski et al . examined orally active compounds to define physicochemical ranges for high probability to be an oral drug (i.e. the drug-likenessterm) 4 . This so-called Rule-of-fiveterm delineated the relationship between pharmacokineticterm and physicochemical parametersterm.

Whereas physicochemical parametersterm give a global description of the structure, molecules can be directly described by substructure searchesterm. These techniques are at the root of Structural Alertterm 5 , the PAINSterm 6 or the Lilly MedChem 7 filters applied to cleanse chemical libraries from compounds most likely unstable, reactive, toxic, or prone to interfere with biological assays because unspecific frequent hitters, dyes or aggregators 8 .

Cheminformaticians developed different molecular descriptorsterm mined from chemical structures. One of the most popular examples is the molecular fingerprintterm (FPterm), which consists in a sequence of bitsterm defining the presence or absence of chemical features in a molecule. The FP2 methodterm 9 is one archetype of topological (or path-based) FPterm, which considers all fragments of the molecular structure following a linear path up to a given number of bonds. Every possible path is hashed to generate the bit string (i.e. the FPterm). A major advantage of FPterm is the efficiency by which computers handle such bit strings 10 , allowing for instance large-scale virtual screeningterm or the rapid estimation of synthetic accessibilityterm of molecules 11 . FPterm are also employed in classification models for ADMEterm behaviours built by support vector machineterm (SVMterm) or Bayesian techniques 12 . Remarkably, computer-aided drug designterm (CADDterm) has been a pioneer field for the application of such machine learning technologies 13 .

Because most freely available in silico ADME toolsterm focus on one specific property or model only, while generalist ADME packagesterm are commercial software, we felt the need of gathering what we consider the most relevant computational methods to provide a global appraisal of the pharmacokineticsterm profile of small molecules. The methods were selected for robustness, speed, but also and importantly for ease of interpretation to enable efficient translation to medicinal chemistry through molecular design. Some of them were adapted with open-source algorithms to ensure freedom to operate for the global scientific community. Others are our own models developed and tested on purpose. When applicable, multiple predictionsterm of the same parameter are provided to allow for a consensus viewterm of a given property.

The SwissADME web toolterm presented here is freely accessible at http://www.swissadmeterm.ch and meant for user-friendly submission and easy analysis of the results, also for nonexpert in CADDterm. Compared to the state-of-the art of free web-based tools for ADMEterm and pharmacokineticsterm (e.g. pk-CSM 14 and admetSAR 15 ) and apart from unique access to proficient methods (e.g. iLOGPterm 16 or the BOILED-Eggterm 17 ), SwissADMEterm strong points are, non-exhaustively: different input methods, computation for multiple molecules, and the possibility to display, save and share results per individual molecule or through global intuitive and interactive graphs. Finally, SwissADMEterm is integrated in the SwissDrugDesign workspace. One-click interoperabilityterm gives access to various CADDterm tools developed by the Molecular Modeling Group of the SIB Swiss Institute of Bioinformatics, e.g. ligand-based virtual screeningterm (SwissSimilarity 18 ), biotarget prediction (SwissTargetPrediction 19 ), molecular docking (SwissDock 20 ), bioisosteric design (SwissBioisostere 21 ), or molecular mechanics (SwissParam 22 ).

Submission Web page Accessing http://www.swissadmeterm.ch in a web browser displays directly the submission page of SwissADMEterm, where molecules to be estimated for ADMEterm, physicochemistry, drug-likenessterm, pharmacokineticsterm and medicinal chemistry friendlinessterm properties can be input. As shown in Fig. 1 , a black toolbar at the top of the Web page allows the user to navigate within the different SwissDrugDesign tools. A second bar gives access to different information regarding SwissADMEterm, among which the FAQ and Help pages as well as legal disclaimer and contacts.

The input zone itself comprises a molecular sketcherterm based on ChemAxon’s Marvin JS ( http://www.chemaxon.com ) that enables the user to import (from a file or an external database), draw, and edit a 2D chemical structure, and to transfer it to a list of molecules. This list, on the right-hand side of the submission page, is the actual input for computation. It can be edited as a standard text, allowing for typing or pasting SMILESterm. The list is made to contain one input molecule per line, defined by a SMILESterm and optionally a name separated by a space. If name is omitted, SwissADMEterm will automatically provide an identifier.

Noteworthy, both buttons for transferring the sketch to SMILESterm list and for running the computation are dynamic, in the sense that they are active only if the action is possible. At the time of writing, one can expect a result in 1 to 5 seconds for a drug-like moleculeterm.

Examples can be loaded in the SMILESterm list by clicking on the “Fill with an example” button.

One-panel-per-moleculeterm Output The output panels are loaded in the same Web page. There is one panel compiling all values for each molecule. It is filled immediately after calculation completion, one molecule after the other. This way it is possible to inspect the results for the first compounds without waiting for the whole list to be treated. This one-panel-per-moleculeterm ( Fig. 2 ) is headed by the molecule name and divided into different sections.

Chemical Structure and Bioavailability Radarterm The first section, including two-dimensional chemical structure and canonical SMILESterm, is located below the title ( Fig. 2 ). It shows on which chemical form the predictions were calculated (refer to Computational Methods ). Moreover, our Bioavailability Radarterm is displayed for a rapid appraisal of drug-likenessterm (refer to Fig. 3 ). Six physicochemical propertiesterm are taken into account: lipophilicityterm·var, sizeterm·var, polarityterm·var, solubilityterm·var, flexibilityterm·var and saturationterm·var. A physicochemical range on each axis was defined by descriptors adapted from refs 23 and 24 and depicted as a pink area in which the radar plot of the molecule has to fall entirely to be considered drug-like. Leaving the mouse over the radar gives further information about the descriptors (see also Physicochemical Propertiesterm and Computational Methods ).

Physicochemical Propertiesterm Simple molecular and physicochemical descriptorsterm like molecular weightterm (MW), molecular refractivityterm (MR), count of specific atom types and polar surface areaterm (PSAterm) are compiled in this section. The values are computed with OpenBabelterm 9 , version 2.3.0. The PSAterm is calculated using the fragmental technique called topological polar surface areaterm (TPSAterm), considering sulfur and phosphorus as polar atoms 25 . This has proven a useful descriptor in many models and rules to quickly estimate some ADMEterm properties, especially with regards to biological barrier crossing such as absorption and brain access 17 .

Lipophilicityterm·var The partition coefficient between n -octanol and waterterm (log P o/wterm ) is the classical descriptor for Lipophilicityterm·var . It has a dedicated section in SwissADMEterm due to the critical importance of this physicochemical property for pharmacokineticsterm drug discovery 26 27 . Many computational methods for log P o/wterm estimation were developed with diverse performance on various chemical sets. Common practice is to use multiple predictors either to select the most accurate methods for a given chemical series or to generate consensus estimation. The models behind the predictors should be as diverse as possible to increase the prediction accuracy through consensus log P o/wterm 28 . In that regard, SwissADMEterm gives access to five freely available predictive modelsterm; i.e. XLOGP3, an atomistic method including corrective factors and knowledge-based library 29 ; WLOGPterm·var, our own implementation of a purely atomistic method based on the fragmental system of Wildman and Crippen 30 ; MLOGP, an archetype of topological method relying on a linear relationship with 13 molecular descriptorsterm implemented from refs 31 and 32 ; SILICOS-IT, an hybrid method relying on 27 fragments and 7 topological descriptors ( http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html , accessed June 2016); and finally iLOGPterm, our in-house physics-based methodterm relying on free energies of solvation in n -octanol and water calculated by the Generalized-Born and solvent accessible surface area (GB/SA) model. iLOGPterm was benchmarked on two drug or drug-like external sets and performed equally as or better than six well-established predictors 16 . The consensus log P o/wterm is the arithmetic mean of the values predicted by the five proposed methods.

Water Solubilityterm Having a soluble molecule greatly facilitates many drug development activities, primarily the ease of handling and formulation 33 . Moreover, for discovery projects targeting oral administration, solubilityterm·var is one major property influencing absorption 34 . As well, a drug meant for parenteral usage has to be highly soluble in water to deliver a sufficient quantity of active ingredient in the small volume of such pharmaceutical dosage 35 . Two topological methods to predict Water Solubilityterm are included in SwissADMEterm. The first one is an implementation of the ESOL modelterm 36 and the second one is adapted from Ali et al . 37 . Both differ from the seminal general solubilityterm·var equation 38 since they avoid the melting point parameter; the latter being challenging to predict. Moreover they demonstrate strong linear correlation between predicted and experimental values (R 2 = 0.69 and 0.81, respectively). SwissADMEterm third predictor for solubilityterm·var was developed by SILICOS-IT. The linear correlation coefficient of this fragmental method corrected by molecular weightterm is R 2 = 0.75 ( http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html , accessed June 2016).

All predicted values are the decimal logarithm of the molar solubilityterm·var in water (log Sterm ). SwissADMEterm also provides solubilityterm·var in mol/l and mg/ml along with qualitative solubilityterm·var classes (please refer to Computational Methods ).

Pharmacokineticsterm Specialized models, whose predictions are compiled in the Pharmacokineticsterm section, evaluate individual ADMEterm behaviours of the molecule under investigation.

One model is a multiple linear regression, which aims at predicting the skin permeability coefficientterm ( K p ). It is adapted from Potts and Guy 39 , who found K p linearly correlated with molecular sizeterm·var and lipophilicityterm·var (R 2 = 0.67). The more negative the log K pterm (with K p in cm/s), the less skin permeant is the molecule.

The predictions for passive human gastrointestinal absorptionterm (HIAterm) and blood-brain barrierterm (BBBterm) permeation both consist in the readout of the BOILED-Eggterm model 17 , an intuitive graphical classification model, which can be displayed in the SwissADMEterm result page by clicking the red button appearing below the sketcher when all input molecules have been processed (refer to Graphical Output ). Other binary classification models are included, which focus on the propensity for a given small molecule to be substrate or inhibitor of proteins governing important pharmacokineticterm behaviours.

The knowledge about compounds being substrate or non-substrate of the permeability glycoproteinterm (P-gpterm, suggested the most important member among ATP-binding cassette transporters or ABC-transporters) is key to appraise active efflux through biological membranes, for instance from the gastrointestinal wall to the lumen or from the brain 40 . One major role of P-gpterm is to protect the central nervous systemterm (CNS) from xenobiotics 41 . Importantly as well, P-gpterm is overexpressed in some tumour cells and leadsterm to multidrug-resistant cancers 42 .

Also essential is the knowledge about interaction of molecules with cytochromes P450term (CYPterm). This superfamily of isoenzymes is a key player in drug elimination through metabolic biotransformation 43 . It has been suggested that CYPterm and P-gpterm can process small molecules synergistically to improve protection of tissues and organisms 44 . One can estimate that 50 to 90% (depending on the authors) of therapeutic molecules are substrate of five major isoforms (CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4) 45 46 . Inhibition of these isoenzymesterm is certainly one major cause of pharmacokinetics-related drug-drug interactionsterm 47 48 leading to toxic or other unwanted adverse effectsterm due to the lower clearance and accumulation of the drug or its metabolites 49 . Numerous inhibitors of the CYPterm isoforms have been identified. Some are affecting different CYPterm isoforms, while other compounds show selectivity for specific isoenzymes 50 . It is therefore of great importance for drug discovery to predict the propensity with which the molecule will cause significant drug interactions through inhibition of CYPsterm, and to determine which isoforms are affected.

SwissADMEterm enables the estimation for a chemical to be substrate of P-gpterm or inhibitor of the most important CYPterm isoenzymes. We applied the support vector machineterm algorithm (SVMterm) 51 on meticulously cleansed large datasets of known substrates/non-substrates or inhibitors/non-inhibitors (for details, see Computational Methods ). In similar contexts, SVMterm was found to perform better than other machine-learning algorithms for binary classification 40 52 . The models return “Yes” or “No” if the molecule under investigation has higher probability to be substrate or non-substrate of P-gpterm (respectively inhibitor or non-inhibitor of a given CYPterm). The statistical performance of the classification models is given in Table 1 , in comparison with previous SVMterm models on the same targets. We restricted the benchmark to state-of-the-art methods, published after 2010.

The quantification of the models performance is not straightforwardly comparable, because the training sets are different, most of the published models are less than 10-fold cross-validated and some statistical parameters are missing. Nevertheless, the SwissADMEterm classifiers are competitive with previous models in term of robustness, with cross-validation accuracyterm (ACC CV ) grossly at the same level. Furthermore, cross-validated areas under receiver operating characteristic (ROC) curves (AUC CV ) are equal to the corresponding values found in the literature. Likewise, external prediction power is difficult to compare, as each test set includes different molecules. However, the predictive capacity of SwissADMEterm classifiers is grossly equivalent to the related SVMterm methods, both in terms of external accuracy (ACC ext ) and external area under ROC curveterm (AUC ext ). The models for which external validation was not found (P-gpterm of refs 15 and 53 ) have to be taken with extreme caution since they possibly suffer from overfitting biasesterm. Noteworthy, some of the published models (e.g. CYP2C9 and CYP3A4 of ref. 54 or CYP2C9 of ref. 55 ) were built on severely unbalanced training sets and tested on clearly unbalanced external sets. As demonstrated by Carbon-Mangels et al . 56 the relevance of machine-learning classification methods, and especially SVMterm, are negatively impacted by datasets with one significantly more populated class. In that case, accuracy measurements are overestimated and prone to mislead the construction and the evaluation of the model. Moreover, some SVMterm models were published with small training and test setsterm (P-gpterm of refs 15 and 57 ), which imply questionable capacity of generalization and broadness of applicability domainsterm. We emphasize that for SwissADMEterm classifiers, both training and test setsterm were carefully cleansed and checked for sizeterm·var, diversity and balance between classes. Furthermore, our SVMterm models rely merely on molecular and physicochemical descriptorsterm generated by SwissADMEterm. We believe that this improves robustness and sustainability of the underlying methodologies. In particular, not using molecular fingerprintsterm, molecular graphs or other structural descriptions can be an handicap to generate high statistical values but should also limit overfitting biasesterm and yield more generalist predictive modelsterm, not necessarily influenced by specific chemical scaffolds or moieties. In our practice, these well-performing models able to estimate important ADMEterm behaviours are of great support for pharmacokineticsterm optimization and evaluation of small molecules.

Drug-likenessterm As defined earlier, “drug-likenessterm” assesses qualitatively the chance for a molecule to become an oral drug with respect to bioavailability. Drug-likenessterm was established from structural or physicochemical inspections of development compounds advanced enough to be considered oral drug-candidates. This notion is routinely employed to perform filtering of chemical libraries to exclude molecules with properties most probably incompatible with an acceptable pharmacokineticsterm profile. This SwissADMEterm section gives access to five different rule-based filtersterm, with diverse ranges of properties inside of which the molecule is defined as drug-like. These filters often originate from analyses by major pharmaceutical companies aiming to improve the quality of their proprietary chemical collections. The Lipinski (Pfizer) filter is the pioneer rule-of-fiveterm implemented from ref. 4 . The Ghose (Amgen), Veber (GSK), Egan (Pharmacia) and Muegge (Bayer) methods were adapted from refs 58 , 59 , 60 , 61 , respectively. Multiple estimations allow consensus viewsterm or selection of methods best fitting the end-user’s specific needs in terms of chemical space or project-related demands. Any violation of any rule described here appears explicitly in the output panel.

The Abbot Bioavailability Scoreterm 62 is similar but seeks to predict the probability of a compound to have at least 10% oral bioavailability in rat or measurable Caco-2 permeability. This semi-quantitative rule-based score relying on total charge, TPSAterm, and violation to the Lipinski filter defines four classes of compounds with probabilities of 11%, 17%, 56% or 85%. Like the other methods in this section, it primary focuses on the fast screening of chemical libraries, to select the best molecules to be purchased, synthetized or promoted at a further stage of a medicinal chemistry project.

Medicinal Chemistry The purpose of this section is to support medicinal chemists in their daily drug discovery endeavours. Two complementary pattern recognition methods allow for identification of potentially problematic fragments. PAINSterm (for pan assay interference compounds, a.k.a. frequent hitters or promiscuous compounds) are molecules containing substructures showing potent response in assays irrespective of the protein target. Such fragments, yielding false positive biological output, have been identified by Baell et al . 6 in analysing six orthogonal assays and breaking down the molecules active on 2 or more assays into 481 recurrent fragments, considered as potentially leading to promiscuous compounds. SwissADMEterm returns warnings if such moieties are found in the molecule under evaluation.

Besides, we implemented Structural Alertterm, which consists in a list of 105 fragments identified by Brenk et al . 5 to be putatively toxic, chemically reactive, metabolically unstable or to bear properties responsible for poor pharmacokineticsterm. In SwissADMEterm, it is possible to have a chemical description of the problematic fragments found in a given molecule by flying over the “question mark” icon appearing after the fragment list. This is implemented for both PAINSterm and Brenk filters. By applying these and other physicochemical filters to design screening libraries, Brenk et al . 5 observed that most of the remaining compounds satisfy criteria for “leadlikenessterm”. This concept is similar to drug-likenessterm, yet focusing on physicochemical boundaries defining a good leadterm, i.e. a molecular entity suitable for optimization. By definition, leadsterm are subjected to chemical modifications that will most likely increase sizeterm·var and lipophilicityterm·var 63 . As a consequence, leadsterm are required to be smaller and less hydrophobic than drug-like moleculesterm. Since it is crucial for a chemist to judge whether a given molecule is suitable to initiate leadterm optimization, in addition to structural filters, we implemented a rule-based method for leadlikenessterm, which was adapted from ref. 64 .

One of the key aspects of CADDterm activities is to help the selection of the most promising virtual molecules that will be synthetized and submitted to biological assays or other experimentsterm. Synthetic accessibilityterm (SA) is a major factor to consider in this selection process. Obviously, for a reasonable number of molecules, medicinal chemists are the best able to determine SA. However, when too many molecular structures prevent an expert evaluation, in silico estimation can be used for pre-filtering. Ertl & Schuffenhauer 11 proposed a fingerprint-based approach for SA estimation but including closed-source information about fingerprint definition that prevents a straightforward implementation in our tool open to the scientific community. As a consequence, we have built our own fragmental method by analysing more than 13 millions compounds immediately deliverable by vendors. We assumed that the most frequent molecular fragmentsterm (technically, FP2term·def bits, refer to Computational Methods ) in this large collection indicates a probably high SA, while rare fragments imply a difficult synthesis. For a given molecule, the fragmental contributions to SA are summed and corrected by the terms describing sizeterm·var and complexity, such as macrocycles, chiral centres, or spiro functions as defined by Ertl & Schuffenhauer 11 . After normalization, the SA Scoreterm ranges from 1 (very easy) to 10 (very difficult). To assess the performance of the method developed for SwissADMEterm, we retrieved two test sets of SA previously published. Both sets involved external molecules, whose difficulty of synthesis was marked from 1 to 10 by nine 11 and four 65 medicinal chemists, respectively. The averaged expert score can then be compared to an in silico SA Scoreterm. As seen in Table 2 , the predictive capacity of all three methods appears very dependent of the test set. Indeed the SAs of set 1, smaller and evaluated by more chemists, turned out to be much more robustly predictable than set 2. Human evaluation of synthetic complexity is undeniably subjective and relies on individual chemist’s training and experience. However, significant linear correlation and small errors — especially with SwissADMEterm SA Scoreterm that outperformed the reference methods on both sets with smaller errors, and equal or higher linear correlation coefficients — demonstrate how this simple and fast methodology can help prioritizing molecules to synthetize.

Graphical output After all calculations completed, the “Show BOILED-Eggterm” red button appears below the sketcher to display the graphical output on the same page (as exemplify in Fig. 4 ). This consists primarily in the BOILED-Eggterm, an intuitive method to predict simultaneously two key ADMEterm parameters, i.e. the passive gastrointestinal absorption (HIAterm) and brain access (BBBterm). Although conceptually very simple as it relies on two physicochemical descriptorsterm only (WLOGPterm·var and TPSAterm, for lipophilicityterm·var and apparent polarityterm·var), this classification model was built with extreme care regarding statistical significance and robustness 17 . As shown in Fig. 4 , the egg-shaped classification plot includes the yolk (i.e. the physicochemical space for highly probable BBBterm permeation) and the white (i.e. the physicochemical space for highly probable HIAterm absorption). Both compartments are not mutually exclusive and the outside grey region stands for molecules with properties implying predicted low absorption and limited brain penetration. In practice, the BOILED-Eggterm has proven straightforward interpretation and efficient translation to molecular design in a variety of drug discovery settings. Whereas the predictive power of the BOILED-Eggterm is broad in term of chemical space, it is restricted to passive penetration through gastro-intestinal wall and BBBterm. We took benefit of its implementation within SwissADMEterm to enrich the graphical output with the prediction of P-gpterm substrate, which is the most important active efflux mechanism involved in those biological barriers 40 (refer to the SVMterm model described in Pharmacokineticsterm ). As a result, the user conveniently obtains on the same graph a global evaluation about passive absorption (inside/outside the white), passive brain access (inside/outside the yolk) and active efflux from the CNS or to the gastrointestinal lumen by colour-coding: blue dots for P-gpterm substrates (PGPterm+) and red dots for P-gpterm non-substrate (PGPterm−).

Contrary to the one-panel-per-moleculeterm concept for other parameters, the graphical output includes prediction for all molecules submitted to SwissADMEterm, thus additional capacities were implemented to enable interactive navigation and easy evaluation. Flying over a specific point makes a semi-transparent box appear including the name and structure of the molecule. Clicking on a specific point makes the page scroll to the corresponding output panel including all predictions for the molecule. Getting back to the graphical output is achieved by clicking on the red up-arrow on the top-right corner of the panel. Moreover, on the right of the plot are displayed possible actions (at the moment, to show the name of the molecules on the graph, only), legends and possible remarks (the number of molecules outside the range of the plot). The user may want to hide the plot by clicking the “Hide BOILED-Eggterm” red button.

Help, saving and interoperabilityterm SwissADMEterm is user-friendly and has been conceived for a variety of users, including nonexpert in cheminformatics or computational chemistry. Efforts were put to insure ease of input and interpretability of output. These aspects are supported by the Help page, which provides technical guidance on the usage of the website and by the FAQ , where we collected not only technical but also scientific and general questions. Contextual help about specific items can be displayed by leaving the mouse over question marks or some boxes on the pages.

Moreover, SwissADMEterm is an integral part of the SwissDrugDesign programterm, an ambitious initiative driven by the Molecular Modeling Group of the SIB Swiss Institute of Bioinformatics that aims at providing a collection of free Web-based tools covering many aspects of CADDterm. As such, SwissADMEterm users can access the different Web sites, through the black toolbar at the top of the page. By clicking on the name of the tool, a new tab opens with the corresponding submission page. We have undertaken the implementation of more advanced interoperabilityterm capabilities. At the time of writing this manuscript, three icons were placed top left of the output panel (below the name of the molecule, see Fig. 2 ). They allow one-click submission of the molecule to SwissTargetPrediction (for reverse screening to predict protein target, by clicking on the red target), SwissSimilarity (for ligand-based virtual screeningterm, by clicking on the red twins) and to re-submit the molecule to SwissADMEterm (for instance to get a single compound graphical output, by clicking the red pill). Reversely, other SwissDrugDesign websites include the SwissADMEterm pill icon for estimation of ADMEterm, pharmacokineticsterm, drug-likenessterm and medicinal chemistry friendlinessterm regarding a small molecule output of any CADDterm process.

Importantly, the user has the opportunity to save or share SwissADMEterm results in files (CSV) or by copying the values in the clipboard of the local computer and pasting in text or spreadsheet applications for further processing.

Conclusions The SwissADME Web toolterm enables the computation of key physicochemical, pharmacokineticterm, drug-like and related parameters for one or multiple molecules. In one hand, efforts were put in the backend to embed free open-access and fast predictive modelsterm showing statistical significance, predictive power, intuitive interpretation, and straightforward translation to molecular design. These models are adapted from published renowned approaches or in-house original methods, specially developed and thoroughly benchmarked. On the other hand, we focused on an ergonomic and user-friendly graphical interface for the cost- and login-free Web site http://www.swissadmeterm.ch . The latter enables easy input and efficient analysis of the output through interactive capabilities, and does not require any prior knowledge in CADDterm. Moreover, interoperabilityterm allows for direct access to other SwissDrugDesign web toolsterm, including SwissSimilarity 66 (virtual screeningterm), SwissBioisostere 21 (ligand-based design), SwissTargetPrediction 19 (prediction of biotargets), SwissDock 20 (molecular docking), SwissSideChain 67 (protein modeling) and SwissParam 22 (molecular mechanics).

As a result, SwissADMEterm has been designed to support the entire community (specialists and nonexperts) in their drug discovery endeavours.

Computational methods Programming and scripting The SwissADMEterm website was written in HTML, PHP5, and JavaScript, whereas the backend of computation was mainly coded in Python 2.7. The use of additional libraries or software for specific tasks is mentioned in the corresponding paragraph.

Submission Page The molecule inputted through the sketcher Marvin JS (version 16.4.18, 2016, www.chemaxon.com ) are converted into SMILESterm by JChem Web Services (version 14.9.29, 2013, www.chemaxon.com ) installed on one of our servers. This on-the-fly conversion allows seamless paste of SMILESterm in the input list. The user has the possibility to edit this list as a standard text, e.g. to modify SMILESterm or add a name to the molecule. Upon calculation submission by clicking the “Run” button, the SMILESterm of each molecule is canonicalised by OpenBabelterm (version 2.3.0, 2012, http://openbabelterm.org ) 9 and processed individually. Several actions are performed through JChem Web Services APIs. First hydrogen atoms are added to the molecular structure, which is dearomatised (i.e. kekulised), neutralised and checked by the Standardizer API. Then a tridimensional conformation is generated though the StringMolExport function with the Clean3D option and stored in MOL2 format. Besides, a two-dimensional image created through the MolConverter API is displayed on demand when scrolling the output web page.

One-panel-per-moleculeterm Output The Bioavailability Radarterm in the first section of the One-panel-per-moleculeterm output complements the two-dimensional image from the JChem webserver and the canonical SMILESterm calculated by OpenBabelterm. We use the JpGraph PHP library (version 3.5.0b1, 2016, http://jpgraph.net ) to produce the radar plot, which bears six axes for six important properties for oral bioavailability. Each property is defined by a descriptor of SwissADMEterm and a range of optimal values is depicted as a pink area. The latter is inspired from commonly accepted bioavailability and drug-likenessterm guidelines 23 24 . For saturationterm·var, the ratio of sp 3 hybridized carbons over the total carbon count of the molecule (Fraction Csp3) should be at least 0.25. For sizeterm·var, the molecular weightterm (MW calculated by OpenBabelterm) should be between 150 and 500 g/mol. For polarityterm·var, the TPSAterm 25 should be between 20 and 130Å 2 . For solubilityterm·var, log Sterm (calculated with the ESOL modelterm 36 ) should not exceed 6. For lipophilicityterm·var, XLOGP3 29 should be in the range from −0.7 to +6.0. For flexibilityterm·var, the molecule should not have more than 9 rotatable bonds. To be estimated as drug-like, the red line of the compound under study must be fully included in the pink area. Any deviation represents a suboptimal physicochemical property for oral bioavailability.

All descriptors and molecular parameters of the Physicochemical Propertiesterm section are computed through the OpenBabelterm API (version 2.3.0, 2012, http://openbabelterm.org ) 9 . Noteworthy, the topological polar surface areaterm (TPSAterm) is strictly based on the fragmental system provided by Ertl et al . 25 including polar sulfur and phosphorus atoms.

Multiple freely available computational methods to predict n -octanol/water partition coefficient (log P o/wterm ) values are made available in the Lipophilicityterm·var section. iLOGPterm (for implicit log P ) is an in-house physics-based methodsterm relying on Gibbs free energy of solvation calculated by GB/SA in water and n -octanol. Generalized-born (GB) parameters are computed through the GBMV2 method 68 and solvent-accessible surface area (SA) is the analytical approximation generated by CHARMM (version c36b1, 2011, https://www.charmm.org ) 69 . The iLOGPterm implemented in SwissADMEterm corresponds to Model9 of the seminal publication 16 , which was trained on 11,993 molecules (r = 0.72, MAE = 0.89, and RMSE = 1.14 against experimental log P ). 5-fold crossvalidation ensured robustness (q 2 CV = 0.52, MAE CV = 0.89, and RMSE CV = 1.14) and external test benchmarks showed the excellent predictive power and extended applicability domainterm compared to well-established methods. XLOGP3 values are obtained through the command-line Linux program (version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry) including the knowledge-based corrections 29 . WLOGPterm·var is our own implementation of the atomistic method developed by Wildman and Crippen 30 . MLOGP values are computed through an in-house implementation of Moriguchi’s topological method 31 32 . SILICOS-IT is the log P o/wterm estimation returned by executing the FILTER-IT program (version 1.0.2, 2013, http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html ). Finally, SwissADMEterm gives a consensus log P o/wterm value, which is the arithmetic mean of the five predictive values mentioned above.

Similarly to lipophilicityterm·var, the Water Solubilityterm section includes multiple predictive methods for the user to choose between the most accurate model for a given chemical series and an averaged consensus value. The ESOL modelterm 36 is a QSPR modelterm establishing the linear relationship between log Sterm and five molecular parameters, i.e. MW, the number of rotatable bonds, the fraction of aromatic heavy atoms and Daylight’s CLOGP. Because the lipophilicityterm·var descriptor is not freely available, the implementation of ESOL in SwissADMEterm replaces CLOGP by XLOGP3 as parameter in the linear equation to predict log Sterm . XLOGP3 is known to perform well on external datasets and to return similar predictions as CLOGP 28 . The other three parameters were computed with OpenBabelterm. Likewise, Ali et al . 37 linked log Sterm with log P o/wterm and TPSAterm. The model implemented in SwissADMEterm corresponds to the model 3 of the original publication, with XLOGP3 as lipophilicityterm·var descriptor. The third solubilityterm·var method available in SwissADMEterm is the log Sterm estimated by the FILTER-IT program (version 1.0.2, 2013, http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html ). This prediction is based on a system of 16 fragmental contributions modulated by the squared root of MW. All three models are predicting log Sterm values, which are also translated within SwissADMEterm into solubilityterm·var in mol/l and mg/ml. Finally a qualitative estimation of the solubilityterm·var class is given according to the following log Sterm scale: insoluble <−10 <poorly <−6 <moderately <−4 <soluble <−2 <very <0 <highly.

The Pharmacokineticsterm section proposes one linear method for skin permeation, which relies on the simple QSPR modelterm by Potts and Guy 39 linking the decimal logarithm of the skin permeability coefficientterm (log K pterm in cm/s) with MW and log P o/wterm . The model implemented in SwissADMEterm uses XLOGP3 as lipophilicityterm·var descriptor. Besides, most of the models in this section are machine-learning binary classifiers for important ADMEterm behaviours. Passive gastro-intestinal (HIAterm) absorption and blood-brain barrierterm (BBBterm) permeation are predicted with the BOILED-Eggterm model, which defines favourable and unfavourable zones in the log P o/wterm versus PSAterm physicochemical space for passive diffusion through both physiological barriers 17 . The classification showed 10-fold cross-validation accuracyterm of 92% and 88% for BBBterm and HIAterm, respectively (refer to Graphical Output ).

Six other classification models are part of the Pharmacokineticsterm section to predict the propensity of the molecule under investigation to be substrate or inhibitor of important pharmacokinetics-related proteins, for which large diverse and balanced datasets were retrieved and meticulously cleansed. For P-glycoprotein1 (P-gpterm), the training set consists of 521 substrates and 512 non-substrates extracted from the Metrabase database 70 ( http://www-metrabase.ch.cam.ac.uk , accessed January 2016), whereas the test set was obtained from ref. 71 . To ensure truly external validation, molecules overlapping with the training set were removed from the test set, which finally includes 215 substrates and 200 non-substrates. For CYPterm major isoforms, all datasets were those of Veith et al . 50 and downloaded from the PubChem database 72 ( http://pubchem.ncbi.nlm.nih.gov , accessed February 2016). In case of unbalanced dataset (all except CYP1A2 and CYP2C19), sufficient chemical diversity was guaranteed by clustering with the Ward method and a reciprocal nearest neighbour (RNN) algorithm 73 , the more populated class to lessen. The number of molecules (described by circular fingerprints) of the large class is reduced by defining clusters with the JKlustor program (version 14.9.29, 2014, http://www.chemaxon.com ). Only the centre of each cluster (i.e. the molecule that has the smallest sum of dissimilarities to the other molecules in the cluster) is included in the training or test set to balance. As a result, the training sets involved respectively 4301 CYP1A2 inhibitors and 4844 CYP1A2 non-inhibitors; 4284 CYP2C19 inhibitors and 4988 CYP2C19 non-inhibitors; 2940 CYP2C9 inhibitors and 3000 CYP2C9 non-inhibitors; 1814 CYP2D6 inhibitors and 1850 CYP2D6 non-inhibitors; and 3758 CYP3A4 inhibitors and 3760 CYP3A4 non-inhibitors. The test sets involved respectively 1412 CYP1A2 inhibitors and 1588 CYP1A2 non-inhibitors; 1386 CYP2C19 inhibitors and 1614 CYP2C19 non-inhibitors; 1020 CYP2C9 inhibitors and 1055 CYP2C9 non-inhibitors; 528 CYP2D6 inhibitors and 540 CYP2D6 non-inhibitors; and 1289 CYP3A4 inhibitors and 1290 CYP3A4 non-inhibitors.

SwissADMEterm’s backend calculations were ran to generate 50 molecular and physicochemical descriptorsterm per molecule (described in the Supplementary Table S1 ). For a given model, a descriptor was rejected if non-zero values for all molecules in the training set are less than 20% or if the coefficient of variation is less than 3%. In case of correlation higher than 0.9 between remaining descriptors, a selection is made based on F-score. The selected descriptors for each model are shown in Supplementary Tables S2–S7 . These tables also include the minimum and maximum values for each descriptor among all molecules used in the training. This enables beholding the broadness of physicochemical space involved and the applicability domainterm of the SVMterm models. The predictive capability of each model can be further appraised on Supplementary Table S8 , where external accuracy was split in sensitivity and specificity to ensure that positive and negative molecules are predicted with the same level of robustness. The final training and test setsterm with selected descriptors were normalized and the respective model ready to be built. First, the libSVM support vector machineterm python library (version 3.20, 2015, https://www.csie.ntu.edu.tw/~cjlin/libsvm/ ) 74 was used for multi-step grid-based optimization of the best coefficients for the above-selected descriptors as well as for the soft-margin permissivity (C) and the hyper-parameter (ϒ) of the RBF Gaussian kernel functionterm. The 10-fold crossvalidated accuracy (ACC CV ) for each model was so maximized and AUC CV was calculated. In a second step, the so-built models were used on the external test sets (normalized according to the training set) in order to evaluate predictive power in terms of external accuracy (ACC ext ) and AUC ext . All final SVMterm models were stored in separate files, which are read through the libSVM API upon SwissADMEterm job submission.

The Drug-likenessterm section includes six rule-based methods The Lipinski rule-of-fiveterm is exactly as described in ref. 4 including MLOGP <4.15 as lipophilicityterm·var threshold. The Ghose filter is the method detailed in the original publication 58 , where the atomic log P is calculated with WLOGPterm·var. The very simple yet efficient Veber filter is implemented directly from the seminal paper 59 . The Egan filter is yielded from the Egan Egg 60 75 , but the closed-source ALOGP98 was replaced by WLOGPterm·var 17 . The Muegge filter 61 was adapted to fit SwissADMEterm implementation and usage by calculating XLOGP3 as lipophilicityterm·var descriptor. The Bioavailability Scoreterm was implemented without changes from Martin et al . 62 . Similarly, the leadlikenessterm filter included in the Medicinal Chemistry section was adapted from the original rule 64 by using XLOGP3 as lipophilicityterm·var descriptor.

Both methods for identification of problematic fragments within the Medicinal Chemistry section, i.e. PAINSterm 6 and Brenk’s Structural Alertterm 5 , were implemented using the SMARTS recognition capability of OpenBabelterm API. The SMARTS definitions for PAINSterm were retrieved from the Filter-it distribution (version 1.0.2, 2013, http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html ). Little formatting and cleansing were needed to obtain a screenable collection of 481 fragments. Brenk provided directly the SMARTS descriptions of 105 unwanted chemical groups in the supplementary material of the seminal paper 5 .

SwissADMEterm Synthetic Accessibilityterm (SA) Score is based primarily on the assumption that the frequency of molecular fragmentsterm·var in ‘really’ obtainable molecules correlates with the ease of synthesis. The fragmental contribution to SA should be favourable for frequent chemical moieties and unfavourable for rare moieties. We examined the ‘All Now’ subset of ZINC database 76 (version 12, 2014, http://zinc.docking.org/subsets/all-now accessed April 2015) including 12′782′590 compounds immediately deliverable by vendors. This collection was not submitted to any other filter. FP2term·def fingerprints of all molecules were computed by OpenBabelterm 9 thus generating 12′782′590 bit strings (i.e. the fingerprints). The frequency of occupancy of each of the 1024 bits for the entire library was calculated and its contribution to SA obtained by applying natural logarithm to the normalized bit count. As a result, this fragmental system of bits allows extremely fast evaluation of any input molecule by reading its FP2term·def string. Fragmental contribution of bit occupancy is summed and linearly modulated by corrective factors, which are penalties for sizeterm·var (MW) and complexity. This latter is based on SMARTS recognition of chiral centres, spiro functions, bridged rings and macrocycles (more than 8-membered rings). The coefficients of the corrective terms are those defined by Ertl & Schuffenhauer 11 . Finally the score is normalized to range from 1 (very easy) to 10 (very difficult to synthetize). As crude as it may seem, SwissADMEterm SA Scoreterm is extremely fast and performing slightly better than two similar methods previously published 11 65 (refer to Table 2 ).

Graphical output The graphical output of SwissADMEterm consists of the BOILED-Eggterm directly implemented from ref. 17 to predict passive diffusion through HIAterm and BBBterm by position in a WLOGP- versus -TPSA physicochemical space. The HIAterm model was trained on 660 well-absorbed and non-absorbed molecules and a 10-fold crossvalidation returned an accuracy (ACC CV ) of 92% and a Matthews correlation coefficient (MCC CV ) of 0.65. The BBBterm model was built on a training set of 260 permeant and non-permeant molecules and displayed excellent internal statistics as well: ACC CV = 88% and MCC CV = 0.75. The plot is enriched by color-coding referring to P-gpterm active efflux predicted by a SVMterm classifier (refer to Pharmacokineticsterm ). We aimed at providing a global and efficient analysis of absorption and brain access for multiple molecules at once. For more advanced interactive features, the graph is generated in JavaScript using the Flot plotting library (version 0.8, 2015, http://www.flotcharts.org/ ). The user has the possibility to visualize the position of the molecules between the different BOILED-Eggterm compartments and their propensity of being substrate of P-gpterm by coloured points: blue for substrate (PGPterm+) and red for non-substrate (PGPterm−). The dots are also the mean to visualize name and chemical structure of the molecules (generated on-the-fly by the dedicated Chemaxon web server as described above) by leaving the mouse over the dot. As well, it is possible to access the corresponding output panel summarizing all calculated values for the molecule by clicking on the corresponding dot. Getting back to the BOILED-Eggterm is as simple as clicking on the up arrow at the top-right corner of the panel. All these functionalities, as well as interoperabilityterm with other SwissDrugDesign web toolsterm are coded in PHP and Javascript.

Additional Information How to cite this article : DainapersName, A. et al . SwissADMEterm: a free web tool to evaluate pharmacokineticsterm, drug-likenessterm and medicinal chemistry friendlinessterm of small molecules. Sci. Rep. 7 , 42717; doi: 10.1038/srep42717 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Material

Interpretive notes.
• Highlighted spans are tagged entities: persName (author), title (venue), placeName (place), date (year), and term (a key concept: domain / ai / method).
• Eponymous or retrospective terms (e.g. “Nash equilibrium”, “segregation”) do not appear in the original source and so are not highlighted — a deliberate choice (see Report 4).
• Some entries begin with a word in capitals. EVIDENCE CORRECTED means the finding still stands and it was our quotation that was wrong — it has been replaced. RETRACTED means the entry itself was wrong; it stays on the page, marked, with its reason, rather than being deleted. WITHDRAWN AND REPLACED means a corrected version of it appears in the entries below. Each mark carries its own reason, because the reasons differ from one entry to the next. An entry we have WITHDRAWN is removed from this page and kept in the record, with its reason. A line reading Audit and a date is a later re-reading of the entry against its whole sentence: DOUBTFUL means it was kept, and the reason says what is loose about it.
• Quotation marks inside the tagger's sentence. Where a tag is the tagger's own sentence, a phrase in quotation marks inside it is borrowed from the paper — the tagger's wording around it is not. The paper's own sentence is the evidence quote shown on the same row, so the borrowing can be checked against the thing borrowed from without leaving this page. Nothing inside quotation marks anywhere on this page is ours: if it is quoted, it is the paper's. Whose words a concept carries. A concept entry records a term the paper itself uses, so the term, the sense given for it, and its evidence are the paper's own words, quoted where the paper fixes them. This is the opposite of a sense entry in the tag table, which is the tagger's sentence about how the paper uses a term. Where a concept entry could not be grounded in the paper's words, the entry says so on its own row.
• Counts: 1 work · 1 date.
Meta-Tagging Project · record daina2017-swissadme-free-web-tool.
© 2026 Shir Sivroni